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SUMMARY
It has recently been shown that patients with unconjugated 
hyperbilirubinaemia due to Gilbert's syndrome have reduced 
activity of the enzyme protoporphyrinogen oxidase in circulating 
leucocytes. This may be explained by the further observation 
that unconjugated bilirubin competes with protoporphyrinogen for 
binding to protoporphyrinogen oxidase. In order to further 
investigate the effect of unconjugated hyperbil irubinaemia on 
porphyrin metabolism and haem biosynthesis studies have been 
performed in the Gunn rat which has unconjugated hyperbil irubi­
naemia and raised plasma bilirubin concentrations. 
Protoporphyrinogen oxidase activity was found to be reduced in 
the liver of the Gunn rat compared to heterozygous controls with 
normal plasma bilirubin concentrations. This reduction of 
protoporphyrinogen oxidase activity was not accompanied by any 
increase in the activity of the initial and rate-controlling 
enzyme of the pathway delta-aminolaevulinic acid synthase. In 
contrast to hepatic tissue, the activities of both protoporphy­
rinogen oxidase and delta-aminolaevulinic acid synthase were 
normal in renal tissue of the Gunn rat. Porphyrin excretion 
was reduced in the Gunn rat compared to that in heterozygous 
controls.
Further studies were performed to investigate the effects of 
unconjugated hyperbi1irubinaemia on haem biosynthesis in the 
brain of the Gunn rat. This was studied as the major effect of 
hyperbil irubinaemia is brain damiage and the mechanism by which 
it occurs is unknown. Inherited partial enzyme deficiencies in 
haem biosynthesis are known to produce neurological damage.
Therefore the possibility that bilirubin induced brain damage 
might be due to inhibition of protoporphryinogen oxidase 
activity and hence deficient neuronal haem synthesis, was 
investigated. Optimal conditions for the measurement of 
protoporphyrinogen oxidase activity were determined in the brain 
and found to be identical to those which provided optimal 
activity in hepatic tissue. The activity of protoporphyrinogen 
oxidase in brain tissue homogenates from Gunn rats was similar 
to that in heterozygous rats with normal bilirubin concentra­
tions. This was also the case in neonatal Gunn rats in whom 
kernicterus had been induced by the displacement of bilirubin 
into the brain by sulphonamide treatment. Delta-aminolaevuli­
nic acid synthase activities were also similar in the homozygous 
Gunn rat and heterozygous controls. These findings make it 
unlikely that the brain damage induced by hyperbilirubinaemia 
is due to inhibition of protoporphyrinogen oxidase activity and 
impaired neuronal haem biosynthesis.
The above studies concerned the effect of disturbed haem 
catabolism on haem biosynthesis. The latter part of the 
studies extended the theme of the investigation by examining the 
effect of the administration of Tin-protoporphyrin, an inhibitor 
of haem biosynthesis, on haem biosynthesis in acute porphyria. 
The effect of administering Tin-protoporphyrin and haem 
arginate alone and in combination on succinyl acetone induced 
porphyria in rats was studied. This animal model proved to be 
unsatisfactory as the haem arginate given alone did not 
significantly reduce the over-production of the porphyrin
precursor, delta-aminolaevul inate. This may be explained by 
inhibition of aminolaevulinic acid dehydratase by succinyl 
acetone so increasing aminolaevulinic acid overproduction in 
most body tissues. The effect of the haem arginate is largely 
confined to the liver. Studies in 1 patient during clinical 
attacks proved more encouraging. They showed that the co­
administration of Tin-protoporphyrin with haem arginate 
prolonged both the biochemical response and clinical remission 
induced by haem arginate therapy. These findings indicate that 
co-administration of Tin-protoporphyrin and haem arginate may be 
used as prophylactic therapy in patients experiencing recurrent 
attacks of acute porphyria.
Except where acknowledged, all the work performed which forms this 
thesis was carried out by myself.
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CHAPTER 1
ItJTRODUCTION
1
THE BIOSYNTHESIS OF HAEM
The pathways of biosynthesis and degradation of haem have 
been of major interest for many years. Haem consists of a 
porphyrin molecule with a ferrous iron atom in its nucleus (see 
Figure 1). Iron is only one of the metals with which this 
tetrapyrrole can combine, magnesium being the other most common 
one. These metalloporphyrins are found throughout nature in 
plants, yeasts, bacteria, avian and mammalian tissues and are 
central to a large number of biological reactions. Synthesis 
of haem has been identified in virtually all mammalian tissues 
(Granick & Urata, 1963 ; Bottomley & Smithee, 1968; Barnes et 
al, 1971; Briggs et al, 1976; Paterniti et al, 1978) with the 
liver and bone marrow being the richest sources. As the 
prosthetic group of various proteins, haem is involved in many 
biological oxidation reactions. Haemoglobin transports oxygen 
in the red cell, catalase prevents accumulation of toxic hydro­
gen peroxide and various cytochromes are involved in several 
aspects of cellular respiration, ihe predominant one in liver, 
cytochrome P450 (cyt P450), has the ability to metabolise a wide 
range of xenobiotics and potentially toxic endogenous compounds.
Haem biosynthesis consists of eight well characterised 
steps (see Figure 2), elucidated from work with isotopic tracers 
initiated 35 years ago (Neuberger & Scott, 1953; Shemin, 1955) 
and involves both mitochondrial and cytosolic enzymes. From 
the readily available precursors succinyl coenzyme A (succinyl 
CoA) produced in the citric acid cycle and the amino acid 
glycine, the first intermediate in the pathway, 5-aminolaevuli­
nic acid (ALA) is formed. Condensation of two ALA molecules
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FIGURE 1 : THE MOLECULAR STRUCTURE OF HAEM
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FIGURE 2 : THE HAEM BIOSYNTHETIC PATHWAY
produces porphobilinogen (PBG) a monopyrrole which cyclises to 
form uroporphyrinogen, the first of the colourless porphyrino­
gens, the reduced intermediates of the porphyrins. Stepwise 
decarboxylation and oxidation then leads to the deep red 
coloured protoporphyrin IX (PROTO) via coproporphyrinogen and 
protoporphyrinogen. The final step involves incorporation of 
Fe^+ to form haem. The enzym.es of haem biosynthesis have been 
closely studied and a brief summary of current knowledge of each 
of these follows. Particular attention will be paid to 5- 
aminolaevulinate synthase (ALA-synthase), the first and rate 
limiting enzyme of the pathway and protoporphyrinogen oxidase 
(PROTO-O), the penultimate and most recent enzyme to be 
described. These enzymes are especially of interest as the 
effects of bilirubin on protoporphyrinogen oxidase and any 
resultant effects on ALA-synthase will be assessed in this 
thesis.
1.1.1 5-Aminolaevulinic Acid Synthase (E.C. 2.3.1.37)
ALA-synthase catalyses the condensation of succinyl CoA and 
glycine to form an.inolaevul inic acid (ALA). Pyridoxal 
phosphate (vitamin B6) acts as a cofactor in the reaction 
(Schulman & Richert, 1P56) which is thought to proceed via 
reaction of glycine with enzyme bound pyridoxal phosphate to 
form a stable Schiff base carbanion. The stable reaction 
product can then react with succinyl CoA producing anocamino- 
fjketo adipic acid and losing CoA. On decarboxylation ALA is 
produced (Figure 3). In a secondary role pyridoxal phosphate 
helps prevent inactivation of ALA-synthase (Beattie et a l ,
3
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FIGURE 3 : THE MECHANISM OF FORMATION OF ALA BY ALA-SYNTHASE
1985). ALA-synthase activity has been studied in many tissues 
including the heart (Briggs et al, 1976), adrenal gland (Condie 
et a l , 1976), spleen (Ebert et al 1970), kidney (Barnes et al, 
1971) and brain (Paterniti et al, 1978). Most of the earlier 
work concentrated on defining the hepatic activity and it was 
quickly established that ALA-synthase controlled the rate of the 
reaction. It is now well documented that ALA-synthase is 
important in the regulation of the haem biosynthetic pathway in 
hepatic tissue as detailed in section 1.3.2. However in recent 
years the role of this enzyme in the control of haem biosynthe­
sis, in erythroid tissue has been disputed and contradictory 
evidence has implicated ALA-synthase, ferrochelatase and PBG- 
deaminase (Beru & Goldwasser, 1985) in regulatory roles - see 
section 1.3.3. Genetic and other advances have allowed closer 
investigation of the possibility that the enzymes have different 
roles to play depending on tissue. It is now widely believed 
that tissue specific control of haem biosynthesis does exist and 
this is supported by several pieces of evidence. The structure 
of ALA-synthase is thought to vary slightly in different 
tissues, and it has been shown that the enzymic proteins display 
a different molecular mass in liver and erythroid tissue 
(Grandchamp et al, 1987). Certain properties of the enzyme 
have also been shown to vary according to the tissue source. 
These pieces of evidence are in support of tissue specific roles 
for ALA-synthase. This may also prove to be the case for the 
other enzymes. The hepatic enzyme is inducible by a large 
variety of endogenous and exogenous factors while this is not
4
generally the case for the erythroid form of the enzyme. 
Studies of brain ALA-synthase have also shown that this enzyme 
has unique properties and these are further discussed in Chapter 
3.
ALA-synthase is located within the mitochondrion, loosely 
bound to the inner membrane (Patton & Beattie, 1973). Cytoso­
lic activity has been recorded, but is probably due to the 
presence of newly formed enzyme since synthesis of ALA-synthase 
occurs on the rough endoplasmic reticulum in the cytoplasm 
before translocation to the mitochondrion (Hayashi et al, 1970). 
Cytoplasmic ALA-synthase has a higher molecular weight than the 
mitochondrial form with slight variations depending on the 
source of tissue and species studied. Using various purifica­
tion techniques on rat liver cytosolic ALA-synthase was shown to 
consist of three subunits molecular weights 51 000, 79 000 and 
120 000 daltons (Ohashi & Kikuchi, 1979). The two larger 
subunits detected in cytosol are thought to be catalytical ly 
inactive. The active form is thought to be a dimer of the 
51 000 dalton subunit and it appears this is the only subunit 
transported into the mitochondrion (Nakakuki et al, 1980; Ohashi 
& Kikuchi, 1979).
The half-life of the enzyme is very short with values of 34 
minutes recorded in young rats (Vfoods, 1973; VJoods & Murthy, 
1974) and 60-70 minutes recorded in adult rats (Marver et a l , 
1966a; 1966b) and this is one of the criteria which initially 
made it likely that the enzyme catalysed the rate controlling 
step of the pathway. At the molecular level the half-life of 
the mRNA for ALA-synthase in rats is thought to be of sirailar
5
duration to that of the enzyme itself (Tschudy et al, 1965; 
Marver et al, 1966b).
Measurement of hepatic ALA-synthase activity has shown a 
range from! 20 - 80 nmoles ALA formed/g liver/hour in humans 
(Strand et a l , 1970; Sweeney et al, 1970) to 200-800 pmol/mg 
protein/hour in rats. From studies with purified enzyme in 
rats, development of both hepatic and brain ALA-synthase 
activities appear to follow a similar pattern with the highest 
activity recorded in the first three weeks of life, tapering off 
to the adult values already listed (De Matteis, 1981; Woods, 
1974). The cytochromes are formed in these early weeks of life 
and it has been suggested that haem requirement will be at a 
peak during this period. This would explain the necessity for 
higher ALA-synthase activity. Hepatic ALA-synthase is an 
inducible enzyme and its activity is affected by many foreign 
substances (Granick, 1966; Marver et al, 1966a), in addition to 
haem requirements (Moore et al, 1987). The role of the enzyme 
in control of the pathway of haem biosynthesis will be more 
fully discussed in section 1.3.
1.1.2 Aminolaevulinic Acid Dehydratase (E.C. 4.2.1.24)
ALA-dehydratase (ALA-D) is the first cytosolic enzyme in the 
pathway of haem biosynthesis, and catalyses the condensation of 
two molecules of ALA to form PEG, eliminating two molecules of 
water (Shemin, 1972). The structure of the enzyme has been 
closely studied in various mammalian tissues and purification of 
the bovine liver form revealed a quaternary cube-like structure 
consisting of eight subunits each with molecular weight 35 000
6
dal tons and thought to be identical (Wu et a l , 1974). The 
catalytic process involves subsequent binding of ALA molecules 
to the enzyme (Shemin, 1976). The presence of two highly 
active sulphydryl groups in the active site is thought to be one 
important contribution to the enzyme's activity. Initially an 
ALA molecule binds to one side of the active site of the enzyme 
forming a Schiff base. This later becomes the part of PBG 
bearing the propionic acid side chain (Jordan & Gibbs, 1985). 
The presence of further substrate allows another ALA molecule to 
enter the active site and eventually leads to formation of the 
PBG molecule shown in Figure 4. EDT’A inhibits ALA-D activity, 
and this loss can be restored by addition of zinc (VJilson et 
al, 1972). More recently the importance of zinc has been 
emphasised (Finelli et al, 1975) as an activator of ALA-D 
activity effective at the site of synthesis of the enzyme. A 
high affinity binding site has been identified on each subunit 
of the enzyme and occupation may result in protection of the 
sulphydryl groups in the active site. Most other metals inhibit 
ALA-D (VJilson et al, 1972; Chiba & Kikuchi, 1978) with the 
greatest sensitivity to non-competitive inhibition by lead 
(Gibson & Goldberg, 1970). These effects are again counteracted 
by zinc (Finelli et al, 1975). The mechanism appears to be 
competition which occurs between lead and zinc binding to the 
enzyme, with lead inhibiting and zinc activating.
Other reagents inhibit ALA-D. Important ones to be consi­
dered are ethanol and succinyl acetone. Ethanol is thought to 
cause oxidation of sulphydryl groups (Moore et al, 1971) while
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succinyl acetone blocks the site of formation of the Schiff base 
(Tschudy et al, 1981). The similarity in structure of this 
inhibitor to native ALA demonstrated in Figure 5 is thought to 
explain the mechanism of inhibition. Succinyl acetone causes 
irreversible inhibition and in severe cases can interfere with 
haem biosynthesis.
1.1.3 Porphobilinogen Deaminase (E.C. 4.3.1.8) & Uroporphyrinogen 
III Cosynthase (E.C. 4.3.1.75)
The polymerisation and cyclisation of four molecules of PEG 
to form the first porphyrinogen is carried out in the cytoplasm 
by a two enzyme system comprising PBG-deaminase (uroporphyrino- 
gen-I-synthase, hydroxymethyl bilane synthase) and uroporphyri- 
nogen-III-cosynthase. The product which goes on to form haem, 
uroporphyrinogen-III (UPO'gen III), is asymmetrical and can only 
be formed in the presence of URO'gen-III-cosynthase. The action 
of PBG-D alone forms URO'gen I, an uncommon molecule which 
cannot be converted to haem and is present in the disease 
states which are covered in section 1.4. The complex reaction 
is started by PBG-deaminase which catalyses a head to tail 
condensation of four PBG molecules to form hydroxymethylbilane 
(I1MB) or preuroporphyrinogen. This linear tetrapyrrole is the 
substrate for URO'gen-III-cosynthase to form the asymmetrical 
URO'gen III (Jordan et al, 1979), see Figure 6.
PBG-deaminase has been purified from human, bacterial and 
plant sources with the molecular weight of the human enzym.e 
estimated at 38 000 dal tons (Anderson & Desnick, 1980). URO'­
gen-III-cosynthase has been purified from bacteria with 
molecular weight between 30 000-40 000 daltons (Hart &
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B a t t e r s b y ,  1985) and from  r a t  l i v e r ,  m o le c u la r  w e ig h t  42 000 
d a l to n s  (Kohashi e t  a l ,  1984).
PBG-deaminase has lo w e r  a c t i v i t y  th a n  most o f  th e  haem 
b i o s y n t h e t i c  enzymes e x c e p t in g  A LA -syn th a se  and so has been 
p roposed  as a se co n d a ry  c o n t r o l  p o i n t  o f  haem b io s y n t h e s i s  
(B ro d ie  e t  a l ,  1977). In  s u p p o r t  o f  t h i s ,  a c t i v i t y  has been 
shown to  in c re a s e  i n  an a t te n .p t  to  compensate f o r  a b lo c k  in  
haem s yn th e s is  (Piper e t  a l ,  1986). I n h ib i t o r s  re p o r ted  in c lu d e  
sulphonamides which are r e v e r s ib le  and n o n -c o m p e t i t iv e  _in v i t r o  
(P e te rs  e t  a l ,  1980), haem p r e c u r s o r s  e s p e c i a l l y  PRCTO'gen 
(Meissner e t  a l ,  1990) and b i l i r u b i n  (P iper e t  a l ,  1986) poss ib ­
l y  because o f  i t s  s i m i l a r i t y  in  s t r u c tu r e  to  HMB and PROTO'gen 
IX .
1.1.4 Uroporphyrinogen Decarboxylase (E.C. 4.1.1.37)
U ro p o rp h y r in o g e n  d e c a rb o x y la s e  (URO-D) c a t a l y s e s  th e  l a s t  
c y t o s o l i c  s te p  i n  th e  b io s y n t h e s i s  o f  haem, s e q u e n t i a l l y  
removing fo u r  carboxym ethy l s u b s t i tu e n ts  from URO'gen to  form 
c o p r o p o rp h y r in o g e n  (COPRO'gen). i n  sequence , r i n g  D r e a c ts  
f i r s t  and most q u i c k ly  and is  fo l lo w e d  by c lo c k w is e  decarboxy­
l a t i o n  o f  r i n g s  A, B and C (Jackson  e t  a l ,  1976) see F ig u re  7.
There  i s  d is a g re e m e n t  o v e r  t h e  s p e c i f i c i t y  o f  URO-D. 
S e v e ra l au thors  have re p o r ted  URO I I I  i s  p r e f e r e n t i a l l y  decarbo- 
x y l a t e d  ( E ld e r ,  1977, E ld e r  & T o ve y ,  1977) b u t  Rasmussen and 
Kushner (1979) found  no e v id e n c e  f o r  a p r e f e r r e d  s u b s t r a t e  
a l th o u g h  they d id  f in d  d i f fe re n c e s  in  accum u la t ion  o f  in te rm e­
d ia te s .
URO-D has been p u r i f i e d  from bov ine  l i v e r ,  m o le c u la r  w e igh t
9
'<b 
i
UROPORPHYRINOGEN 
DECARBOXYLASE P
Me
* Me
C02
+
UROPORPHYRINOGEN
DECARBOXYLASE
COPROPORPHYRINOGEN
FIGURE 7 : ENZYMIC REACTION CATALYSED BY UROPORPHYRINOGEN
DECARBOXYLASE
57 000 d a l to n s  (Straka & Kushner, 1983) and human e ry th ro c y te s ,  
m o le c u la r  w e ig h t  46 000 (De V e r n e u i l  e t  a l ,  1983a). From 
k i n e t i c  d a ta  th e  enzyme seems to  have  a t  l e a s t  two s e p a ra te  
a c t i v e  s i t e s  (Ce V e r n e u i l ,  1983a)
The enzyme i s  s e n s i t i v e  to  s u lp h y d ry l  m o d i f i c a t i i o n  and i s  
in h ib i t e d  by copper, mercury and p la t in u m  ions. I n a c t i v a t io n  
o c c u r s  on e x p o s u r e  t o  p o l y c y c l i c  h y d ro c a rb o n s  eg 3 -M e - 
ch o lan th ren e  ( S in c la i r  e t  a l ,  1984) and/ _in v i t r o , i r o n  (Smith & 
F r a n c is ,  1983).
1-1.5 COproporphyrinogen Oxidase (E.C. 1-3-3-3)
C o n v e rs io n  o f  COPRO'gen I I I  t o  p r o t o p o r p h y r i n o g e n  IX  
(PROTO'gen IX) i s  c a ta ly s e d  by the  m ito c h o n d r ia l  enzyme copropo­
rphyr inogen  ox idase (COPRO-O). The enzyme i s  v e ry  s p e c i f i c  f o r  
COPRO'gen I I I ,  so t h a t  any COPRO'gen I  formed a t  th e  p r e v io u s  
s te p  c a n n o t  p roceed  a lo n g  th e  pa thw ay o f  b io s y n t h e s i s  o f  haem 
( B a t l l e  e t  a l , 1965). The r e a c t i o n  com bines o x i d a t i o n  and 
d e c a rb o x y la t io n  o f  p ro p io n y l  res idues  on r in g s  A and B r e s p e c t i ­
v e l y  to  produce v i n y l  groups (Ahktar e t  a l ,  1976). M o le c u la r  
oxygen i s  r e q u i r e d  as a hyd rogen  a c c e p to r  (Sano & G ra n ic k ,  
1961).
The enzyme i s  lo c a te d  i n  th e  in te rm e m bran e  space o f  th e  
m itochond r io n  and may be lo o s e ly  bound by the membrane (E lde r & 
Evans, 1978),
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1.1.6 Protoporphyrinogen Oxidase (E.C. 1.3.3.4)
Protoporphyrinogen oxidase (PROTO-G), the penultimate enzyme 
of the pathway of haem biosynthesis, is the most recently 
identified and was proven to exist after Jackson and coauthors 
(Jackson et al, 1974) showed with isotopic markers that all six 
hydrogen atoms in COPRO'gen are removed from the same side of 
the porphyrin ring. Further work by Poulson and Polglase 
(Poulson & Polglase 1975; Poulson, 1976) localised the enzyme 
activity to the mitochondrial fraction. In all eukaryotic 
cells studied oxygen is required as an electron acceptor before 
the reaction can proceed. More recent work has localised PROTO- 
0 activity to the inner mitochondrial membrane (Deybach et al, 
1985), as an intrinsic protein oriented towards the cytosolic 
side of the membrane (Ferriera et al, 1988) and evidence exists 
supporting the presence of a membrane complex with some type of 
interaction between the terminal three enzymes of the pathway 
occurring. A miodel for organization of the terminal portion 
of the pathway has been proposed (Ferreira et al, 1988) and is 
demonstrated in Figure 8.
PRCTO-O has been p u r i f i e d  and p a r t i a l l y  c h a ra c te r is e d  from 
mouse l i v e r  m i t o c h o n d r ia  ( D a i l e y  & K a r r ,  1987),  r a t  l i v e r  
m ito ch on d r ia  (K o la rov  e t  a l ,  1983), b a c t e r ia l  and p la n t  sources 
(Jacobs & Ja cob s , 1981; 1984; 1987). The m u r in e  and y e a s t  
PROTO-O enzymes have re p o r te d  m o le c u la r  w e ig h ts  o f  65 000 
d a l to n s  but the p la n t  enzyme, i s o la te d  from b a r le y  o rg a n e l le s ,  
has a r e p o r te d  m o le c u la r  w e ig h t  o f  36 000 d a l t o n s  (Jacobs & 
Ja cob s , 1987) a lo n g  w i t h  s e v e r a l  d i f f e r e n t  p r o p e r t i e s  t o  th e  
n o n -p la n t  enzymes. These d i f fe re n c e s  in  m o le c u la r  w e igh ts  have
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n o t  y e t  been exp la in e d .
I n h i b i t i o n  o f  PKOTG-O a c t i v i t y  has been d e m o n s t ra te d  by 
v a r io u s  p e r o x id i s i n g  h e r b i c i d e s  ( f l a t r i n g e  e t  a l ,  1989) and by 
b i l i r u b i n  in v i t r o  ( F e r r e i r a  & D a i l e y ,  1988). In  humans 
s e v e ra l  d isease s ta te s  lead  to  reduced a c t i v i t y  o f  t h i s  enzyme. 
V a r ie g a te  p o rp h y r ia  p a t ie n ts  have PROTO-O a c t i v i t i e s  reduced to  
around 50% o f  norm al, and lower than normal l e v e l s  o f  a c t i v i t y  
have been recorded in  p a t ie n ts  w i th  G i l b e r t ' s  syndrome, a benign 
s ta te  o f  h y p e rb i l i ru b in a e m ia  a f f e c t in g  around 5% o f  the  popu la ­
t i o n  (M c C o l l  e t  a l ,  1985). I t  has been su gg e s te d  t h a t  th e  
reduced PROTO-O a c t i v i t y  re c o rd e d  i n  such p a t i e n t s  may be 
induced by an i n h ib i t o r y  e f f e c t  o f  b i l i r u b i n  on the p e n u lt im a te  
enzyme o f  haem b io s y n t h e s i s .  T h is  p r o p o s a l  w i l l  be f u r t h e r  
in v e s t ig a te d  in  t h i s  th e s is .
1.1.7 Ferrochelatase (E.C. 4.99.1.1)
F e rro ch e la ta se  or haem synthase c a ta ly s e s  the l a s t  s tep  in  
th e  b io s y n t h e s i s  o f  haem (G o ldbe rg  e t  a l ,  1956) by i n s e r t i n g  
fe r ro u s  i r o n  in t o  the  c e n tre  o f  the  p ro to p o rp h y r in  IX m o lecu le  
r e l e a s i n g  two p r o to n s .  As w i t h  PROTO-O, f e r r o c h e la t a s e  i s  
embedded i n  th e  in n e r  m i t o c h o n d r ia l  membrane w i t h  th e  a c t i v e  
s i t e  fa c in g  in to  the  m ito c h o n d r ia l  m a t r ix  (Jones & Jones, 1969; 
Honeybourne e t  a l ,  1979). Covine and r a t  l i v e r  m ito c h o n d r ia l  
forms have been p u r i f i e d  and m o le c u la r  w e igh ts  o f  around 40 000 
d a l t o n s  re c o rd e d  ( D a i l e y  & F le m in g ,  1983; T a k e ta n i  & 
Tokunaga, 1981). The p re se n ce  o f  l i p i d  i s  e s s e n t i a l  f o r  
enzyme a c t i v i t y  (Sawada e t  a l ,  1969; Take tan i & Tokunaga, 1981) 
and may a c t  by in c r e a s in g  s o l u b i l i z a t i o n  o f  th e  p o r p h y r in
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i n t e r m e d ia t e .  A d d i t i o n a l l y  th e  c a r b o x y l i c  g ro up s  on f a t t y  
a c id s  may p r o v id e  th e  o p t im a l  c o n d i t i o n s  f o r  app roach  o f  the  
p o r p h y r in  t o  th e  enzyme a c t i v e  s i t e .  A n o th e r  r e q u i r e m e n t  f o r  
a c t i v i t y  i s  the  presence o f  s u lp h y d ry l  yroups (Labbe & Hubbard, 
1961). I t  has been p o s tu la te d  th a t  the  o x id a t io n  o f  PROTO'gen 
c o u ld  be l in k e d  in e x t r i c a b l y  w i th  the a c t io n  o f  fe r ro c h e la ta s e ,  
the  te rm in a l  enzyme o f  the  pathway us ing  the  a v a i l a b le  reduc ing 
e q u iv a le n ts  to  d r i v e  the  re d u c t io n  o f  i r o n  (Moore e t  a l ,  1987). 
F e rro ch e la ta se  is  no t  s p e c i f i c  f o r  e i t h e r  o f  the  two su b s tra te s  
i t  com bines and so o th e r  d i v a l e n t  m e ta l  io n s  and p o r p h y r in  
analogues can be u t i l i s e d  (Jones & Jones, 1969; Labbe & Hubbard, 
1961; Honeybourne e t  a l ,  1979). However s e v e ra l  m e ta ls  such as 
c o b a l t ,  z in c  and lead i n h i b i t  a c t i v i t y  o f  the enzyme (Taketan i & 
Tokunaga, 1981). I n h ib i t i o n  a ls o  occurs  w i th  h igh  concen tra ­
t i o n s  o f  b o th  s u b s t r a t e  and p r o d u c t ,  and has been in d uce d  i n  a 
severe  form in  e xpe r im en ta l an im a ls  w i th  3 ,5 -d ie th o x y c a rb o n y l-  
1 , 4 - d ih y d r o c o l  1 i d i n e  (DDC). T r a n s m e th y la t io n  f ro m  DDC to  a 
n i t ro g e n  on PROTO IX causes s te reochem ica l a l t e r a t i o n  o f  one o f  
th e  p o r p h y r in  r i n g s  p r e v e n t in g  b in d in g  o f  th e  i r o n  m o le c u le  
(O r t iz  de M o n te l la n o ,  1981).
1.2 DEGRADATION OF HAEM
As a l re a d y  mentioned haem is  an e x trem e ly  v e r s a t i l e  m o le cu le  
and has many fu n c t io n s .  IP  m a in ta in  i n t r a c e l l u l a r  haem c o n te n t  
co ns ta n t  fo rm a t io n  and deg rada t ion  occurs , w i th  o ld  haem being 
removed from the  haemoproteins, i r o n  removed f o r  reuse and the  
p o rp h y r in  m o ie ty  broken down fo r  e x c re t io n .  B iodeg rada t ion  o f  
haem o c c u rs  v i a  a much s h o r t e r  pa thw ay th a n  th e  s y n t h e t i c  one
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w i t h  e i t h e r  one o r  two s te p s  in  a n im a ls .  In  b i r d s ,  r e p t i l e s  
and amphibia the  enzyme haem oxygenase c le a v e s  the t e t r a p y r r o l i c  
r in g  and the r e s u l t i n g  l i n e a r  t e t r a p y r r o le ,  b i l i v e r d i n ,  can be 
excre ted . In  mammals however, a f u r th e r  s tep  c a ta ly s e d  by the  
enzyme b i l i v e r d i n  reductase produces b i l i r u b i n .  The pathway o f  
b io d e g rad a t io n  o f  haem i s  shown in  F igu re  9.
Labelling studies in man have showed appearance of active 
bilirubin in three distinct pools. By far the largest fraction 
of body haem is incorporated into haemoglobin in the erythrocyte 
and consequently bilirubin from around 80% of haem is seen at 
the expected time of red cell breakdown (approximately 120 
days). The remaining fraction of bilirubin is detected much 
earlier in a double peak which is thought to be hepatic in 
origin. Turnover of haemoproteins such as cyt. P450 and 
catalase occurs much more rapidly than that of haemoglobin and 
explains the majority of the peak. This is described as early 
labelled bilirubin. However a small proportion can be detected 
even earlier, within minutes of administration of labelled 
bilirubin. It is widely believed that this, portion arises from 
breakdown of newly formed haem in the so called free haem pool. 
The free haem pool is a small and constantly turning over source 
of haem in the body which has an important role to play in 
regulation of haem _in vivo. The concept of the free haem pool 
is more fully discussed in section 1.3.1. A more detailed 
discussion of the biological and chemical degradation of haem 
and its end product, bilirubin follows.
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1.2.1 Haem Oxygenase (E.C. 1.14.99.3)
B io lo g i c a l  deg ra da t ion  o f  haem occurs by o x id a t iv e  c leavage  
o f  the  x-methene b r id ge  o f  the  m o le cu le  to  form equa l amounts o f  
b i l i v e r d i n  lXp<; carbon monoxide (CO) and i ro n .  Th is  re a c t io n  i s  
c a ta ly s e d  by th e  m ic ro s o m a l enzyme system  haem oxygenase  
(Tenhunen e t  a l ,  19f"-; 1972) and has an a b s o lu te  requirem ent fo r  
a reduc ing  e q u iv a le n t  and m o le c u la r  oxygen (King & Brown, 1978) 
(see F igu re  9). IiADPII i s  the t e s t  reduc ing agent a l th o u g h  NADH 
has been shown to  be a c t i v e  i n  th e  r a t  l i v e r  sys tem  (H ino e t  
a l ,  1979). Immunochemical s tu d ie s  demonstrated the  f l a v o p r o t e i n  
IJADPH-cytochrome c re d u c ta s e  i s  n e c e s s a ry  to  th e  r e a c t i o n  
(Schacter, 1972) and th a t  i n te r a c t io n s  w i th  haem oxygenase and 
b i l i v e r d i n  re d u c ta s e  were  o c c u r r in g  (Yosh inaga  e t  a l ,  1982). 
The d e ta i le d  mechanism o f  co nve rs ion  o f  haem to  b i l i v e r d i n  i s  
n o t  t o t a l l y  c l e a r  b u t  f r e e  haem i s  known to  be th e  p r e f e r r e d  
s u b s t r a t e ,  so h a e m o p ro te in  c le a v a g e  does n o t  appear t o  be 
in v o lv e d .  The mechanism by which the  a po p ro te in  and haem are 
s p l i t  re q u ire s  f u r t h e r  research. B i l i v e r d i n  fo rm a t io n  i s  though t 
to  o c c u r  th ro u g h  s e v e r a l  in t e r m e d ia t e s  and one p o s s i b l e  
mechanism i s  s c h e m a t i c a l l y  r e p re s e n te d  i n  F ig u re  9. T h is  
t h e o r y  supposes t h a t  haem b in d s  to  haem oxygenase fo r m in g  an 
i n t e r m e d ia t e  w i t h  s p e c t r a l  p r o p e r t i e s  s i m i l a r  to  cy toch ro m e  
P450. T h is  i s  f o l l o w e d  by r e a c t i o n  w i t h  oxygen t o  fo rm  cx- 
hydroxyhaem which can then s p l i t  le a v in g  the e n z y m e - b i l i v e rd in -  
Fe complex and carbon monoxide. The f i n a l  s tep  i s  re le a s e  o f  
i r o n  and b i l i v e r d i n  from the  enzyme. In  t o t a l  t h r e e  m o le s  o f  
m o le c u la r  C> 2  are re q u ire d  f o r  each m o le cu le  o f  haem broken down. 
T h is  mechanism has n o t  been c o n f i rm e d  and th e  r o l e  o f  haem
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oxygenase a f t e r  c leavage  o f  the <xrnethene b r id ge  i s  no t  c e r ta in .  
(For re v ie w  see Schacter, 1988 or Brown e t  a l ,  1989).
Protohaem i s  th e  b e s t  s u b s t r a t e  f o r  th e  enzyme, b u t  s e v e r a l  
o th e r  haem compounds can re a c t  w i th  the haem oxygenase system, 
in c lu d in g  mesohaem, deuterohaem, coprohaern, and some s y n th e t ic  
a n a lo g u e s  o f  p ro tohaem  eg haemin I I I  (Frydman e t  a l , 1979). 
Some o f  these compounds even have h ighe r a f f i n i t y  f o r  the enzyme 
th a n  th e  n a t u r a l  s u b s t r a t e .  The absence o f  i r o n ,  as i n  th e  
p o rp h y r in s ,  produces an u n s u i ta b le  s u b s tra te .  The presence o f  
c e r t a in  o the r m e ta ls  in  the p o rp h y r in  nuc leus  such as t i n ,  z in c  
and manganese r e s u l t  i n  m e t a l l o p o r p h y r i n s  w h ich  b in d  more 
t i g h t l y  to  the enzyme than the  n a t iv e  s u b s t ra te  and so i n h i b i t  
enzyme a c t i v i t y .  T in  p r o t o p o r p h y r in  has been p roposed  as a 
u s e fu l  agent in  reduc ing the  h y p e rb i l i ru b in a e m ia  assoc ia ted  w i th  
c e r t a i n  c o n d i t i o n s  (S im io n a t to  e t  a l ,  1985; Anderson  e t  a l , 
1986; Kappas e t  a l ,  1988). In  c o n t r a s t  c o b a l t - p r o t o p o r p h y r i n  
a d m in is t r a t io n  r e s u l t s  in  increased enzyme a c t i v i t y .  C o n tro l  o f  
haem m etabolism  by s y n th e t ic  m eta l lo p o rp h y r  in s  has been r e c e n t ly  
s t u d ie d  (Drummond, 1987). The e f f e c t s  o f  t i n  p r o t o p o r p h y r in  
(Sn-PROTG) on th e  b i o s y n t h e s i s  and c a ta b o l i s m  o f  haem w i l l  be 
examined l a t e r  in  t h i s  chap ter and in  more d e t a i l  in  Chapter 8.
The enzyme p r o t e i n  was i n i t i a l l y  i s o l a t e d  and p a r t i a l l y  
p u r i f i e d  f rom  r a t  l i v e r  m ic rosom es , SDS p o l y a c r y l a m id e  g e l  
e le c t ro p h o re s is  r e v e a l in g  two bands o f  m o le c u la r  w e igh ts  68 
000 and 34 000 (M aines e t  a l ,  1977). F u r th e r  work on s p le e n  
enzymes f ro m  p o r c in e  and b o v in e  s o u rc e s  have  d e m o n s t ra te d  
m o le c u la r  w e igh ts  around the  30 000 mark (Yoshida e t  a l ,  1974;
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Yoshinaga e t  a l ,  1982a).
Haem oxygenase i s  a n o th e r  i n d u c i b l e  enzyme making i t  an 
im p o rta n t  fa c to r  in  the c o n t r o l  o f  i n t r a c e l l u l a r  haem l e v e l s  as 
w i l l  be d is c u s s e d  in  s e c t i o n  1.3. V a r io u s  c h e m ic a l  and 
b io l o g i c a l  agents can induce haem oxygenase. The presence o f  
c o b a l t ,  cadmium, s i l v e r ,  t i n  and n ic k e l  induce a c t i v i t y  (Maines 
& Kappas 1974; 1976a; 1976b). S imultaneous a d m in is t r a t io n  o f
manganese and z in c  com p lexes  a re  re p o r te d  to  p r e v e n t  th e  
i n d u c t i o n  by th e  l i s t e d  m e ta l  io n s  (Drummond & Kappas, 1980). 
These o b s e r v a t io n s  add to  th e  com p lex  n a tu r e  o f  th e  e f f e c t  o f  
m e ta ls  on haem deg rada t ion  s ince  these same m eta l ions  combined 
w i t h  th e  PROTO r i n g  le a d  to  i n h i b i t i o n  o f  th e  enzyme. A
r e v ie w  o f  th e  e f f e c t  o f  m e ta ls  on haem oxygenase has been 
r e c e n t l y  p u b l is h e d  (Sunderman, 1987). O the r  e x p e r im e n ta l  
m a n ip u la t io n s  which r e s u l t  in  increased haem oxygenase a c t i v i t y  
in c lu d e  a d m in is t r a t io n  o f  chem ica ls  eg pheny lhyd raz ine  (Maines & 
Veltm an, 1984), f a s t in g ,  a d m in is t r a t io n  o f  i n s u l i n ,  g lucagon, o r 
c y c l i c  AMP. The e f f e c t s  o f  non-m eta l agents on haem oxygenase 
a c t i v i t y  a re  d e s c r ib e d  more f u l l y  e ls e w h e re  (Bakken e t  a l ,  
1972).
R e ce n t ly  g e n e t ic  ev idence has re v e a le d  th a t  two isoenzymes 
o f  haem oxygenase e x i s t ,  o n ly  one o f  which is  in d u c ib le  (Maines 
e t  a l ,  1986). The j - h y s io lo g ic a l  s ig n i f i c a n c e  o f  these iso fo rm s 
has y e t  to  be determined.
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1.2.2 Biliverdin Reductase (E.C.1.3.1.24)
In  mammalian t is s u e s  b i l i v e r d i n  i s  f u r t h e r  reduced to  b i l i r u ­
b i n ,  s t r u c t u r e  shown in  F ig u re  10, by th e  enzyme b i l i v e r d i n  
re d u c ta s e .  NADPII b in d s  to  th e  enzyme c r e a t i n g  h ig h  a f f i n i t y  
b in d in g  s i t e s  f o r  b i l i v e r d i n ,  which on c o n ta c t  w i th  the  enzyme 
can th e n  be c o n v e r te d  t o  b i l i r u b i n  (Tenhunen e t  a l ,  1970). 
B i l i v e r d i n  reductase i s  found in  the  c y to s o l  o f  many t is s u e s  and 
has been p u r i f i e d  f ro m  r a t  l i v e r  (Noguch i e t  a l ,  1979) w i t h  
m o le c u la r  w e igh t o f  32 000 d a l to n s .  P redom inan t ly ,  conve rs io n  
o f  b i l i v e r d i n  IXtx occurs , but the b i l i v e r d i n  reductase a c t i v i t y  
i s  n o t  s p e c i f i c  and the presence o f  o th e r  isomers o f  b i l i v e r d i n  
le a d s  to  p r o d u c t io n  o f  th e  c o r re s p o n d in g  isom er o f  b i l i r u b i n .  
However th e  c o n v e r s io n  o f  , X and S iso m e rs  o f  b i l i v e r d i n  i s  
u n l i k e l y  to  be a f u n c t io n a l  r o le  o f  the  enzyme s ince  haem oxyge­
nase s p e c i f i c a l l y  c le a v e s  the  cx methene b r id ge  le a d in g  a lm os t 
e x c l u s i v e l y  t o  b i l i r u b i n  IXcx(Tenhunen e t  a l ,  1968). The 
p re sen ce  o f  excess  a c t i v i t y  o f  t h i s  enzyme (Tenhunen, 1972), 
im p l i c a t e s  th e  lo w e r  enzyme a c t i v i t y  o f  haem oxygenase  as th e  
ra te  l i m i t i n g  s tep  in  the breakdown o f  haem.
1.2.3 Excretion of Bilirubin
B i l i r u b i n  i s  the end p roduc t o f  p h y s io lo g ic a l  deg rada t io n  o f  
haem. A lthough  the  s t r u c tu r e  o f  b i l i r u b i n  i s  represen ted  as a 
l i n e a r  t e t r a p y r r o l e  in  F ig u re  10 t h i s  a rra n g e m e n t i s  n o t  th e  
p r e f e r r e d  s t r u c t u r e  i n  th e  body. A d d i t i o n  o f  two H+ io n s  
a l l o w s  i n t r a m o l e c u l a r  b on d in g  to  o c c u r  between th e  s l i g h t l y  
n e g a t i v e ly  charged c a r b o x y l i c  ac id  oxygens and the  two a d jace n t 
amino g ro u p s .  The r e s u l t  i s  a r i g i d  s t r u c t u r e  shown in  F ig u re
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FIGURE 10 : THE REACTION CATALYSED BY BILIVERDIN REDUCTASE
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11 as determined by X-ray crystallography. This is virtually
insoluble in water (Bonnett et al, 1976). Oily the trans form 
of bilirubin IX can undergo intramolecular bonding and it is 
this property which makes bilirubin potentially toxic to the 
body. The toxic effects of bilirubin are more fully discussed 
in section 1.5.2 with reference to kernicterus.
On release of bilirubin from the reticuloendothelial system 
to the circulation, the body is protected from any adverse 
effects of the bile pigment by the tight binding to albumin 
which occurs in plasma. The equilibrium which exists between 
free and albumin bound bilirubin leads to only a tiny 
percentage of free biliburin under normal circumstances. 
Bilirubin is removed from the circulation by the hepatocyte 
and evidence supports the theory that transport across the 
plasma membrane is carrier mediated. The exact nature of this 
process is still under investigation. Dissociation of 
bilirubin from albumin on contact with the hepatocyte membrane 
does not seem to be followed by instantaneous equilibration 
between the bound and free forms and simple diffusion into the 
cell (Sorrentino et al, 1987). In vitro studies have shown 
that dissociation of bilirubin from albumin is too slow to 
account for the rate of uptake of bilirubin which occurs in 
vivo (Wolkoff et al, 1979). However, addition of uncomplexed 
albumin seems to competitively inhibit uptake (Weisiger et al, 
1982). The attractive concept of a specific albumin receptor 
has not been backed up by experimental evidence and suggestions 
have been made that non-equilibrium binding of bilirubin occurs
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FIGURE 11 : THE INTRAMOLECULARLY BONDED FORM OF BILIRUBIN IXa
(Weisiger, 1985) or that the hepatocyte has certain peculiar
characteristics which would facilitate uptake (for review see 
Sorrentino et al, 1987). After entry to the liver cell
intracellular binding to a specific bilirubin binding protein 
called ligandin (or Y protein) (Kamisaka et al, 1975) occurs, 
and this prevents efflux back into the circulation.
Intracellularly bilirubin disrupts normal cellular processes 
and can under certain circumstances kill cells. The mechanisms 
by which bilirubin exerts this effect are not well understood. 
Bilirubin is known to uncouple oxidative phosphorylation 
(Cowger et al, 1965; Diamond & Schmid, 1967). More detailed 
analysis has revealed one aspect of this is inhibition of some 
mitochondrial linked dehydrogenases (Noir et al, 1972) and 
aminotransferases, including enzymes responsible for production 
of ATP (McLoughlin & Howell, 1987). Inhibition of RNA 
synthesis, protein and carbohydrate synthesis in the brain have 
been reported (Katoh et al, 1975; Nandi Majumdar et al, 1974; 
Greenfield, 1974). Bilirubin has also been shown to bind to 
membrane lipids (Mustafa & King, 1970) and it has been proposed 
from in vitro studies that incorporation into synaptosomal 
membranes and subsequent crystallisation may affect membrane 
function and contribute greatly to toxicity of bilirubin in the 
brain (Vazquez et al, 1988). However, no particular mechanism 
has been proven (for review see Sarnat, 1984).
Excretion of bilirubin is facilitated by conjugation with 
uridine diphosphate glucuronic acid producing either bilirubin 
monoglucuronide or bilirubin diglucuronide. The enzyme UDP
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glucuronyl transferase (UDP-GT), present in the microsomal 
fraction of the hepatocyte (Dutton, 1966), catalyses glucu- 
ronidation as shown in Figure 12. The monoglucuronides and 
diglucuronide (the main product) are water soluble and can enter 
the biliary system. From the bile ducts and gall bladder 
bilirubin glucuronides are secreted into the gastro-intestinal 
tract where intestinal bacteria cause degradation to urobilino­
gen and related products. A small amount of the urobilinogen is 
reabsorbed from the G.I. tract but the majority is oxidised to 
urobilin and then ercreted in the faeces.
1.2.4 Non-Biological Degradation of Haem
Most o f  the in fo rm a t io n  a v a i l a b le  on the  b io de g rad a t io n  o f  
haem has been determined by the  use o f  models o f  b io de g rada t io n .  
The most common model used i s  t h a t  o f  c o u p le d  o x id a t i o n .  
A d d i t io n  o f  a s trong  reducing agent in  the  presence o f  O2  causes 
r a p id  breakdown o f  haem w i t h  s im u l ta n e o u s  o x id a t i o n  o f  th e  
r e d u c ta n t .  Common re d u c in g  a g e n ts  used a re  a s c o rb a te  and 
h y d r a z in e  (Lemberg, 1935). H aem op ro te ins  can be d i r e c t l y  
o x id is e d  us ing t h i s  system and ev idence  shows th a t  the  p r o te in  
m o ie ty  appears to  be i n f l u e n t i a l  in  d e te rm in ing  which methene 
b r id ge  comes under a t ta c k  (Drown e t  a l ,  1989).
Treatment o f  expe r im en ta l an im a ls  w i th  drugs such as a l l y l i -  
sopropy lacetam ide  (AIA) leads to  accum u la t ion  o f  green p igments 
in  the l i v e r .  Th is  type o f  drug causes s u ic id e  in a c t i v a t i o n  
o f  c y t .  P450 haem l e a d i n g  t o  p r o d u c t i o n  o f  N - a l k y l a t e d  
p o rp h y r in s ,  compounds which are o f  i n t e r e s t  in  the s tudy  o f  cy t .  
P450 systemi (O r t iz  de Monte l l a n o ,  1983).
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FIGURE 12 : STRUCTURES OF THE GLUCURONYL CONJUGATES OF
BILIRUBIN
Haem. and p o r p h y r in  d e r i v a t i v e s  were c h a r a c t e r i s e d  by 
methods using s trong  o x id is in g  agents such as hydrogen perox ide  
(Rudiger, 1968). Th is  tyg e o f  o x id a t io n  produced fragments o f  
the  haem r in g  bu t th e re  i s  no ev idence to  co n f irm  th a t  t h i s  is  
comparable to  the p h y s io lo g ic a l  system o f  breakdown.
1.3 REGULATION OF THE HAEM METABOLIC PATHWAY
P roduc t ion  o f  haem i s  re g u la te d  m a in ly  by the  i n t r a c e l l u l a r  
l e v e l s  o f  haem i t s e l f  (G ra n ic k ,  1966; M a rv e r  e t  a l ,  1966; 
Marver e t  a l ,  1968). The presence o f  haem r e s u l t s  in  n e g a t ive  
feedback on the  f i r s t  enzyme o f  the b io s y n th e t ic  pathway, ALA- 
s y n th a s e ,  t o  reduce  th e  r a t e  o f  haem s y n th e s is .  A t  th e  same 
t im e  haem in d u c e s  th e  haem oxygenase  sys tem  so in c r e a s in g  
breakdown. S im u lta ne o us ly  p ro d u c t io n  o f  the p r o te in  m o lecu les  
w h ic h  com bine w i t h  haem such as th e  c y t .  P450 a p o p r o te in  o r  
g l o b i n ,  i s  s t im u la t e d .  C o n v e rs e ly  haem d e f i c i e n c y  le a d s  to  
s t i m u l a t i o n  o f  haem p r o d u c t io n  w h i l e  i n h i b i t i n g  breakdown by 
n e g a t i v e  fe e d b a ck  ty p e  mechanism. The f in e  ba lance achieved 
between these processes e f f i c i e n t l y  r e g u la t e s  haem p r o d u c t io n  
and p r e v e n t s  a c c u m u la t io n  o r  d e f i c i e n c y  o f  haem under no rm a l 
c ircum stances.
T h is  mechanism has been w e l l  c h a r a c t e r i s e d  in  th e  l i v e r .  
Th is  t is s u e  is  the main s i t e  o f  haem p ro d u c t io n  fo r  haemoprotein 
fo rm a t io n  and accounts fo r  fo rm a tion  o f  more than 15% o f  t o t a l  
body haem. In  the e r y th r o id  t is s u e  where the  la r g e s t  p ro po r­
t i o n  o f  body haem (a round  80%) i s  fo rm ed , th e  s i t u a t i o n  i s  n o t  
as w e l l  d e f in e d ,  m a in ly  due to  th e  d i f f i c u l t y  i n  o b t a in in g  
s u f f i c i e n t  amounts o f  t is s u e  fo r  s tudy.
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A LA -syn th a se  possesses  c h a r a c t e r i s t i c s  o f  a r e g u l a t o r y  
enzyme. A c t i v i t y  i s  n o rm a l ly  v e ry  low, b u t  can be a f fe c te d  by 
requ irem ent fo r  the end p roduc t o f  the pathway, haem. Turnover 
i s  more r a p id  th a n  t h a t  of: most o th e r  m i t o c h o n d r ia l  p r o t e i n s  
( B e a t t ie  & S t ru c h e l ,  1970).
The bes t known r o le  o f  haem, th a t  o f  oxygen t r a n s p o r ta t io n ,  i s  
c a r r i e d  o u t  by h a e m o g lo b in  in  the  red  c e l l s  and t h i s  ha era i s  
formed in  the bone marrow. Hepatic  haem becomes in co rpo ra te d  
i n t o  h a e m o p ro te in s  such as c a t a l a s e ,  t r y p to p h a n  p y r r o l a s e ,  
cytochrome b5 and the major one, cytochrome P450. M u l t i p l e  forms 
o f  c y t .  P450 e x i s t ,  u n s u r p r i s i n g  because o f  th e  v a r ie d  r o l e  o f  
th e  cy toch rom e  in  d ru g  n e t a t o l i s m .  C y t.  P450 i s  r e s p o n s ib le  
f o r  d e t o x i f i c a t i o n  o f  x e n o b i o t i c s  r a n g in g  f r o m  d r u g s  t o  
e n v i r o n m e n ta l  p o l l u t a n t s ,  w h ich  w ou ld  be h a r m fu l  to  th e  body 
under p ro longed exposure. Some n a t u r a l l y  o c c u r r i n g  s t e r o i d s  
a re  a l s o  m e ta b o l is e d  by t h i s  system . The cy to ch ro m e  P450 
sys tem  has an e x t r a o r d in a r y  a b i l i t y  to  a d a p t  and r e a c t  w i t h  a 
huge v a r ie t y  o f  drugs and chem ica ls  even on f i r s t  exposure. On 
e x p o s u re  c y t .  P450 c o n te n t  in c re a s e s  r e s u l t i n g  i n  a h ig h e r  
p ro p o r t io n  o f  new ly syn thes ised  haem being in co rpo ra te d  in to  the  
cy to ch ro m e . To p r e v e n t  haem d e f i c i e n c y ,  b io s y n t h e s i s  i s  
s t im u la t e d .  Thus i n  h e m a t ic  t i s s u e  th e  haem b i o s y n t h e t i c  
pathway is  f i n e l y  tuned to  accomodate increased requ irem ent f o r  
haem.
Erythroid tissue however has little of the ability of 
biotransformation present in liver since the majority of haem 
produced is for incorporation into haemoglobin. In contrast to
23
the  l i v e r  increased requirem ent fo r  haem tends to  be met by an 
in c re a s e d  r a t e  o f  c e l l u l a r  d i f f e r e n t i a t i o n ,  p ro d u c in g  more 
c e l l s .
I t  i s  c l e a r  t h a t  s tu d y  o f  th e se  t i s s u e s  has r e v e a le d  
fu n d a m e n ta l  d i f f e r e n c e s  i n  the  c o n t r o l  o f  haem b io s y n t h e s i s .  
In  s u p p o r t  o f  t h i s  r e c e n t  g e n e t i c  e v id e n c e  has shown t h a t  
g e n e t i c  sequences w h ich  p roduce  h e p a t i c  and e r y t h r o i d  ALA- 
s y n th a s e  a re  coded f o r  by s e p a ra te  genes ( R id d le  e t  a l ,  19B9) 
w i t h  th e  e r y t h r o i d  fo rm  h i g h l y  s p e c i f i c  to  t h i s  t i s s u e .  The 
genes f o r  the  two d i f f e r e n t  is o fo r m s  a re  lo c a te d  on d i f f e r e n t  
chromosomes (Bishop e t  a l ,  1990). D if fe re n c e s  in  haem b io syn th e ­
t i c  c o n t r o l  w i l l  now be considered in  more d e t a i l .
1.3.1 Control in the Hepatocyte
AIA-synthase possesses c h a r a c te r is t i c s  o f  a re g u la to r y  enzyme 
and, as w i l l  now be d iscussed, much ev idence  suppo rts  the  the o ry  
o f  t h i s  enzyme as th e  r a t e  c o n t r o l l i n g  enzyme in  l i v e r  c e l l s .  
The v e r y  lo w  a c t i v i t y  o f  h e p a t i c  A L A -syn th ase  i s  s t i l l  
s u f f i c i e n t  to  m a in ta in  adequate p ro d u c t io n  o f  haem under normal 
c i r c u m s ta n c e s ,  how ever in c re a s e d  haem re q u i r e m e n t  t r i g g e r s  
i n d u c t i o n  o f  th e  enzyme. T h is  u l t i m a t e l y  le a d s  to  miore haem 
b e in g  p ro d u c e d ,  s in c e  th e  in t e r m e d ia t e  enzymes o f  th e  pathway 
are n o rm a l ly  p resen t in  excess. The mechanism o f  in d u c t io n  i s  
v i a  de novo  s y n th e s is  o f  A L A -syn th a se  (G ra n ic k  & G ra ta ,  1963). 
The t r i g g e r  f o r  i n d u c t i o n  i s  th o u g h t  to  be a d e p l e t i o n  o f  th e  
end p ro d u c t  o f  th e  pa thw a y , haem. T h is  i s  u s u a l l y  caused by 
g re a te r  than normal demands fo r  the f i n a l  haemoprotein p ro du c t,  
m a in ly  c y t .  P450.
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P ro d u c t io n  o f  c y t .  P450 in c r e a s e s ,  so u s in g  more haem, on 
expo su re  to  a w ide  range o f  s u b s ta n c e s  some o f  w h ich  have
already been mentioned. Several mechanisms by which haem
causes ALA-synthase induction and regulates its own synthesis
have been proposed. These all rely on the existence of free
haem p o o ls  which appear to  c o n s is t  o f  so f a r  unmeasured, s m a l l
amounts of haem. The sources of the free haem pools are
thought to  be new ly syn thes ised  haem be fo re  in c o rp o ra t io n  in to
h a e n io p ro te in  and haem s p l i t  f rom  h a e m o p ro te in  s o u rc e s  b e fo r e
breakdown (Granick & Sassa, 1971; Yannoni & Robinson, 1975;
Grandchamp et al , 1981). It is assumed the free haem pools
e x i s t  i n  a l l  s u b c e l l u l a r  f r a c t i o n s  o f  th e  c e l l  so t h a t  an
e q u i l i b r iu m  e x is t s  between m ito c h o n d r ia l  endoplasmic re t ic u lu m
and c y t o s o l i c  f r e e  haem in  th e  p o o l  s i m i l a r  t o  th e  s i t u a t i o n
shown in  F igu re  13. Th is  haem is  assumed to  tu r n  ove r r a p id l y .
The p o s s i b l e  mechanisms by w h ic h  haem may r e g u la t e  i t s  own
s y n th e s is  f o l l o w .
Possible Mechanisms of End Product Regulation
a) Haem produced may directly inhibit the activity of ALA-
synthase .
b) Haem may repress translation of the messenger RNA (mRNA)
coding f o r  the  enzyme.
c) Haem may have  an a d v e rs e  e f f e c t  on t r a n s c r i p t i o n  th u s  
decreas ing  a v a i l a b i l i t y  o f  mRNA coding f o r  ALA-synthase.
d) Haem may i n h i b i t  t r a n s l o c a t i o n  o f  th e  m a tu re  enzyme to  
m ito ch o n d r ia .
I t  has been repo r ted  th a t  haemin d i r e c t l y  i n h i b i t s  the enzyme 
(A ok i e t  a l ,  1971) c o n s i s t e n t  w i t h  a ) ,  b u t  s t u d ie s  w i t h  
exogenous haemin have shown t h a t  A L A -s y n th a s e  a c t i v i t y  i s
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FIGURE 13 : INTERRELATIONSHIP OF THE FREE HAEM POOL IN 
CONTROL OF HAEM BIOSYNTHESIS
supressed a t  haem co n c e n tra t io n s  fa r  te lo w  those which would be 
n e c e s s a ry  f o r  a d i r e c t  e f f e c t  when c a l c u l a t e d  f ro m  th e  
co ns ta n t o f  1-2 x 10“ ^ ( S in c la i r  & G ran ick , 1976; S r iv a s ta v a  e t  
a l ,  1980). Haem l e v e l s  in  the m itochond r ia  d id  no t appear to  
be h ig h  enough t o  i n h i b i t  enzyme a c t i v i t y  d i r e c t l y  b u t  m ig h t  
r e s u l t  i n  i n h i b i t i o n  o f  s y n th e s is  o f  A LA -syn th ase  (W o lfso n  e t  
a l ,  1979). T h is  i s  one a rea  w h ich  m e r i t s  f u r t h e r  s tu d y .  I t
has been shown t h a t  haem re p re s s e s  t r a n s l a t i o n  o f  th e  mRNA o f  
A L A -syn th a se  ( T y r e l l  & L a r k s ,  1972) and t h a t  t r a n s c r i p t i o n  i s  
abnormal (W hit ing , 1976). Thus i t  appears t h a t  a com bina tion  
o f  v a r io u s  e f f e c t s  o f  haem, r e s u l t  in  the  c o n t r o l  o f  ALA-synthase 
a c t i v i t y .  In d u c t io n  o f  ALA-synthase i s  m o d if ied  by v a r io u s
fa c to r s .  In  c h ic k  embryo hepatocytes c u l tu r e d  under c o n t r o l le d  
c o n d i t io n s ,  i n s u l i n  i s  req u ire d  f o r  in d u c t io n  ( S in c la i r  e t  a l ,  
1979). The p re sen ce  o f  g l u c o c o r t i c o i d s  i s  c o n d u c iv e  to  ALA- 
synthase in d u c t io n .  H a rvc r  and o th e rs  showed th a t  in d u c t io n  o f  
A L A -syn th a se  i s  le s s  marked in  adrena lec tom ised  ra ts  a l tho u gh  
these compounds do no t by them se lves e x e r t  an induc ing  e f f e c t .  
Th is  e f f e c t  has been shown to  d i r e c t l y  in v o lv e  the l i v e r  (Bock 
e t  a l ,  1971). In  r a t s  and o th e r  mammals, d i e t  i s  an im p o r t a n t  
f a c to r  w i th  a la rg e  i n t a k e  o f  g lucose  and p r o te in  rep ress ing  
in d u c t io n .  In  c o n t ra s t  f a s t in g  enhances the in d u c t io n  o f  ALA- 
synthase .
The rate limiting reaction of haem biosynthesis can also be 
controlled by other factors. Concentration of both substrates 
must be in excess for the reaction to proceed and haem biosyn­
thesis has been controlled by limiting the amount of glycine
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available under experimental conditions. Similarly absence of 
pyridoxal phosphate, an essential cofactor to the enzyme 
activity, prevents ALA formation and so results in haem 
deficiency.
1.3.2 Cbntrol in Erythroid Tissue
V?here regulation of hepatic haem biosynthesis has many well 
defined aspects, the situation in the erythroid tissue is much 
less clear. This has been largely due to the difficulty in 
obtaining sufficient numbers of mammalian cells for study. 
Early work using chick blastoderm led to the belief that regula­
tion of the pathway was by a similar mechanism to that in liver 
(Levere & Granick, 1967). Subsequently virtually all recent 
studies have used cell culture techniques to observe the haem 
biosynthetic pathway and the results obtained present a more 
complex picture than that of hepatic control. Studies using 
erythroleukemic cell cultures of murine and human origin and 
normal bone marrow colonies np vitro suggest that regulation of 
the pathway in erythroid tissue is not through feedback control 
on ALA-synthase activity. It has been shown that dimethyl- 
sulphoxide (DLSC) administration leads to increases in ALA- 
synthase activity, globin, mRNA, ALA.-D, PBG-D, and consequently 
results in increased production of haemi in the T3-C1-2 clone of 
Friend cells (Ross et al, 1972; Sassa, 1976). A similar 
pattern has been observed in other clones of Friend cells 
(Sassa, 1980; Rutherford et al, 1979). Certainly it appears 
that ALA-synthase alone is not the rate limiting enzyme for 
formation of haem in erythroid cells. In fact evidence
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s u g g e s ts  t h a t  f e r r o c h e la t a s e  may be more im p o rta n t  in  c o n t r o l  
s ince  the increased l e v e l s  o f  haem observed above occur o n ly  
a f t e r  a c t i v i t y  o f  f e r r o c h e la t a s e  i s  r a is e d .  In  a d d i t i o n ,  i n  
c o n t ra s t  to  the s i t u a t io n  in  the l i v e r  i t  has been reported  th a t  
a d m in is t r a t io n  o f  hemin leads  to  increased ALA-synthase a c t i v i t y  
i n  e r y t h r o i d  t i s s u e  (Hoffm an, 1980). Thus th e  s i t u a t i o n  i n  
e r y t h r o i d  t i s s u e  i s  v e r y  d i f f e r e n t  t o  t h a t  i n  l i v e r  w i t h  
i n d u c t i o n  o f  a l l  enzymes in  th e  pathway o c c u r r in g  b e fo r e  more 
haem i s  produced. The l i k e l y  r o le  o f  fe r ro c h e la ta s e  as a ra te  
c o n t r o l l i n g  enzyme a l s o  d e m o n s t ra te s  th e  d i f f e r e n c e s  in  th e  
mechanism o f  c o n t r o l  o f  haem b io s y n t h e s i s  i n  t h i s  t i s s u e  when 
compared to  the l i v e r .
F u r th e r  e v id e n c e  o f  t i s s u e  s p e c i f i c  r e g u l a t i o n  has been 
obta ined  from murine Harderian g land  (M a rg o l is ,  1971), ca rd ia c  
t is s u e  (B riggs e t  a l ,  1976) and lymphocytes and s k in  f i b r o b la s t s  
o f  p a t ie n ts  w i th  acute i n t e r m i t t e n t  p o rp h y r ia  (Bonkowsky e t  a l ,  
1975).
1.4 THE PORPHYRIAS
The e ig h t  s te p s  o f  th e  pathway o f  haem b io s y n t h e s i s  have 
a lre a d y  been d iscussed. A b n o rm a l i t ie s  co u ld  c o n c e iv ib ly  occur 
a t  any o f  th e s e  s ta g e s ,  r e s u l t i n g  in  d is e a s e .  P o r p h y r ia  i s  a 
gene ra l term encompassing s e v e ra l  d i s t i n c t  d iseases o f  p o rp h y r in  
m etabo lism , u s u a l l y  due to  a h e re d i ta ry  enzymatic d e fe c t  a t  som.e 
stage in  the  pathway o f  haem b io s y n th e s is .  When the  c l i n i c a l  
symptoms and b iochem ica l d e fe c ts  are cons ide red, the  p o rp h y r ia s  
are c l a s s i f i e d  as e i t h e r  acute o r non-acute. A l t e r n a t i v e l y  the  
p o rp h y r ia s  can be c l a s s i f i e d  accord ing  to  the  t is s u e  o f  o r i g i n
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o f  the  enzymatic d e fe c t  thus d e f in in g  them as e i t h e r  h e p a t ic  or 
e r y th r o p o ie t i c .  In  a d d i t io n  c e r t a in  p o rph y r ia s  can be acqu ired . 
A number o f  endogenous and exogenous f a c t o r s  may r e s u l t  i n  
d is tu rba n ces  in  p o rp h y r in  m etabo lism  and these are more f u l l y  
d is c u s s e d  in  s e c t io n  1.4.3.
1.4.1 The Acute Porphyrias
As the t i t l e  suggests each o f  these p o rp h y r ia s  are charac te ­
r is e d  by the occurrence o f  an acute a t ta c k  fo l lo w e d  by a p e r iod  
o f  r e m is s io n .  The a t t a c k s  a re  o f  v a r i a b l e  l e n g t h  and a re  
u s u a l l y  p r e c ip i ta te d  by exogenous fa c to r s  such as drugs. L inks 
have  a ls o  been made w i t h  endogenous compounds such as s t e r o i d  
hormones. D is c r e t e  ty p e s  o f  compounds can cause an a c u te  
p o r p h y r i c  a t t a c k .  The th r e e  most common d is e a s e s ,  a c u te
in t e r m i t t e n t  p o rp h y r ia  ( A l l ) ,  h e re d i ta ry  co p ropo rphy r ia  (HC) and 
v a r ie g a t e  p o r p h y r ia  (VP) a l l  r e s u l t  in  o v e r p r o d u c t i o n  o f  th e  
e a r l y  haem p re cu rso rs  ALA and PBC. In  PC and VP o v e rp ro d u c t io n  
o f  p re cu rso rs  formed l a t e r  in  the pathway occurs and o f te n  leads  
to  cutaneous le s io n s .
In  a t ta c k  p a t ie n ts  s u f fe r  c l i n i c a l  symptoms in c lu d in g  abdomi­
n a l  p a in ,  p e r i p h e r a l  n e u ro p a th y  and a u to n o m ic  n e u ro p a th y .  
P h o t o s e n s i t i v i t y  can d e v e lo p  in  HC and VP, due to  th e  o v e r ­
p ro d u c t io n  o f  po rph y r in s .
AIP i s  th e  commonest fo rm  o f  a c u te  p o r p h y r ia  w i t h  th e  
a c t i v i t y  o f  PDG-D, th e  enzyme r e s p o n s ib le  f o r  c o n d e n s in g  PBG 
m o le cu le s ,  reduced to  around 50% o f  normal l e v e l s  (Meyer e t  a l ,  
1972). Th is  re d u c t io n  in  a c t i v i t y  has been observed th roughou t 
th e  body i n  l i v e r ,  e r y t h r o c y t e s ,  c u l t u r e d  s k in  f i b r o b l a s t s ,
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c u l t u r e d  a n in io t ic  c e l l s  and ly m p h o c y te s  (M oore e t  a l , 1987). 
L e s p ite  the  enzyme o e f ic ie n c y  being conmonly id e n t i f ie d  in  n.any 
fa m ily  members o f  s u ffe re rs  o n ly  a s m a ll f r a c t io n  o f h e te ro zy ­
gous p a t ie n ts  p re s e n t  w i th  c l i n i c a l  symptoms o f  th e  d is e a s e . 
The re m a in d e r, a round 90%, a re  d e s c r ib e d  as la t e n t  cases . 
A tta c k s  o f AIP occur a f te r  p ub e rty  and are more conmon in  women 
th a n  men. T h is  has su gg e s te d  a l i n k  w ith  th e  sex hormones 
(Kappas e t  a l ,  1932). In  h e r e d i ta r y  c o p ro p o rp h y r ia  (HC)
COPRO-C a c t i v i t y  is  lo w e r th a n  n o rm a l and t h i s  has been 
dem onstrated in  le u k o c y te s , c u ltu re d  s k in  f ib r o b la s t s ,  lympho­
c y te s  and h e p a t ic  b io p s ie s  (B ro d ie  e t  a l ,  1977b; E ld e r  e t  a l ,  
1976; Grandchamp & Pordmann, 1971; Hawk e t  a l ,  1978). Homozy­
gous s u f fe re rs  have been id e n t i f ie d  w ith  v i r t u a l l y  no COPRO-O 
a c t i v i t y  and th e se  p a t ie n t s  d is p la y  v e ry  s e v e re  c l i n i c a l  
symptoms (Grandchamp e t  a l ,  1977; 1980). In  v a r ie g a te
p o r p h y r ia  th e re  has been c o n t r o v e r s y  as to  th e  s o u rc e  o f  th e  
enzyme d e fe c t w ith  both  ptOTC-O and fe r ro c h e la ta s e  im p lic a te d . 
In  e r y t h r o id  c e l l s  and f i b r o b la s t s  o f  some VP p a t ie n ts  50% o f  
norm al fe r ro c h e la ta s e  a c t i v i t y  has been recorded ( V i l jo e n  e t  a l ,  
1979) In  c o n t r a s t  n o rm a l a c t i v i t y  has been o b s e rv e d  by o th e r  
g ro u p s  (S ie p k e r & K ram er, 1985 ), and r e p o r ts  have  d e s c r ib e d  a 
s im i la r  percentage re d u c tio n  in  PROTO-oxidase a c t i v i t y  (Brenner 
& B loom er, 1980; Deybach e t  a l ,  1981). P a tie n ts  w ith  v i r t u a l l y  
no PROTO-oxidase e x is t  su p p o rtin g  the  th e o ry  th a t  the d e fe c t is  
in  th e  p e n u lt im a te  enzyme o f  th e  pa thw ay (Kordac e t  a l  , 1984; 
Murphy e t  a l ,  1986). B io c h e m ic a lly  h ig h  amounts o f  p ro to p o rph y­
r i n  a re  e x c re te d  in  th e  s t o o l  o f  th e s e  p a t ie n ts  and t h i s  is  
o f t e n  accom panied by a s l i g h t  in c re a s e  in  c o p ro p o rp h y r in
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e x c r e t io n .  C l i n i c a l  symptoms o f  an a t ta c k  o f  a c u te  p o r p h y r ia  
in c lu d e  severe  abdom inal p a in , p e r ip h e ra l neuropathy and autono­
m ic neuropathy. A d d i t io n a l ly  in  11C and VP cutaneous le s io n s  
o f te n  d e v e lo p .  T h is  i s  th o u g h t to  be due to  p o r p h y r in  
d e p o s it io n  near the  su rfa ce  o f  the  sk in . The p h o to s e n s it iv i ty  
which sometimes d e ve lo p s  i n t e n s i f i e s  on e xpo su re  to  s u n l ig h t .  
E x a c e rb a tio n  o f  th e  c l i n i c a l  symptoms o c c u rs  as th e  n e g a t iv e  
feedback n o rm a lly  opera ted b> haeiii on ALA-synthase a c t i v i t y  is  
a b s e n t. The r e s u l t i n g  in c re a s e  in  A L A -syn th a se  a c t i v i t y  
in te n s i f ie s  the  b u i ld -u p  o f ALA, PEG and porphyrinogens.
More re c e n t ly  a d e f ic ie n c y  in  ALA-D has been id e n t i f ie d  in  a 
s m a ll  number o f  cases (B ird  e t  a l ,  1979; Doss e t  a l ,  1979). 
Symptoins a re  id e n t i c a l  to  th o s e  seen in  A IP  w ith  e x te n s iv e  
p e r ip h e ra l and c e n t ra l nervous system neuropathy w ith o u t photo­
s e n s i t i v i t y  (Brandt & Doss, 1981). The s t ru c tu re  o f  the enzyme 
is  known to  be abnormal (be V e rn e u il e t  a l ,  1985) w ith  a c t i v i t y  
o f  a round  50% n o rm a l in  h e te ro z y g o te s  and a lm o s t a b s e n t in  
homozygotes. T h is  c o n d it io n  has been termed p lum boporphyria .
G e n e t ic a l ly  th e  enzyme d e f ic ie n c ie s  w h ich  p ro du ce  a c u te  
p o r p h y r ia  a re  t r a n s m it te d  in  a u to s o m a l d o m in a n t fa s h io n .  
I n v e s t ig a t io n s  in t o  HC p a t ie n ts  have  showed a m iutant gene 
p ro d u c t e x is ts  and th is  is  though t to  have v i r t u a l l y  no a c t i v i t y  
(Grandchamp & Mordmann, 1977).
A l l  d iagnosed p o rp h y rie s  are adv ised  to  a vo id  a la rg e  number 
o f th e ra p e u tic  drugs s in ce  a d m iin is tra tio n  o fte n  p re c ip i ta te s  an 
a t ta c k .  In  a d d i t io n  th e  l i n k  o f  th e  d is e a s e  to  sex horm ones is  
s treng thened  by imany women s u f fe re rs  hav ing  a tta c k s  a t  c e r ta in
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stages of the menstrual cycle. From human and animal evidence 
a drug list of recommended safe drugs and drugs most commonly 
producing attack (unsafe drugs) has been compiled (Moore & 
McColl, 1988). Ifiis publication also lists drugs which have 
been shown to be safe for administration to porphyric patients.
1.4.2 The Non-Acute porphyrias
Three separate diseases are known as the non-acute 
porphyrias. These are cutaneous hepatic porphyria (CHP) also 
known as porphyria cutanea tarda, erythropoietic protoporphyria 
(EPP) and congenital erythropoietic porphyria (CP). Generally 
these diseases have more serious consequences for the patients 
with the condition gradually worsening with increasing age.
PCT or cutaneous hepatic porphyria exists in two forms. In 
both, activity of URO-D is reduced. In congenital PCT reduced 
activity is seen in the liver (Kushner et al, 1976), erythro­
cytes and skin fibroblasts (Felsher et al, 1978). In these 
fairly rare cases the reduced activity is thought to result from 
an alteration to enzyme structure leading to decreased substrate 
affinity. Higher susceptibility to Fe^+ inhibition has also 
been shown (Mukerji et al, 1985). The more common form of the 
diseaseis acquired in later life by patients who have no family 
history of porphyria. Alcoholic liver disease is prevalent among 
these patients, but the condition has also been linked with 
states of iron overload and the contraceptive pill, unlike the 
familial form hepatic URO-D activity alone is reduced. A small 
number of cases of CHP are a direct result of exposure to 
polyhalogenated hydrocarbons, for example hexachlorobenzene but
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l i t t l e  in fo r m a t io n  is  a v a i la b le  on enzyme a c t i v i t i e s  in  
s u f fe re rs .  L iv e r  d y s fu n c tio n  is  seen in  most p a t ie n ts  b u t i t  
is  u n c le a r whether th is  is  due to  an u n d e r ly in g  m e ta b o lic  d e fe c t 
o r s im p ly  a r e s u l t  o f  th e  a q u ire d  fa c to r s  w h ich  r e s u l t e d  in  
p ro d u c tio n  o f  the  d isease  (Topi & D 'A lessandro , 1976).
E ry th ro p o ie t ic  p ro to p o rp h y r ia  (EPL) is  an in h e r ite d  p o rp h y r ia  
w here fe r r o c h e la ta s e  a c t i v i t y  is  reduced  to  le s s  th a n  50% o f  
norm al. E ry th ro c y t ic  p ro to p o rp h y r in  is  g r e a t ly  increased and 
th e re  is  increased e x c re tio n  in  faeces. EPP a ls o  has a h e p a tic  
com ponent (Gray e t  a l ,  1964; Carnes e t  a l ,  1968) e s p e c ia l l y  in  
la t e r  ye a rs , when b u i ld -u p  o f  p ro to p o rp h y r in  in  t h is  t is s u e  and 
th e  h e p a t o b i l ia r y  sys tem  can le a d  to  d y s fu n c t io n  w h ic h  may be 
f a t a l  (P o h -F itz p a tr ic k , 1985). Most o f the  excess p ro to p o rph y­
r i n  i s  p ro b a b ly  d e r iv e d  fro m  bone m arrow  e r y t h r o b la s t s  and 
h e p a to c y te s  (Gray e t  a l  , 1964) w ith  a s m a ll  c o n t r ib u t io n  fro m  
o th e r t is s u e s .
C o n ge n ita l p o rp h y r ia  (CP) or G unther's d isease  is  the  ra re s t  
type o f  p o rp h y r ia  and has a severe  p ro g n o s is , w ith  no p a t ie n ts  
s u r v iv in g  m id d le  age and a h ig h  d e a th  r a te  in  e a r ly  l i f e .  
E nzym a tic  d e fe c ts  o c c u r p r im a r i l y  in  UEO'gen 111 c o s y n th a s e  
(Romeo & L e v in , 1969; Moore e t  a l ,  1978) and le a d in g  to  produc­
t io n  o f  h ig h  am ounts (g re a te r  th a n  80%) o f  s e r ie s  I  t o t a l  
p o rp h y rin s  which can proceed no fu r th e r  in  the  pathway and are 
excre ted  in  u r in e . Faecal p o rp h y r in  e x c re tio n  is  a ls o  increased 
and in c re a s e d  a c t i v i t y  o f  PBG deam inase has been re p o r te d  
(Nordmann & Deybach, 198 2). URO-decarboxylase a c t i v i t y  is  a ls o  
d im in is h e d  (E o fs ta d  e t  a l ,  1973). The e x c r e to r y  p a t te r n  o f  
p o r p h y r in s  can be e x p la in e d  by any o f  th e  above h y p o th e s e s .
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O bse rva tio n  o f e ry th ro b la s ts  in  the  tone marrow showed apparen­
t l y  two d is t in c t  types o f  c e l l ,  one o f  which f lu o re s c e d  s t ro n g ly  
under UV l i g h t ,  the o th e r being normal in  appearance (Schmid e t  
a l ,  1 9 5 4 ). H o w e ve r m ore  r e c e n t  w o rk  s u g g e s ts  t h a t  a l l  
d e v e lo p in g  e ry th ro b la s ts  c a rry  the a l l e l e  fo r  CP and f lu o re s c e n ­
ce is  more e a s i ly  de tec ted  in  sone c e l l s  than o th e rs .
P a t ie n ts  who have  n o n -a c u te  p o r p h y r ia  a l l  s u f f e r  fro m  
v a ry in g  degrees o f p h o to s e n s it iv i t y ,  caused by accum u la tio n  o f  
th e  l a t e r  in te r m e d ia te s  o f  haem b io s y n th e s is .  In  a l l  cases 
e x c re tio n  o f  ALA and PPG remains v i r t u a l l y  norm al. The absence 
o f  p s y c h ia t r ic  symptoms le n d s  s u p p o r t  to  th e  th e o ry  t h a t  
a c c u m u la t io n  o f  th e s e  e a r ly  p re c u rs o rs  o f  th e  pa thw ay is  
in v o lv e d  h e re . PCT g e n e r a l ly  d e v e lo p s  l a t e r  in  l i f e  and th e  
m ain c l i n i c a l  symptom is  in c re a s e d  s k in  f r a g i l i t y ,  w i t h  s k in  
le s io n s  o c c u rr in g  on l i g h t  exposed areas which are  loaded w ith  
p o rp h y r in . EPP p a t ie n ts  expe rie n ce  in te n s e  b u rn in g  s e n s a t io n s  
on exposure to  s u n l ig h t  from an e a r ly  age, and s c a rr in g  q u ic k ly  
occurs. In  la t e r  years , s k in  th ic k e n s  and ages p re m a tu re ly  and 
changes in  te x tu r e  o f  s k in  (o range  p e e l)  is  o c c a s io n a l ly  
o b s e rv e d . In  l a t e r  y e a rs  b u i ld - u p  o f  PROTO in  th e  l i v e r  and 
h e p a to b il ia ry  system: can lead  to  d y s fu n c tio n  which may be f a t a l  
( P o h - F i t z p a t r ic k ,  1985). The m ost s e v e re  p h o t o s e n s i t i v i t y  
re a c tio n s  are  seen in  CP w ith  exposure to  l i g h t  causing  d e v e lo p  
ment o f la rg e  b l i s t e r s  which can b u rs t and u lc e ra te  le a d in g  to  
se co n d a ry  in f e c t io n .  S c a r r in g  is  w id e s p re a d  on exposed s k in  
and o f te n  appendages becorre de fo rm ed  o r even  l o s t  in  l a t e r  
stages o f  the  d isease . H aem olytic  anaemia is  u s u a l ly  p re sen t
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and s p le n o m e g a ly  r e s u l t s  from  th e  need to  r i d  th e  body o f  th e  
h ig h  p ro p o r t io n  o f abnormal red c e l l s .
1.4.3 Experimental Porphyria
As has a lre a d y  been d iscussed in  s e c tio n  1.4 p o rp h y ria  can be 
induced in  man when c e r ta in  drugs a re  a dm in is te re d . S im i la r ly ,  
in d u c t io n  can occur in  o th e r an im a ls  and e xpe rim en ta l p o rp h y r ia  
in  the  roden t has p ro v id e d  an e x tre m e ly  u s e fu l an im al model fo r  
th e  s tu d y  o f  d is tu rb a n c e s  in  haem b io s y n th e s is  (S m ith  & be 
M a t te is ,  19C0). In  n o n - s u s c e p t ib le  humans i .e .  th o s e  w ith  
homozygous n o rm a l genes, and n o r ira l r a t s  th e re  a re  v e ry  few  
c la s s e s  o f drug which cause p o rp h y r ia -1 ik e  symptoms, namely some 
d e r iv a t iv e s  o f branched a l ip h a t ic  acetain ide o r b a rb itu ra te  e.g. 
2 -a l l y  1 -2 - is o p ro p y l ace tamiide (AIA) (Goldberg & R im ington, 1955), 
o r 5 , 5 - d ia l l y lb a r b i t u r i c  a c id  re s p e c t iv e ly ,  DDC o r g r is e o fu lv in ,  
o r re la te d  chem ica ls  (De M a tte is , 1978). W ith in  a few hours o f 
a d m in is tra t io n ,  p o rp h y r in  p re cu rso rs  are  excre ted  in  excess in  a 
p a t te r n  d ep e n d a n t on th e  d ru g  used. On t re a tm e n t  w i th  A IA , 
A L A -syn th a se  a c t i v i t y  i s  in d u c e d , a m ix tu re  o f  p o r p h y r in s  a re  
produced and the l i v e r  assumes a g re e n ish  t in g e . In  the  l i v e r
AIA i n i t i a l l y  s t im u la te s  fo rm a tio n  o f c y t .  P450. O x id a tio n  o f
th e  d ru g  by th e  c y t .  P450 sys tem  th e n  le a d s  to  d e s t r u c t io n  o f  
the  p ro te in  (O r t iz  de M o n te lla n o  & C o rre ia , 1983). Thus haem 
c o n te n t is  fu r th e r  reduced and the pathway is  a c c e le ra te d  to  t r y  
and compensate. T h is  com bina tion  has been proposed as a g e n e ra l 
m echanism o f  a c t io n  f o r  a l 1 y 1 - c o n ta in in g  d ru g s  w h ich  in d u c e  
p o rp h y r ia  (Moore e t  a l ,  1987).
M e tabo lism  o f DDC by the l i v e r  produces a m e ta b o lite  which
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s t r o n g ly  i n h i b i t s  f e r r o c h e la ta s e  (Le M a t te is  e t  a l ,  1900a, 
1980b, 1900c). T h is  a n a lo g u e  o f  p r o to p o r p h y r in ,  N -m e th y l 
p ro to p o rp h y r in  IX is  formed as p a r t  o f the  s u ic id e  in a c t iv a t io n  
o f DDC by c y t .  F450 and r e s u lts  in  a b lo c k  o f  the pathway.
As has a lre a d y  been d iscussed , ha logenated hydrocarbons cause 
a to x ic  form  o f  cutaneous p o rp h y ria  in  humans and th is  c o n d it io n  
can be reproduced in  ra ts  by adding hexachlorobenzene (IICB) to  
the  d ie t  (Salamanca & Salamanca, 1986) a lth o u g h  the mechanism o f 
a c t io n  o f p ro d u c tio n  o f  the p o rp h y r ia  is  u n c e rta in .
1.5 DISORDERS OF HAEM DEGRADATION
The breakdow n pathw ay o f  haem in v o lv e s  o n ly  two in te rm e ­
d ia te s ,  b i l i v e r d i n  ana b i l i r u b i n  and has been d is c u s s e d  in  
s e c t io n  1.2. G e n e r a l ly  mammal ia n  d isease  s ta te s  in v o lv e  the  
end p ro d u c t o f  the  pathway, b i l i r u b in .  Of the  t o t a l  b i l i r u b in  
formed th re e  q u a rte rs  r e s u lts  from breakdown o f  haem oglobin and 
th e  re m a in d e r fro m  d e g ra d a t io n  o f  o th e r  h a e m o p ro te in s . In  
n a tu re  b i l i r u b i n  i s  u s u a l ly  found  in  th e  IXoc. isom er fo rm , 
however tra c e s  o f  non-«c isomers do e x is t ,  formed by the  a c t io n  
o f  b i l i v e r d in  reductase  on v a r io u s  b i l i v e r d in  isom ers.
C le a ra n c e  o f  b i l i r u b i n  fro m  th e  body by c o n ju g a t io n  w i th  
g lu c u r o n ic  a c id  has a lr e a d y  been d is c u s s e d  in  s e c t io n  1.2 .3 . 
H e re d ita r y  d is o r d e r s  o f  th e  m e ta b o lis m  o f  b i l i r u b i n  le a d  to  
abnormal le v e ls  o f e ith e r  unconjugated o r con juga ted  form s o f 
b i l i r u b i n  and a re  term ed h y p e r b i l i r u b in a e m ia s .  S ta te s  o f  
h y p e r b i l i r u b in a e m ia  may o c c u r a t  any o f  th e  fo u r  s ta g e s  o f  
b i l i r u b in  m etabo lism  which fo l lo w .
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a) u p ta k e  fro m  th e  c i r c u l a t i o n  by th e  h e p a to c y te  may be
im p a ire d .
b) in t r a c e l lu la r  s to rage  may be abnorm al.
c) c o n ju g a tio n  may be im pa ired  o r t o t a l l y  absen t.
d) b i l i a r y  e x c re tio n  may be abnormal
When e i t h e r  a ) ,  b) o r c) o c c u rs  th e  r e s u l t  i s  u n c o n ju g a te d  
h y p e rb iliru b in a e m ia . H e re d ita ry  con juga ted  h y p e rb iliru b in a e m ia  
does o c c u r b u t is  r a re .  Much more common a re  d is o r d e r s  where 
h a e m o ly s is  causes th e  e le v a te d  b i l i r u b i n .  Under th e s e  
c o n d it io n s  b i l i r u b i n  p ro d u c t io n  is  in c re a s e d  b u t t h i s  ty p e  o f  
h y p e r b i l i r u b in a e m ia  is  c o n s id e re d  to  be se co n d a ry  to  o th e r  
d is o rd e rs  and is  d iscussed e lsew here  (Fevery e t  a l ,  1980).
1.5.1 Hereditary Conjugated Hyperbilirubinaemia
The c o n ju g a te d  h y p e r b i1 iru b in a e m ia s  a re  two v e ry  ra re  
in h e r ite d  d iseases. The mechanisms by which the  h y p e r b i l i r u b i ­
naemia occurs are d is t in c t  and are described  below .
Dubin-Johnson Syndrome
Dubin-Johnson syndrome was f i r s t  id e n t i f ie d  in  1954 (Dubin & 
Johnson, 1954) and is  c h a r a c te r is e d  by c h ro n ic  n o n -h a e m o ly t ic  
ja u n d ic e  r e s u l t i n g  from  c o n ju g a te d  h y p e rb iliru b in a e m ia . The 
l i v e r  t is s u e  is  b la c k  in  c o lo u r  due to  a p ig m e n t w h ic h  is  
though t to  be re la te d  to ,  b u t d is t in c t  from , m e lan in  (Sonnet e t  
a l ,  1969; Swartz e t  a l ,  1979). L iv e r  fu n c t io n  is  p re d o m in a n tly  
norm al b u t a n a ly s is  o f  p o rp h y r in  e x c re tio n  in  u r in e  shows th a t  
th e  m a in  c o p ro p o rp h y r in  p ro d u c t  is  th e  s e r ie s  I  iso m e r (o v e r 
80%) in s te a d  o f  th e  s e r ie s  I I I  isom er w h ich  is  o b s e rv e d  in  
norm al u r in e  (Kondo e t  a l ,  1976). Heterozygous Dubin-Johnson
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s u ffe re rs  a ls o  have increased co p ro p o rp h y rin  I  e x c re t io n ,  bu t 
to  a le s s e r  e x te n t  w ith  a round  40% re m a in in g  as th e  s e r ie s  I I I  
isom er (B en-E zze r e t  a l ,  1073) The syndrom e is  in h e r i t e d  as an 
autosom al re c e s s iv e  c h a r a c te r is t ic  (Edwards, 1975).
R o to r1s Syndrome
R o to r 's  syndrom e is  an e x tre m e ly  ra re  fo rm  o f  c o n ju g a te d  
h y p e rb iliru b in a e m ia  w hich was a t  one tim e  though t to  be re la te d  
to  D u b in -Jo h n so n  syndrom e b u t is  now re c o g n is e d  as a d i s t i n c t  
c o n d it io n  (U o lk o ff e t  a l , 1976). In  R o to r's  syndrone t ra n s p o r t  
o f  the  o rg a n ic  an ion  su lp hob rom oph tha le in  (BSP) is  im pa ired  by an 
unknown mechanism and l i v e r  p ig m e n ta t io n  is  n o rm a l. U r in a ry  
COPRO e x c re tio n  is  much h ig he r than norm al and a g re a te r percen­
ta g e  th a n  n o rm a l i s  o f  th e  Type I  isom er ( U o lk o f f  e t  a l ,  1976). 
T h is  inc rease  may w e l l  be e x p la in e d  s im p ly  by reduced b i l i a r y  
e x c r e t io n  o f  COPRO le a d in g  to  in c re a s e d  e x c r e t io n  o f  COPRO by 
th e  k idney .
1.5.2 Unconjugated Hyperbilirubinaemia
The term  unconjugated h y p e rb iliru b in a e m ia  co ve rs  a range o f 
d is e a s e s . Two o f  th e s e , k e r n ic te r u s  and G i lb e r t 's  syndrom e, 
have a f a i r l y  common inc id en ce . Unconjugated h y p e rb il i r u b in a e ­
mia occurs when la rg e  amounts o f f re e  b i l i r u b in  p re se n t in  the  
c i r c u la t io n  are unab le  to  b ind  to  a lbum in . T h is  can be due to  
an in h e r i t e d  c o m p le te  o r p a r t i a l  d e fe c t  in  c o n ju g a t io n  as in  
C r ig le r - N a j ja r  syndrome and G i lb e r t 's  syndrome or to  increased  
p ro d u c t io n  o f  b i l i r u b i n .
Jaundice is  produced and th is  can d e v e lo p  in to  the  p o t e n t ia l l y
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Footnote! One important cause of hyperbilirubinaemia is rhesus 
incompatibility. The jaundice occurs in premature infants and 
is severe.
l i f e  th r e a te n in g  c o n d i t io n  o f  k e r n ic te r u s .  Under n o rm a l 
c irc u m s ta n c e s  b i l i r u b i n  is  t i g h t l y  bound to  a lb u m in  in  th e  
serum . More th a n  one b in d in g  s i t e  on a lb u m in  has been 
i d e n t i f i e d  b u t in  th e  body o n ly  one has h ig h  a f f i n i t y  f o r  
b i l i r u b in .  C onsequently , when the  b i l i r u b in  to  a lbum in  r a t io  
exceeas one, b i l i r u b in  is  a llo w e d  access to  the  body c e l l s  where 
i t  i s  p o t e n t i a l l y  t o x ic .  A n im a l m ode ls  e x is t  f o r  some o f  
th e s e  c o n d it io n s  i .e .  th e  m u ta n t Southdown sheep and th e  Gunn 
r a t .  The Gunn r a t  and i t s  s u i t a b i l i t y  f o r  use as a m odel f o r  
v a r io u s  human u n c o n ju g a te d  h y p e rb i 1 i r u b in a e m ia s  w i l l  be 
cons idered  in  Chapter 4 o f t h is  th e s is .  As an a l t e r n a t iv e  to  
n a tu r a l ly  o c c u rr in g  models which a re  ra re , h y p e rb iliru b in a e m ia  
can be induced in  s itu a t io n s  where b i l i r u b in  is  d is p la c e d  from  
a lbum in . S eve ra l d rugs, in c lu d in g  c e r ta in  sulphonam ides have 
t h is  p ro p e rty . The mechanism by which d isp lace m e n t occurs is  
n o t  th o u g h t to  be v ia  d i r e c t  c o m p e t it io n  f o r  th e  same s i t e .  
In s te a d  i t  ap,pears th a t  by b in d in g  to  a n o th e r s i t e  on "s p a re  
a lb u m in "  th e  d ru g  causes a c o n fo rm a t io n a l change to  o c c u r .  
T h is  c o n fo rm a t io n  is  u n a b le  to  b in d  b i l i r u b i n  and so th e  
c o n c e n tra tio n  o f fre e  b i l i r u b in  in c reases . The re s u lta n t  fre e  
unconjugated b i l i r u b in  is  then fre e  to  d i f fu s e  in to  body c e l l s  
where i t  can e x e r t a to x ic  e f fe c t .
N eonata l K e rn ic te ru s
Dy f a r  th e  most common fo rm  o f  h y p e r b i l i r u b in a e m ia  is  th e  
ja u n d ic e  assoc ia ted  w ith  newborn in fa n ts .  T h is  does occur in  
te rm  b a b ie s  b u t te n d s  to  be n o s t  s e v e re  in  p re m a tu re  in f a n t s  
where i t  can d e v e lo p  in to  the l i f e - th r e a te n in g  c o n d it io n  known
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as k e rn ic te ru s . K e rn ic te ru s  produces b ra in  damage o f  v a ry in g  
s e v e r i t y ,  caused by d isp lace m e n t o f  unconjugated b i l i r u b in  from  
th e  c i r c u l a t i o n  in t o  b r a in  t is s u e .  On p o s t-m o rte m , y e l lo w  
s ta in in g  o f  th e  t is s u e  can be c l e a r l y  seen ( M o l l in s o n  & 
C utbrush, 1949; F rie d e , 1975). In  the  neonate th e re  is  le s s  
a lbum in  than in  o ld e r  c h i ld re n  and a d u lts .  T h is , combined w ith  
th e  u n d e rd e v e lo p e d  U D P -g lu c u ro n y l c o n ju g a tin g  system (Brown & 
Z u e le r ,  1958 ), means t h a t  th e  in f a n t  has no ade q ua te  means o f  
d is p o s a l o f  c i r c u la t in g  b i l i r u b in  which is  then fre e  to  form  the  
p o t e n t ia l l y  to x ic  a c id  form  and d e p o s it  in  t is s u e . A ltho u gh  
th e  s e r io u s  b r a in  damage w h ich  was common a t  one t im e  i s  ra re  
now adays, m in o r n e u r o lo g ic a l  im p a irm e n t is  th o u g h t to  o c c u r 
o fte n ,  and n o t id e n t i f ie d  u n t i l  la te r .  Areas o f  the  b ra in  most 
o fte n  a ffe c te d  (p re se n tin g  w ith  in te n se  y e l lo w  c o lo u r  a t  p o s t­
mortem) are  the  basa l g a n g lia ,  hippocampus and c e re b ra l nuc leu s  
(Ish e rw o od  & L a th e , 1982). The s p e c i f i c  m echanism  by w h ic h  
b i l i r u b i n  e n te rs  th e  b r a in  i s  s t i l l  u n c le a r .  One th e o ry  is  
t h a t  f r e e  b i l i r u b i n  can c ro s s  th e  b lo o d  b r a in  b a r r i e r ,  e n te r  
neu rona l c e l l s  and cause damage (Brodersen, 1979; Hansen e t  a l ,  
1979). From _in v i t r o  and a n im a l s tu d ie s  t h i s  w o u ld  be a 
s u i t a b le  e x p la n a t io n  (B ro d e rse n  & A nd e rso n , 1976; Diamond & 
Schm id, 1966; O d e l l  e t  a l ,  1970; N e ls o n  e t  a l ,  1974). N o t 
co n cu rre n t w ith  the  fre e  b i l i r u b in  th e o ry , v e ry  h ig h  le v e ls  o f  
b i l i r u b in  o c c a s io n a lly  do n o t produce k e rn ic te ru s  (Chen e t  a l ,  
1965) and ana lbum inae ic  ra ts  do n o t e x h ib i t  the  c o n d it io n  (Esumi 
e t  a l ,  1980). To e x p la in  t h i s ,  some re c e n t  w ork has p ro d u ce d  
ev idence  th a t  a lbum in  bound b i l i r u b in  e n te rs  the  b ra in  when the  
b lo o d -b ra in  b a r r ie r  is  d is ru p te d  (Lev ine  e t  a l ,  1982). These
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au th o rs  suggest th a t  p e r tu rb a t io n  o f  the  b lo o d  b ra in  b a r r ie r  is  
an im p o rta n t c o n s id e ra t io n  as to  whether k e rn ic te ru s  can occur. 
In  s u p p o r t  o f  t h i s  EEG p a t te r n s  o f  e x p e r im e n ta l r a t s  w h ic h  
re c e iv e d  a lb u m in - b i l i r u b in  w ere o n ly  a b n o rm a l when th e  b lo o d  
b r a in  b a r r i e r  was d is r u p t e d .  The la r g e  v a r i a t i o n s  in  
s u s c e p t i b i l i t y  o f  th e s e  r a t s  to  b r a in  damage m e r i t s  f u r t h e r  
in v e s t i g a t io n  (Wennberg & Hance, 1986). B urgess  and h is
coworkers suggested th a t  the d e p o s ite d  b i l i r u b i n  r e s u l t s  fro m  
d e p o s i t io n  o f  b o th  f r e e  and bound fo rm s  (B u rgess e t  a l ,  1985).
A f te r  e n t r y  o f  b i l i r u b i n  in t o  th e  b r a in  th e  r o le  o f  th e  
complex as opposed to  the  fre e  b i l i r u b in  in  t o x i c i t y  has y e t  to  
be d e te rm in e d .
The m echanism s by w h ich  b i l i r u b i n  e x e r ts  i t s  t o x i c  e f f e c t  
have  been s tu d ie d  b u t no c le a r  c o n c lu s io n s  can y e t  be d raw n. 
O r ig in a l ly  i t  was though t th a t  b i l i r u b in  co u ld  d is s o lv e  in  l i p i d  
membranes and t h i s  was p roposed  as a m echanism  o f  t o x i c i t y  to  
th e  l i p i d  r i c h  CNS. I t  i s  now known t h a t  b i l i r u b i n  a c id  i s  
n o t  l i p o p h i l i c  b u t a t ta c h e s  to  th e  p h o s p h o l ip id  m o le c u le s  
p re se n t in  membranes (Brodersen, 1981; Vazquez e t  a l ,  1988). A 
p o p u la r th e o ry  is  th a t  m ito c h o n d r ia l damage is  the  p rim a ry  e v e n t 
(Jew & W i l l ia m s ,  1977; S c h u tta  e t  a l , 1970)) b u t much e v id e n c e  
has been p resen ted  to  the  c o n tra ry  (Katoh e t  a l ,  1975; S chu tta  & 
Johnson , 1971). T here  is  no d o u b t t h a t  b i l i r u b i n  i s  t o x i c  to  
th e  CNS b u t th e  e x a c t m echanism  by w h ic h  th e  t o x i c i t y  o c c u rs  
needs fu r th e r  s tudy.
On i d e n t i f i c a t i o n  o f  th e  h y p e r b i l i r u b in a e m ic  s t a te  th e
th e ra p ie s  used to  p re v e n t  k e r n ic te r u s  a re  u s u a l ly  q u i t e  
e f f e c t iv e .  O r ig in a l ly  neonates were tre a te d  w ith  an exchange
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blood transfusion but this treatment has been superseded by 
the advent of phototherapy. Phototherapy relies on the fact 
that under illumination with visible light 
bilirubin "disappears". In fact when phototherapy is employed 
bilirubin is metabolised in two ways. Photodegradation 
occurs when bilirubin is oxidised reaction to pyrrole 
fragments which are water soluble and can be identified in 
urine (Porto, 1970). At the same time photo­
solubilisation occurs, a process where geometrical 
isomerisation of bilirubin leads to production 
of more hydrophilic products known as photobilirubins (McDonagh 
et al, 1979). A further step where either of the vinyl groups 
cyclise leads to even more stable water soluble products (the 
photobilirubins II) which can be measured in both serum and 
bile of icteric infants. This is thought to constitute the 
major pathway of bilirubin ’removal’ in the body (Onishi 
et al, 1986) and is represented in Figure 14. However, 
the main problem in treatment of this hyperbilirubinaemia is on 
deciding when the bilirubin will cause kernicterus. Elevation 
of serum bilirubin followed by displacement and development of 
acute symptoms can occur very quickly, and from a relatively 
low serum bilirubin level. Serum bilirubin levels have not 
been shown to be a good predictor of when this will occur. One 
new type of treatment which has been successfully used in 
treatment of hyperbilirubinaemia of the new 
born is administration of tin-PROTO (Simionatto et al, 1985; 
Anderson et a l , 1986; Kappas, 1988). This synthetic
metalloporphyrin binds to haem oxygenase but is 
not degraded. Inhibition of haem oxygenase activity occurs and 
is prolonged (Landaw et al, 1987). No severe side effects have
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FIGURE 14 : A PROPOSED MECHANISM FOR THE PHOTOSOLUBILISATION
OF BILIRUBIN
been re p o r te d  w ith  m i ld  t r a n s ie n t  p h o t o s e n s i t i v i t y  th e  o n ly  
danger.
C r ig le r - N a j ja r  syndrome Type
T h is  is  a v e ry  ra re  d is o rd e r f i r s t  described  by C r ig le r  and 
N a jja r  in  which th e re  is  t o t a l  absence o f h e p a tic  b i l i r u b in  UDP- 
GT ( C r ig le r  & N a j ja r ,  1952). S eve re  h y p e r b i l i r u b in a e m ia  
d e ve lo p s  w ith in  a few hours o f b i r t h ,  and p rognos is  is  severe . 
In  the p a s t few s u ffe re rs  s u rv iv e d  the  neona ta l p e r io d  however 
modern prompt tre a tm e n t w ith  pho to the rapy  has a llo w e d  p a t ie n ts  
to  re a ch  c h ild h o o d  o r e a r ly  a d u lth o o d . U n fo r tu n a te ly  th e se  
p a t ie n ts  a re  l i k e l y  to  succumb to  th e  d is e a s e  l a t e r  in  l i f e .  
A l l  serum b i l i r u b in  is  unconjugated in  p a t ie n ts  w ith  the Type I  
syndrome and i t  has been shown th a t  the syndrome is  tra n s m itte d  
as an autosom al re c e s s iv e  t r a i t  (Szabo & Ebrey, 1963).
C r ig le r - N a j ja r  syndrome lyp e  I I
The phenotype o f  C r ig le r -N a j ja r  Type n  is  s im i la r  to  th a t  
o f  th e  Type I  syndrom e w ith  th e  a c t i v i t y  o f  th e  enzyme UDP-GT 
a ffe c te d . A c t iv i t y  o f the enzyme however is  reduced ra th e r  than 
a b s e n t and so in  c o n t r a s t  to  th e  Type I  th e  c o n d i t io n  is  
u s u a l ly  c l i n i c a l l y  b e n ig n  w ith  unconjugated b i l i r u b in  le v e ls  
h ig h e r  th a n  n o rm a l (a round 10-20 m g /d l)  (Derk e t  a l ,  1975) b u t  
n o t l i f e  th re a te n in g . Increases can occur however on fa s t in g  
o r  d u r in g  i l l n e s s  (G o lla n  e t  a l ,  1975; Gordon e t  a l ,  1976). 
A lth o u g h  le v e ls  o f UDP-GT a c t i v i t y  are  b a re ly  m easurable (Gordon 
e t  a l ,  1976) c o n ju g a tio n  does occur w ith  monoconjugates as the  
m a jo r f r a c t io n  (F e v e ry  e t  a l ,  1977). The reason  f o r  t h i s  is
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unknown. I t  has been su gg e s te d  t h a t  C r i g l e r - N a j ja r  syndrom e 
Type I I  and G i lb e r t 's  syndrom e may be id e n t i c a l  o r t h a t  
G i l b e r t 's  syndrom e may c o n s t i t u t e  a m i ld e r  to rn , o f  th e  same 
d isease  (Smith e t  a l ,  19G7).
G ilb e r t*  s syndrome
G i lb e r t 's  syndrom e is  a b e n ig n  c o n d i t io n  c h a r a c te r is e d  by 
m ild  bu t c h ro n ic  unconjugated h y p e rb i1 iru b in ae m ia  in  the  absence 
o f  h a e m o ly s is .  C l i n i c a l l y  th e re  a re  no symptoms so t h i s  
c o n d i t io n  may go u n o b s e rv e d , and is  o f te n  d is c o v e re d  d u r in g  
o th e r te s ts .  P a tie n ts  have a reduced UDP-CT a c t i v i t y  (B lack  & 
B i l l i n g ,  1969; F e ls h e r  e t  a l ,  1973). T h is  does n o t show a 
n e g a tiv e  c o r r e la t io n  w ith  the le v e l  o f  serum b i l i r u b in  (Metreau 
e t  a l ,  1978 ), in d ic a t in g  a d e fe c t  in  h e p a t ic  b i l i r u b i n  u p ta k e  
a ls o  e x is t s  (B erk e t  a l ,  1970; M a r t in  e t  a l , 1976) in  a d d i t io n  
to  th e  d e fe c t  in  c o n ju g a t io n .  G i lb e r t 's  syndrom e has been 
re p o rte d  as a heterogeneous c o n d it io n  on the bas is  o f  m orphology 
and b i l i r u b in  tu rn o v e r. LTectron  m icrographs o f  the  hepa tocyte  
in  p a t ie n ts  w ith  G i lb e r t 's  syndrom e show two d i s t i n c t  sub­
p o p u la tio n s , one w ith  normal m orphology and the o th e r showing 
changes in  th e  s t r u c tu r e  o f  th e  sm ooth e n d o p la s m ic  r e t ic u lu m  
(Dawson e t  a l ,  1979a; Dawson e t  a l ,  1979b). Z e n e ro li and h e r 
c o lle a g u e s  s u b -d iv id e d  the  syndrome by d if fe re n c e s  in  b i l i r u b in  
tu rn o v e r w ith  one group p re se n tin g  w ith  decreased h e p a tic  uptake 
and c o n ju g a tio n  b u t normal tu rn o v e r and the  o th e r group showing 
n o rm a l u p ta k e , reduced  c o n ju g a t io n  and in c re a s e d  tu r n o v e r  
( Z e n e r o l i  e t  a l , 1982). S im u lta n e o u s  s tu d ie s  o f  th e  two 
p a ra m e te rs  has n o t y e t  been u n d e rta k e n . In  m ost p a t ie n t s
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other liver function tests are normal and no treatment is 
necessary, but it has been shown that treatment with 
phenobarbital results in a decrease in serum unconjugated 
bilirubin (Kawasaki et al, 1982) presumably by affecting UDP-GT 
activity although this has not been proven (Felsher et al, 
1973). In rats the mutant Gunn rat displays a defect in 
conjugation of bilirubin and it has been suggested that this is 
analagous to Crigler-Najjar syndrome Type I. The congenital 
hyperbilirubinaeraia which the rat suffers from does provide a 
useful model for study of hyperbilirubinaemia in an in vivo 
system.
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1.6 AIMS OF THE THESIS
Unconjugated b i l i r u b in  is  p o t e n t ia l l y  to x ic  w ith in  the  body 
as has been shown in  th e  in t r o d u c t io n  o f  th e  th e s is .  In  
in fa n ts ,  excess b i l i r u b in  can g a in  access to  the  b ra in  where i t  
i s  p r e f e r e n t i a l l y  r e ta in e d  and r e s u l t s  in  b r a in  damage. In  
v i t r o , b i l i r u b in  has teen  shown to  cause d is ru p t io n  o f m itochon­
d r i a l  r e a c t io n s  o f  c e l l s  and is  known to  a d v e r s e ly  a f f e c t  
membrane fu n c t io n .  In  b r a in ,  c e r e b e l la r  P u r k in je  c e l l  
h y p o p la s ia  has f r e q u e n t ly  been o b s e rv e d  in  th e  p re s e n c e  o f  
b i l i r u b i n  b u t i t  i s  s t i l l  u n c le a r  w h e th e r t h i s  i s  a d i r e c t  
e f f e c t  o f  d e p o s i t io n  o f  th e  b i l e  p ig m e n t. In  f a c t  th e  
mechanisms by which b i l i r u b in  e x e r ts  i t s  to x ic  e f fe c ts  are  s t i l l  
n o t proven.
R e c e n t ir\ v i t r o  e v id e n c e  has show n b i l i r u b i n  i s  a 
c o m p e tit iv e  in h ib i t o r  o f  the  enzyme PROTG-O. A s im i la r  in  v iv o  
r o le  o f  th e  b i l e  p ig m e n t is  s u p p o rte d  by th e  f in d in g  o f  a 
reduced le u co cy te  PRG'iG-O a c t i v i t y  in  humans s u f fe r in g  from  the  
m i ld  u n c o n ju g a te d  h y p e r b i l i r u b in a e m ia  o f  G i l b e r t 's  syndrom e. 
The s ig n i f ic a n c e  o f  b i l i r u b i n  as a c o m p e t i t iv e  i n h i b i t o r  o f  
PKOTO-O a c t i v i t y  has n o t been assessed.
My in t e n t io n  was to  s tu d y  th e  e f f e c t s  o f  th e  p re s e n c e  o f  
b i l i r u b in  in  v iv o  on the  haem b io s y n th e t ic  pathway p a r t i c u la r l y  
w i th  re fe re n c e  to  any e f f e c t s  on PkOTO-G a c t i v i t y .  Use o f  an 
an im al model a llo w e d  s tudy o f the enzyme a c t i v i t i e s  w ith in  body 
tis s u e s . The u lt im a te  aim was to  de te rm ine  whether b i l i r u b in  
in  th e  b ra in  o f  th e se  a n im a ls  may be d is r u p t in g  n o rm a l haem 
b io s y n th e s is  in  t h is  t is s u e .
Th is  in vo lve d  s e ve ra l s teps
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F ind ing  a s u ita b le  anim al model o f  h y p e rb iliru b in a e m ia .
C h a r a c te r is in g  haem b io s y n th e s is  in  a c c e s s ib le  body t is s u e s  
o f t h is  an im al to  e s ta b l is h  i f  b i l i r u b in  has any e f fe c ts  on haem 
b io s y n th e s is .
Development o f accura te  assays fo r  the  haem b io s y n th e t ic  enzymes 
o f in te r e s t  in  the b ra in  and a s e n s i t iv e  method fo r  measurement 
o f  b ra in  le v e ls  o f  b i l i r u b in .
P ro du c tio n  o f a s ta te  o f k e rn ic te ru s  in  the  h y p e rb il iru b in a e m ic  
anim al model.
Measurement o f b i l i r u b in  c o n te n t in  the  b ra in  o f these i c t e r i c  
a n im a ls  and measurement o f PROTO-O and ALA-synthase a c t i v i t i e s  
in  t h i s  t is s u e  in  o rd e r  to  d e te rm in e  i f  d is r u p t io n  o f  th e  haem 
b io s y n th e t ic  pa thw ay in  th e  b r a in  o c c u rs  as a r e s u l t  o f  t h i s  
c o n d it io n .
I t  was hoped t h a t  th e s e  s tu d ie s  w o u ld  p r o v id e  an in s ig h t  
in to  one p a r t ic u la r  mechanism by w h ich  b i l i r u b i n  causes  b r a in  
t o x i c i t y .
In  a d d i t i o n  to  th e s e  s t u d ie s  m a n ip u la t io n  o f  haem 
deg ra d a tio n  by d is ru p t in g  b i l i r u b in  s y n th e s is  was s tu d ie d  w ith in  
an u n re la te d  system. From the l i t e r a t u r e ,  b i l i r u b in  fo rm a tio n  
has been shown to  be in h ib i t e d  o v e r  lo n g  p e r io d s  o f  t im e  w i th  
Sn-PROTO, and th is  has been d iscussed in  the in t ro d u c t io n .  Sn- 
PROTO has p re v io u s ly  been used in  c o n t ro l o f h y p e rb i l i r u b in a e ­
mia. R e la t in g  to  the haem b io s y n th e t ic  pathway, p re v e n t io n  o f  
o i l i r u b in  fo rm a tio n  would in c re a s e  haem c o n te n t .  T h is  w o u ld  
p ro v id e  a n o v e l way o f  t r e a t in g  d is e a s e  s ta te s  where haem 
d e f ic ie n c y  o c c u rre d  ie  th e  p o r p h y r la s ,  and I  d e c id e d  to  s tu d y  
t h i s  in  a d d i t io n  to  th e  o th e r  w ork as my in t e r e s t  had been 
s t im u la te d . In v e s t ig a t io n s  were undertaken w ith  an an im al model 
to  d e te rm in e  th e  e f f e c t iv e n e s s  o f  Sn-PROTO as a th e r a p e u t ic  
agent in  acute  h e p a tic  p o rp h y r ia , bo th  a lo n e  and in  co m b ina tion  
w ith  the t r a d i t io n a l  haei; a rg in a te  the rapy .
CHAPTER 2
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MATERIALS AND METHODS
T h is  c h a p te r  c o n ta in s  a d e s c r ip t io n  o f  th e  m a te r ia ls  and 
m ethods used to  c o n s t r u c t  th e  th e s is .  Two s e c t io n s  a re  
in c lu d e d , the  f i r s t  d e s c r ib in g  the  m a te r ia ls  and equipment used 
and th e  second th e  m e th o d o lo g y . A l l  th e  m ethods used a re  
e x p la in e d , a t  le a s t  in  summary, w ith  those adapted from  o r ig in a l  
re fe ren ce s  desc ribe d  in  f u l l .
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2.1 MATERIALS AND EQUIPMENT
2.1.1 Materials
R a d i o i s o t o p e s :  [ 2 , 3 - ^ C ]  s u c c in ic  a c id ,  [ 4 - ^ C ]  ALA, [ 2 - - ^  C] 
g ly c in e  were ob ta in ed  from Amersham In te rn a t io n a l p ic ,  Amersham, 
U.K.
Biochemicals: ALA, a n tifo a m  co n ce n tra te s  A and C, a s c o rb ic  a c id , 
b i l i r u b i n ,  coenzyme A, c o p ro p o rp h y r in  I I I  t e t r a m e th y 1 - e s te r , 
d im e th y ls u lp h o x id e ,  4 ,6 - d io x o - h e p ta n o ic  a c id ,  EDTA, e t h y l  
a c e ta te , g lu ta th io n e ,  g ly c in e ,  1 -h e p ta n e s u lp h o n ic  a c id ,  human 
a lb u m in  f r a c t io n  V , magnesium c h lo r id e ,  m e rc a p to e th a n o l, 
p o ta s s iu m  c h lo r id e ,  p o ta s s iu m  h yd ro g e n  p h th a la te ,p o ta s s iu m  
p ho sp h a te  (m onobasic  and d ib a s ic )  , p ro to p o rp h y r in  IX  d im e th y l 
e s te r ,  p y r id o x a l phosphate, sodium a c e ta te , sodium b ic a rb o n a te , 
sodium m a la te , sodium n i t r i t e ,  s u c c in a te , s u c c in ic  th io k in a s e , 
s u lp h a n i l ic  a c id , Trizma h y d ro c h lo r id e , Trizm a base, t r ic h lo r o a ­
c e t i c  a c id  were a l l  o b ta in e d  fro m  Sigma. Haem a r g in a te  was 
o b ta in e d  fro m  L e ir a s .  D i- n - o c ty la m in e  was o b ta in e d  fro m  
A ld r ic h .  E th y la c e to a c e ta te  was from  F lu k a -G a ra n tie . M ercury 
and sodium were from  BDH. Sn p ro to p o rp h y r in , co p ro p o rp h y rin  and 
p o r p h y r in  m e th y l e s te r s  were o b ta in ed  from  P o rp h y rin  P roducts. 
P ara-d im ethylam inobenzaldehyde (p-DMAB) was from  Merck.
T h in  la y e r  chrom atography p la te s  were o b ta in ed  from  Merck.
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2-1.2 Equipment Used in Analyses
Colorimetric Analyses: S pe c tro ph o tom e tric  measurements were made 
on a Pye Unicam SP8-200 U V /v is  d o u b le  beam s p e c tro p h o to m e te r ,  
s p e c tro f lu o ro m e tr ic  d e te c t io n  was c a r r ie d  o u t on a P e rk in  E lmer 
3000 F luorescence spectrom eter.
Blood Measurements: A z in c  h a e m a to f lu o r im e te r  was used to  
measure b lo o d  p o rp h y rin s . A microhaem c e n tr i fu g e  p lu s  haemato- 
c r i t  measurement appara tus was used to  measure h ae m a toc rit.
HPLC: Two systems were used. For g ra d ie n t b i l i r u b in  s e p a ra tio n  
and p o rp h y r in  se p a ra tio n  a H e w le tt Packard system c o n s is t in g  o f  
a 1084B L iq u id  C h ro m a tog ra ph , a 79831A in je c t o r ,  a 79850B LC 
te rm in a l and a G ils o n  Holochrom d e te c to r  was used. For is o c ra -  
t i c  b i l i r u b in  s e p a ra tio n  and ALA p y r r o le  measurement the  system 
c o n s is te d  o f  e i t h e r  a BIO-RAD pump o r a W a te rs  pump, a W a te rs  
U6K in je c to r  o r a rheodyne in je c to r ,  a G ils o n  ho lochrom  d e te c to r  
and a G ils o n  f r a c t io n  c o l le c to r .
Homogenisers: Where p re s e rv a t io n  o f  an enzyme was im p o rta n t a
g la s s  P o tte r E lveh jam  v e s s e l and m o to r pow ered t e f l o n  p e s t le  
were used. The a l t e r n a t iv e  method used a p o ly t r o n  homogeniser 
and in c lu d e d  s o n ic a t io n  in  the  hom ogenisa tion  process.
Centrifuges: For p re p a ra tio n  o f  t is s u e s  a re f r ig e r a te d  MSE
M is t r a l  4L, fo l lo w e d  by e ith e r  an MSE Superspeed 75 u l t r a c e n t r i ­
fuge o r a Beckman L2-65B u l t r a c e n t r i f u g e  was used. To e x tr a c t  
plasma o r serum from  b lo o d  an eppendorf c e n tr i fu g e  o r r e f r ig e ­
ra te d  Heraeus M in ifu g e  GL was used depending on vo lum es.
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Liquid Scintillation Counting: a Canberra Packard T r ic a rb  
s c in t i l l a t i o n  coun te r was used.
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2.2 METHODS FOR PREPARATION OF TISSUE FOR ASSAY
Rats were used in  a l l  experim ents. A d u lt  ra ts  were d e fin e d  
as those 2 months o f  age o r o ld e r .  The young ra ts  were aged 15 
days in  m ost cases a lth o u g h  v a r ia t io n s  o f  1 o r  2 days d id  
sometimes occur.
2.2.1 Strains of Rat Used
E ith e r  W is ta r o r Sprague Dawley ra ts  were used in  deve lopm ent 
o f  enzyme a s s a y s , and in  some cases as c o n t r o ls .  Gunn r a t s  
were used as t e s t  a n im a ls .  These were e i t h e r  b re d  in  th e  
depa rtm en ta l an im a l house (see Chapter 3) o r o b ta ined  from  the  
Royal Free h o s p ita l ,  London by k ind  p e rm iss io n  o f  P ro fe sso r B. 
B i l l i n g .  Gunn x W is ta r  c r o s s  r a t s  w e re  b re d  in  th e  
d e p a r tm e n ta l a n im a l house fro m  Gunn m a le  and W is ta r  fe m a le  
p a re n ts ,  and th e s e  r a t s  were used as c o n t r o l  a n im a ls  in  th e  
m a jo r ity  o f  the  experim ents.
2.2.2 Blood Sampling
Serum b i l i r u b i n  l e v e l s  were d e te rm in e d  in  l i v e  Gunn and 
c o n t r o l  r a t s .  A n im a ls  w ere a n a e s th e t is e d  by in h a la t io n  o f  
e th e r u n t i l  unconscious. The t a i l  v e in  was heated and a s m a ll 
n ic k  made a t  th e  end o f  th e  t a i l .  B lo o d  was rem oved in t o  
e ith e r  a c a p i l la r y  tube fo r  d e te rm in a tio n  o f  whether the  r a t  was 
a homozygous o r  h e te ro z y g o u s  Gunn o r  an e p p e n d o rf tu b e  when 
measurement o f  the  serum b i l i r u b in  le v e l  was to  be made.
53
2.2.3 Sacrifice of Animals and Blood and Tissue Removal
A l l  an im a ls  were d e e p ly  a n a e s th e tised  by in h a la t io n  o f  e th e r,
( i ) B lo o d  R em ova l: th e  a b d o m in a l c a v i t y  was opened and b lo o d
rem oved fro m  th e  h e p a t ic  v e in  in  a d u l t  a n im a ls .  In  young 
a n im a ls  a f te r  opening the  abdom inal c a v i t y  the  diaphragm was c u t 
to  expose th e  d e s c e n d in g  a o r ta ,  fro m  w h ic h  b lo o d  c o u ld  be 
removed.
( i i ) L iv e r :  a f t e r  o p e n in g  o f  th e  a b d o m in a l c a v i t y  th e  l i v e r  was
exc ised  and pe rfused  w ith  ic e  c o ld  s a l in e  v ia  a s y rin g e  in s e r te d  
in to  the  ju n c t io n  o f  the  h e p a tic  v e in  and l i v e r .  In  the  case o f 
young a n im a ls  p e r fu s io n  was s t i l l  c a r r i e d  o u t ,  d e s p i t e  
d i f f i c u l t i e s  in  keeping v e in  and a r te r ie s  in ta c t  under p ressu re  
o f  p e r fu s io n .
( i i i ) K id n e y s : th e s e  w ere  rem oved a f t e r  th e  l i v e r  and as b e fo re ,  
pe rfused  w ith  ic e - c o ld  s a l in e  us ing  a n eed le  in  a d u l t  and young 
an im a ls .
( i v ) B ra in : in  these an im a ls  the  r ib ca g e  was opened and the  descen­
d in g  a o r ta  c la m p ed . The r i g h t  a t r iu m  was p u n c tu re d  w i t h  a 
need le . P e rfu s io n  was ach ieved  by a c a th e te r  in s e r te d  in to  the  
l e f t  v e n t r ic le  f lu s h e d  w ith  ic e -c o ld  s a l in e .  The s a l in e  then  
pen e tra te d  the  b ra in  v ia  the  b lo od  v e s s e ls . When the  s o lu t io n  
ru n n in g  fro m  th e  r i g h t  s id e  o f  th e  h e a r t  was c le a r  (a p p ro x  1m l 
per gram body w e ight) p e r fu s io n  was com ple te . A f te r  exposing 
the  s k u l l  the  neck was snapped w ith  b ra in  c l ip p e r s  and the  s k u l l  
c h ip p e d  away betw een th e  h em isph e re s  o f  th e  b r a in .  C are was 
taken n o t to  damage the  t is s u e . The w ho le  b ra in  c o u ld  then  be 
eased o u t w ith  a need le  and kep t on ic e  u n t i l  use.
A l l  t is s u e s  were kep t a t 0-4°C u n t i l  enzyme assays c o u ld  be
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c a r r ie d  o u t.
2.2.4 Tissue Preparation for Enzyme Assays
(i)Homogenates: t is s u e  in  ic e  c o ld  b u f fe r  was d iced  w ith  s c is s o rs
and hom ogenised u s in g  a p o ly t r o n  h om ogen ise r f o r  30 seconds 
( in c lu d e s  s o n ic a t io n ) .  The homogenate was then ready fo r  use 
in  assays.
( i i ) M i t o c h o n d r ia :  t is s u e  in  an a p p r o p r ia te  ic e  c o ld  b u f f e r  was
homogenised us ing  a P o tte r  E lv e h je m  g la s s  h o m o g e n is in g  v e s s e l 
w ith  motor powered t e f lo n  p e s t le .  The r e s u l t in g  homogenate was 
th e n  c e n t r i fu g e d  a t  lOOOxg a t  4°C f o r  10 m in u te s  to  rem ove 
t is s u e  d e b r is  and the  su p e rn a ta n t decanted in to  u l t r a c e n t r i f u g e  
tubes to  be c e n tr ifu g e d  a t 25 OOOxg a t  4°C fo r  20 m inu tes . The 
s u p e rn a ta n t fro m  t h i s  s p in  was d is c a rd e d  and th e  p e l l e t  
c o n ta in in g  m ito ch o n d ria  kept on ic e  u n t i l  i t  c o u ld  be resuspen­
ded in  assay b u f f e r *  u s in g  a P o tte r -E lv e h je m  homogeniser w ith  
t e f lo n  p e s t le .  Volume fo r  resuspension  v a r ie d  from  t is s u e  to  
t is s u e ,  w i th  vo lu m e  e q u a l to  w e ig h t  fa v o u re d  f o r  l i v e r  and 
k idney and volum e h a l f  o r ig in a l  w e ig h t used fo r  b ra in . Enzyme 
assays  were th e n  c a r r ie d  o u t  a f t e r  s o n ic a t io n  o f  resuspended  
samples fo r  3 b u rs ts  o f 5 seconds a t  15 m icrons.
In  some cases t is s u e s  were p re p a re d  in  0 .2 5 M o la r s u c ro s e . 
O th e rw is e  t is s u e s  w ere  p re p a re d  in  th e  a p p r o p r ia te  b u f f e r  f o r  
the  enzyme assay. These are l i s t e d  under the  methods fo r  each 
enzyme assay.
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( i i i ) M ic r o s o m e s :  sam p les  were p re p a re d  e x a c t ly  as fo r  m ito c h o n d ria  
b u t in  0.25 M o la r sucrose as b u f fe r .  A f te r  c e n t r i fu g a t io n  a t  
25 OOOxg the  su pe rn a ta n t c o n ta in in g  the  microsomes was decanted 
in to  c le a n  u lt r a c e n t r i f u g e  tubes on ic e  and c e n tr ifu g e d  a t  108 
OOOxg a t  4°C f o r  60 m in u te s . The r e s u l t i n g  p e l l e t  c o n ta in e d  
the  microsomes and co u ld  be resuspended in  the  a p p ro p r ia te  assay 
b u f f e r .
( i v ) P re p a ra t io n  o f  Enzyme I n a c t iv a t e d  T is s u e ; a b a tc h  o f  a n im a ls  
were s a c r if ic e d  and t is s u e s  removed as b e fo re . Homogenates o r 
m ito ch o n d ria  were p repared as p r e v io u s ly  noted. D e te r io ra t io n  
o f  enzyme a c t i v i t y  was ach ieved  by e i th e r  o f  two means:-
a) Heat D e n a tu ra tio n : prepared t is s u e  was heated in  a w a te r ba th  to
te m p e ra tu re s  o f  65 to  75°C. T h is  caused d e n a tu r a t io n  o f  th e  
enzyme w ith o u t  a l t e r i n g  p r o te in  c o n fo rm a t io n ,  and l a r g e l y  
p re v e n te d  n o n -e n zym ic  o x id a t io n  o f  PROTO’gen to  PROTO in  th e  
PROTO-O assay.
b) Freeze Thaw D e n a tu ra tio n ; prepared t is s u e  was re p e a te d ly  sub jec­
ted to  -20°C and m ild  hea t (50°C).
T issue  tre a te d  in  e ith e r  o f  the  above two ways was then  s to re d  
a t  -20°C  in  a l iq u o t s  and thawed f o r  use as t is s u e  b la n k s  in  
enzyme assays. The method o f  cho ice  was th a t  o f  hea t dena tu ra ­
t io n  s in ce  the  fre e z e  thaw techn ique  seemed to  be le s s  e f f e c t iv e  
a t  d e s tro y in g  enzyme a c t i v i t y .
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2.2.5 Collection of Urine and Faeces
I n d iv id u a l  r a t s  were k e p t in  m e ta b o l ic  cages f o r  24 hou r 
p e r io d s . Over t h is  p e r io d  u r in e  and faeces were c o l le c te d  and 
kep t da rk  to  p re v e n t any d e te r io ra t io n  o f  haem p re c u rs o rs  which 
occurs on exposure to  l i g h t .
2.3 MEASUREMENT OF ENZYME ACTIVITIES
2.3.1 5—Aminolaevulinic Acid Synthase (E.C.2.3.1.37)
Two assay methods were used to  measure ALA-synthase in  bo th  
t is s u e  hom ogenates and m ito c h o n d r ia l  s u s p e n s io n s . B o th  o f  
th e s e  were ra d io c h e m ic a l assays  where a ra d io a c t iv e  p re c u rs o r 
was incubated  under o p tim a l c o n d it io n s  fo r  p ro d u c tio n  o f  ALA, so 
g e n e ra t in g  a r a d io a c t iv e  p ro d u c t .  The r a d io l a b e l le d  ALA 
p ro d u c t co u ld  then be q u a n tita te d .
i )  [2 - ^ C ]  g ly c in e  was used as s u b s tra te . The method was adapted 
from  th a t  o f  Freshney and Paul (Freshney & P a u l, 1970).
T is s u e  o b ta in e d  was hom ogenised in  4 vo lu m e s  o f  a b u f f e r  
made up o f  two p a r ts  s a l in e  to  one p a r t  " in c u b a t io n  b u f f e r "  
c o n ta in in g  500mM sucrose, 25mM magnesium c h lo r id e ,  0.2mM EDTA, 
8mM m e rc a p to e th a n o l, ImM g ly c in e ,  and made up in  a 50mM 
p o ta s s iu m  p h o sp h a te  b u f f e r  to  pH7.0. 2 0 0 p l was th e n  added to
2 0 0 p l [2 14C] g ly c in e  d is s o lv e d  in  a b u f f e r  c o n ta in in g  50mM 
g ly c in e ,  500mM sodium m a la te , 2mM magnesium c h lo r id e  and 0.4mM 
p y r id o x a l phosphate in  a 50mM potass ium  phosphate b u f fe r  pH6.8 
(c o n ta in s  2 .5pC i p e r tu b e ) .  The 4 0 0 p l sam p le  was in c u b a te d  
w ith o u t shaking a t 37°C fo r  one hour and the  re a c t io n  stopped by 
a d d in g  one te n th  (4 0 p l)  40% TCA c o n ta in in g  6m M ola r n o n -
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ra d io a c t iv e  o r "c o ld "  ALA. A f te r  s o n ic a t io n  fo r  15 seconds a t  
15 m ic ro n s  th e  sa m p les  c o u ld  be s to r e d  a t  -2 0 °C  u n t i l  h ig h  
v o lta g e  e le c tro p h o re s is  which was a lw ays w ith in  2 days o f  assay.
The ALA formed was separa ted from  contam inants  by h ig h  v o lta g e  
e le c t r o p h o r e s is .  Sam ples were s p o t te d  o n to  c h ro m a to g ra p h y  
pap e r and d r ie d .  The pap e r was soaked in  5mM p o ta s s iu m  
hydrogen p h th a la te  and b lo t te d .  H igh v o lta g e  e le c tro p h o re s is  
was f o r  30 m in u te s  a t  3000 v o l t s .  A f te r  d r y in g  th e  ALA s p o t 
was id e n t i f ie d  us ing  n in h y d r in  sp ray , is o la te d  and counted in  a 
p c o u n te r  e i t h e r  a f t e r  c o m b u s tio n  w i th  a sam p le  o x id is e r  and 
c o m b in a t io n  w ith  s c i n t i l l a n t  o r by d i r e c t  a d d i t io n  o f  th e  ALA 
c o n ta in in g  spo t to  s c i n t i l l a n t .  ALA formed was c a lc u la te d  per
p ro te in ,  us ing  the  DPM's in  the  g ly c in e  sp o t as a s tandard .
i i )  [2 ,3 ^ C ] s u c c in ic  a c id  was used as s u b s tra te . The c o n d it io n s
used in  th e  o r i g i n a l  m ethod by F itz s im o n s  (F itz s im o n s  e t  a l ,  
1984) were checked fo r  o p tim a l b ra in  ALA-synthase a c t i v i t y  (see 
c h a p te r  3 ).
B ra in  homogenates o r m ito ch o n d ria  were p repared as in  s e c tio n
2.2.3 in  A L A -syn th a se  b u f f e r  c o n ta in in g  250mM s u c ro s e , 5mM 
M gC l2 , 45mM g ly c in e ,  40mM t r i s  b ase , 2mM EDTA in  d i s t i l l e d  
w a te r. For optimum pH, 50mM potassium  d ihyd rogen  o rthophospha te  
was added to  h a l f  th e  b u f fe r  and t h i s  used to  pH th e  r e s t  to  pH
7.5 a t  37°C.
When l i v e r  o r k idney  t is s u e  ALA-synthase a c t i v i t y  was to  be 
measured, the  ALA-synthase b u f fe r  was e x a c t ly  as th a t  f o r  b ra in  
measurement except fo r  c o n c e n tra tio n  o f  g ly c in e  which was ra is e d  
to  lOOmM.
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40Opl of tissue in ALA-synthase buffer was added to 50pl 2mM 
4,6-dioxoheptanoic acid in ALA-synthase buffer plus 2.5 pCi 
[2,34C ] succinic acid dissolved in 20mM succinate solution. 
After vortex mixing the samples were incubated for 1 hour at 
37°C without shaking. Tissue blanks were regularly run. The 
reaction was stopped with 250pl ice-cold TCA (10%) and the 
sample cooled in ice. 4mM ALA (50pl) was then added for 
identification of the ALA pyrrole peak followed by 500pl 1M 
sodium acetate. After mixing the samples were spun in an 
eppendorf centrifuge. The supernatant was removed with a 
pasteur pipette and the pellet discarded. For formation of the 
pyrrole, 50pl ethylacetoacetate was added. Samples were loosely 
capped and heated to 100°C for 20 minutes. After cooling in 
ice 2.5ml distilled water was added to dilute the sample for 
purification. This ALA-pyrrole could be stored overnight if 
necessary in the dark at 4°C.
Determination of recovery in the samples was necessary due 
to the extensive manipulation and this was achieved using [414C] 
ALA. 2.5pCi radioactive ALA was added to incubation buffer, 
cold ALA, TCA and sodium acetate as before. The pyrrole was 
made by addition of 150pl ethylacetoacetate.
Sample blanks contained either no tissue (buffer only) or 
tissue after inactivation of enzyme, and all components of the 
samples.
The pyrrole was isolated from radioactive and structural 
contaminants by Sep-pak ODS cartridges (Waters). Cartridges 
were activated with acetonitrile then methanol. Addition of
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water provided a favourable environment for application of ALA 
pyrrole. The pyrrole is preferentially retained. After 
drying the pyrrole was eluted with methanol. The samples were 
then dried down under N 2 and resuspended in 1:1 methanol:water 
(lOOjjl). Half of this was injected into a ODS reverse phase 
HPLC column. The system was isocratic with a mobile phase 
consisting of 37:63 parts methanol to water and containing the 
base pairing agent heptane sulphonic acid at a concentrationof 
5mM dissolved in 20ml per litre IN acetic acid. Solvent was 
always filtered and degassed before use. On elution from the 
HPLC column fractions of the peak and those surrounding were 
collected. After addition of scintillant these were counted. 
Recovery was assessed by using [4-^4 C] ALA which had been under 
identical conditions to the samples.
Calculation: Background DPM's were subtracted from the
fractions containing the peak. The resulting figure was 
corrected for recovery (calculated from [^4C] ALA sample) and 
total volume of sample. To convert DPM to pmoles ALA in the 
sample the specific activity of the [2,314C] succinic acid and 
concentration of cold succinate had to be considered.
pmoles ALA formed per = c o rre c te d  DPM in  ALA p y r ro le
hour ---------------  -------
DPM per nmol [ 14C] s u b s tra te
enzyme activity could then be calculated per milligram protein.
Method i) was the first method to be used and the activity of 
ALA synthase was measured in liver and kidney samples, both in 
homogenates and mitochondria. However it soon became clear
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that this method was not producing reproducible results for 
brain tissue, and therefore the Fitzsimons method was tried and 
provided an alternative which gave comparable results in both 
liver and brain as is shown in Chapter 3. This method was 
adopted for all tissues. All results were reported in pmol ALA 
produced/mg tissue/hour.
2.3.2 5-Aminolaevulinic Acid Dehydratase (E.C. 4.2.1.24)
Measurement of ALA-D activity is achieved by quantitation of 
the product of the reaction, PBG. Tissue preparations contai­
ning the enzyme activity were incubated with exogenous ALA for 
one hour and the PBG produced reacted with para- 
dimethylbenzaldehyde (p-DMAB) to produce a pink compound which 
is measured spectrophotometrical ly at 555m.
For rat liver samples 2g of tissue was homogenised in 6ml 
lOOmM sodium phosphate buffer pn 6.8 using polytron homogeniser 
(with sonication). 200pl was then added to three identical 
tubes containing 1.3ml water at 37°C. After equil ibr ium at 
this temperature was reached the reaction was started by 
addition of 1ml of lOmM ALA dissolved in sodium phosphate buffer 
as before. Immediately a zero time sample was taken by 
stopping the reaction in one of the triplicate samples with 10% 
TCA. The remaining duplicate samples were run for 1 hour and 
then the reaction stopped with 1ml of 10% TCA as for the zero 
time. The precipitated protein was centrifuged at 1 500xg for 
15 minutes to remove turbidity and the clear supernatant 
containing PBG decanted and added to an equal volume of
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Ehrlich's reagent (p-DMAB)*. Development of colour took 5 
minutes and the colour in the samples read against zero times. 
Activity was expressed in pmoles PBG/g protein/hour.
C a lc u la t io n
p n o l PBG/g p ro te in /h  = OP X 18.81 * 60
protein (mg/ml)
ALA-D activity is greatly inhibited in the presence of lead. 
To prevent the possibility of any contamination all glass was 
acid washed and the assays were carried out in plastic tubes.
Ehrlich's Reagent: 2.5g pDMAB was added to 30ml glacial acetic
acid. 24.5ml perchloric acid was added and the solution made 
up to 100ml with more glacial acetic acid. The solution was 
always made up fresh, on the day of use and used within one hour 
usually.
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2.3.3 COproporphyrinogen Oxidase (E.C.1.3.3.3)
Measurement of the enzyme COPRO-O is achieved by quantita­
ting COPRO produced fluorimetrically. In this reaction COPRO'- 
gen substrate is added to the tissue preparation containing 
enzyme. The method used was modified from that of Batlle 
(Batlle et al, 1965). Conversion of COPRO to COPRO'gen 
requires the action of a strong reducing agent. For these 
experiments a 3% sodium mercury amalgam was used. 3g non­
oxidised sodium was diced and heated under toluene until the 
sodium appeared as silver liquid spheres. Mercury (2.5ml) was 
added slowly with careful mixing and the amalgam allowed to 
cool. The toluene was decanted and amalgam washed with 
petroleum ether (40-60°C). After carefully drying the solid 
block was ground to a fine powder with a mortar and pestle and 
stored in a sealed glass boiling tube. Amalgam prepared in 
this way was active for one to two weeks, longer if stored under 
nitrogen. The pH of amalgam is very high (pH >11) and so 
before addition to tissue amalgam is filtered out from the 
substrate using a sinter glass funnel and the pH returned to the 
range of the assay with 40% and 10% MOPS acid.
For each COPRO-O assay tissue homogenate or mitochondria were 
prepared and resuspended in 0.15M KC1. 400ul of the resuspen­
ded mitochondria were added to a 10ml conical flask containing 
lml lOOmM Tris buffer pH 7.4. After mixing, the solution was 
placed in a water bath at 37°C. Coproporphyrinogen solution 
was prepared by diluting stock coproporphyrin standard, kept at 
4°C in lOmM KOH, with more lOmM KOH to a final concentration of 
lOOmM. This solution was added to sodium amalgam and shaken
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for a few minutes until no fluorescence was visible under a UV 
light ie COPRO'gen had been formed. After correction of the pH 
to approx pH 7, 1ml of this substrate was added to the diluted 
tissue preparation in the water bath and a one hour incubation 
carried out in the dark. The final concentration of substrate 
in the reaction was 50mM. The reaction was stopped by addition 
of 5ml 4:1 ethyl acetate/acetic acid. Samples were stored at 
-20°C until extraction of coproporphyrin could be carried out.
Extraction of Coproporphyrin: The contents of the conical 
flasks were transferred to separating funnels and after addition 
of more 4:1 ethyl acetate/acetic acid to rinse the flask, washed 
with saturated sodium acetate. All porphyrins were extracted 
using 15% HC1, and after returning the pH to neutral with sodium 
acetate, ether was added. Water was then added to remove any 
remaining acid and the coproporphyrin extracted from the organic 
phase using 0.1N HC1. Protoporphyrin was extracted using 5% 
HC1. The acid extractions were filtered and read on a fluoro- 
meter set at wavelengths 395nm excitation and 595nm emmission 
against a coproporphyrin standard.
Calculation
FU2 * 4.2 * V2 
Protein * V3
where FU2 = fluorescence reading of acid extracted volume 
V2 = acid volume obtained
V3 = volume of tissue homogenate added (in ml)
The results were expressed as nmol PROTO/mg protein/hour
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2.3.4 Protoporphyrinogen Oxidase (E.C.1.3.3.4)
The principle of the PROTO-O assay is similar to that of the 
COPRO-O assay. The substrate PROTO'gen is produced using a 
strong reducing agent then added to tissue preparation 
containing enzyme activity and formation of the product PROTO 
quantitated. One important difference is the high level of 
non-enzymic conversion of PROTO'gen to PROTO which occurs on 
exposure to light which means the assay has to be carried out in 
darkness. Levels of product are measured directly fluorometri- 
cally. Immediately after addition of substrate at 37°C in the 
dark, an aliquot is removed and used as a zero time. At ten 
minute intervals further aliquots are removed and the change in 
fluorescence is proportional to the amount of PROTO produced, 
providing a measure of PROTO-O activity when related to protein 
content.
All assays were carried out on mitochondria which had been 
resuspended in the appropriate volume of 0.15M KC1 which 
resulted in protein contents of not greater than 2mg/ml. It 
was found that addition of 20pl/ml of the detergent Tween 20 
before sonication minimised the effect of different 
concentrations of protein. Mitochondrial suspensions of tissue 
were sonicated immediately before addition of 40Ctyul to 1.1ml 
50mM Tris buffer pH 9.2 for liver, kidney and brain. The 
reaction vial at 37°C contained 0.3mMolar glutathione (GSH), a 
reducing agent, to help prevent autooxidation of the substrate. 
A reagent blank was set up containing 400pl Tris buffer instead 
of tissue suspensions to measure residual non-enzymic oxidation 
of protoporphyrinogen to protoporphyrin (PROTO). A tissue
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blank was also used, containing killed tissue see section 2.2.3 
part iv). This accounted for any PROTO produced by remaining 
oxidising agents present in the tissue preparation.
The substrate, PROTO’gen was prepared by adding 0.4mM PROTO 
in N/7 sodium bicarbonate (approximately 5ml) to 6g sodium 
amalgam on ice in the dark and shaking for between 2 and 5 
minutes, until no fluorescence was visible under UV 
illumination. The clear PROTO'gen was then filtered using a 
glass sinter funnel and the pH brought down to approx pH 9.0 
using either 10% or 40% MOPS acid. lOOpl of the substrate was 
then added to the tissue /buffer mixtures at 37°C and the tubes 
were vortexed. The concentration of substrate was determined 
to be above the I'm for PROTO'gen. Immediately a 50pl aliquot 
was diluted with 3.1ml 50mM Tris buffer again containing GSH. 
This gave a manageable reading on the fluorometer. Fluoresce­
nce in this solution was determined in a spectrofluorometer at 
wavelengths Ex 40r>nm Emm 635nm against a COPRO standard. The 
fluorometer contained a red filter to help in sensitivity of 
determining the colour of the forming PROTO. Slits were set at 
lOnm. The 50pl sampling procedure was repeated after 10 
minutes in brain tissue and 20 minutes in liver and kidney 
mitochondria. The change in fluorescence readings reflected 
the PROTO'gen oxidase activity.
Generation of PROTO for substrate; protoporphyrin methyl ester 
is the most stable form of PROTO. lmg aliquots were hydrolysed 
with 10 drops of a 70% solution of HC1 overnight in the dark in
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a sealed container. The resultant PROTO acid was freeze dryed 
and storing at -20°C. Prior to the assay, one aliquot was 
thawed in the dark and N/7 sodium bicarbonate solution was added 
to dissolve the PROTO. This gave a concentration of 
approximately 0.4mHolar. The dark red PROTO was then added to 
amalgam and converted to PROTO'gen as described earlier in the 
section.
Calculation
a) (FU7 * .0328 * 1 130/50) - (FU6 * .0328 * 1500/50) represents the
change in fluorescence in the sample. FU7 = final fluorescence 
value and FU6 = initial fluorescence with .0328 a constant for 
the standard and 1500/50 and 1450/50 representing the volume of 
the reaction vessel in ul before and after sampling.
b) (Q6E * .0328 * 1450/50) - (Q6F * .0328 * 1500/50) represents the 
change in fluorercence in the blank sample (autooxidation). 
Q6E = final fluorescence value and Q6F = initial fluorescence 
value. The other constants are as above.
b) was subtracted Prom a) and a correction applied for 
The result was divided by (.4 * T6 * 562.7 * protein) where .4 
= volume of homogenate added, T6 = time of incubation and 562.7 
is the formula weight for PROTO.
The final result was expressed as nmol PROTO/mg protein/hour.
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2.4 PORPHYRIN AND PRECURSOR MEASUREMENTS
2.4.1 5—AMINOLAEVULINIC ACID IN URINE
Measurement of ALA levels in urine was carried out using kits 
supplied by BIO-RAD. The details of the method are available 
in the BIO-RAD Laboratories Technical Bulletin No.4208 (1979). 
In principal, urine at pH 5-6 (altered with glacial acetic acid) 
which has had PBG removed was dripped onto a column containing a 
cation exchange resin. ALA was then retained on the column 
while urea and other contaminants were washed through with 
water. Elution of ALA foLlowed by a period of condensation 
with acetylacetone resulted in a pyrrole derivative which pro­
duced a coloured compound on reaction with pDMAB (Ehrlich's 
reagent for urine) . uuantitation was carried out on a 
spectrophotometer, with results being calculated from the molar 
extinction coefficient of the complex at 555nm ( mM=62), and 
reported as either nmoles ALA excreted per litre for spot 
samples or pmol ALA per 24 hours for 24 hour collections of 
urine.
Ehrlich's Reagent for Urines:
lmg pDMAB was added to 8ml perchloric acid and the volume 
made up to 50ml with glacial acetic acid. This solution was 
prepared fresh on the day of assay and used within 3 hours.
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2-4.2 Porphobilinogen in Urine
PBG was measured in urine by kits from BIO-RAD, with details 
provided by BIO-RAD Laboratories Technical Bulletin No.4208 
(1979). Acidified urine (pH 5-6) was passed through an anion 
exchange column and PBG was retained. After elution Ehrlich's 
reagent for urines (see previous page) was added and the 
coloured compound produced quantified as in 2.4.1. Results 
were reported as nmoles PBG excreted per litre or pmol PBG per 
24 hours as appropriate.
2.4.3 Total Porphyrin in Urine
Total porphyrin was measured in urine using kits from BIO-RAD 
Laboratories. The procedure followed was adapted from BIO-RAD 
Laboratories Technical Bulletin No.4003 (1981). Columns were 
shaken to resuspend the ion exchange resin and allowed to drain. 
After the resin had settled the columns were rinsed with 10ml 
distilled water. After draining, 1ml urine (0.5ml if total 
porphyrin was expected to be very high and so saturation of the 
column was likely to occur) was added and allowed to drain 
before 10ml distil led water was drained through the column to 
remove any interfering chemicals. Porphyrins were eluted with 
2 aliquots of 2ml 3M HC1 and the fluorescence of the sample 
determined at wavelengths 396nm excitation and 594nm emission. 
The concentration of total porphyrin was calculated against a 
coproporphyrin standard of known concentration. Results were 
reported as pg porphyrin excreted per litre or 24 hours as 
appropr iate.
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2.4.4 Porphyrin Excretion by HPDC
By us ing  h ig h ly  s e n s i t iv e  HPLC techn iques  i t  is  p o s s ib le  to  
separa te  the  d i f f e r e n t  p o rp h y r in s  w hich a re  e xc re te d  in  u r in e  -  
URO, hep ta , hexa, and p e n ta -c a rb o x y lie  p o rp h y r in s , coproporphy­
r i n  and p r o t o p o r p h y r in .  Two ty p e s  o f  a s s a y  h a v e  b ee n  
d e v e lo p e d , one u s in g  f r e e  p o r p h y r in s  and th e  o th e r  r e ly in g  on 
d e r iv a t is a t io n  o f  the  p o rp h y r in s  to  t h e i r  co rrespond ing  m e thy l 
e s te r s .  The free m ethod r e q u ir e s  le s s  p r e p a r a t io n  b u t  ru n  
tim es  are  le n g th y  and p re p a ra tio n  o f  a r e l i a b le  s e t o f  s tandards  
d i f f i c u l t .  For these reasons, o n ly  the  p o rp h y r in  e s te r  method 
was employed in  measurement o f  p o rp h y r in s  in  r a t  e x c re ta .
i) Preparation of rat urine
20ml of rat urine from pooled 24 hour urine collections was 
adjusted to approximately pH 6 with glacial acetic acid. lg of 
talc was added and the mixture left to stir in the dark for 15 
minutes. Talc absorbed the porphyrin and was then dried 
firstly in a Buchner funnel and then more thoroughly by baking 
at 90°C for 1 hour. Addition of 15ml methanol/conc. sulphuric 
acid mixture (95/5 v/v) stripped the porphyrins from the talc 
into solution. Both the porphyrin containing solution and talc 
were left in the dark at room temperature for 16 hours. This 
allowed formation of porphyrin esters. Any residual porphyrin 
ester remaining on the talc was removed by addition of 2 x 5ml 
aliquots of chloroform. These were added to the original 
methanol/sulphuric acid solution followed by 10ml water to 
separate the organic and aqueous phases. The aqueous phase 
was discarded and the water wash repeated. 3% sodium bicarbonate
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was then added and the solution washed with another two aliquots 
of water. The resulting chloroform phase was shaken with 
anhydrous sodium sulphate (O.lg) and filtered before evaporating 
to dryness under air. The porphyrin ester residue was dissol­
ved in 20pl chloroform and 800pl mobile phase for HPLC added. 
After a final filtration step through 0.2pm filters (Gelman 
Sciences) a portion of the sample was injected. Sample injec­
tion volumes varied with the type of sample. For Gunn rats 
50pl injections were required while control rat porphyrin esters 
could be resolved after injection of only lOpl. Samples were 
quantitated against porphyrin methyl ester standards (Porphyrin 
Products, Utah, USA).
ii) HPLC of porphyrin methyl esters
Chromatography was performed on the Hewlett Packard system 
described in section 2.1.2. with a silica column (200 x 46mm) 
and solvent containing n-heptane/ethylacetate/chloroform/methanol 
(60:25:12.5:2.5) at a flow rate of 1.2 ml/min. Detection was 
by fluorescence at Ex. 405nm Emm. 625nm. An example of a 
chromatogram from a standard run is shown in Figure 15.
2.5 PORPHYRIN MEASUREMENT IN FAECES
Rats were confined to metabolic cages for 24 hours and the 
collections of fauces kept dark. Faecal matter was homogenised 
and porphyrins were extracted with acid. Faecal coproporphyrin 
and protoporphyr i.n were quantitated against a coproporphyrin 
standard of known concentration at Emm. 594nm with Ex. set at 
396nm.
After a 24 hour period of collection the total amount of
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1 = PROTO, 2 = COPRO, 3 = PENTA, 4 = HEXA, 5 = HEPTA, 6 = URO 
(MESO)
FIGURE 15 : TYPICAL HPLC TRACE OF STANDARD SET OF PORPHYRIN
ESTERS
faeces was weighed and homogenised in approximately half the w/v 
water with the polytron homogeniser. Porphyrins were then 
extracted from a l-2g aliquot. A small proportion was removed 
for wet weight/dry weight estimation. This was weighed then 
baked for at least 6 hours at 100°C and reweighed.
Glacial acetic acid, 5-10ml, was added to the aliquot for 
extraction and then this made up to a 10% solution with ether. 
After thorough mixing deposits were removed by centrifugation at 
lOOOxg for 10 minutes. Porphyrin present could then be identi­
fied under UV illumination in the supernatant and the pellet 
was discarded. The suspension was transferred to a separation 
flask for extraction of porphyrins. The solution was washed 
twice with 3% sodium acetate, the first wash being used to rinse 
the discarded container minimising porphyrin loss and the 
aqueous phase discarded each time. 20ml of a 0.005% solution 
of iodine (freshly made up) was added to oxidise any PROTO'gen 
and again the aqueous phase discarded. After a further wash with 
water, porphyrins were extracted from the remaining organic 
phase with acid. Faecal coproporphyrin was extracted using 
10ml aliquots of 0.1N HC1 (until the final aliquot showed no 
fluorescence) and protoporphyrin was extracted from the 
remaining solution with 5% HCl (5ml aliquots). Both acid 
fractions were volumed, filtered with Whatmans No 1 filter paper 
and read against a coproporphyrin standard at the wavelengths 
already mentioned.
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HPLC o f fa e c a l samples
A known weight of faeces was added to excess methanol/— 
sulphuric acid (95:5 v/v). This mixture was stirred to extract 
porphyrins and then left standing to enable esters to form. 
The resultant mixture was filtered as for the urine and the 
residue washed with chloroform. The porphyrin esters were then 
prepared and applied to an HPLC column in a manner identical to 
that of urine.
2.6 CYTOCHROME P450 MEASUREMENT
In the liver cytochrome P450 is the major productof haem 
formed. Measurement of this haemoprotein is likely to detect 
any disturbances in haem synthesis in hepatic tissue. Measure­
ment of cyt. P450 was carried out in microsomal preparations of 
rat hepatic tissue by a modification of the method of Qmura and 
Sato (Omura & Sato, 1964). Identification of cyt. P450 was by 
the difference spectrum recorded at 450nm on reaction of the 
microsomal preparation with carbon monoxide (CO).
Microsomes were prepared in 0.15M KC1 to minimise haemoglo­
bin adsorption as described in section 2.2.4. Pelleted 
microsomes were resuspended in potassium phosphate buffer using 
a Potter-Elvehjem glass homogeniser with teflon pestle to a 
solution containing between 2-4mg/ml protein. This solution 
was split evenly between two glass cuvettes path length 1cm. 
The test cuvette was bubbled with CO for 10 seconds then 5mg 
sodium dithionite added to both the test and blank cuvettes and 
mixed. The test cuvette was then bubbled with CO for a further 
10 seconds and mixed and the difference spectrum recorded in a
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double beam spectrophotometer over the wavelength range 400nm to 
500nm.
C a lc u la tio n
A  e450-495 * 3,2 * 1000 
91 * 1 * protein content (mg/ml)
where A  E is the difference in optical density between the 
peak at 450nm and the trough at 495nm
2.7 DETERMINATION OF CONJUGATED AND TOTAL BILIRUBIN IN SERUM/PLASMA
Several laboratory methods have been developed which measure 
bilirubin in serum. These are all variations of the Van den 
Bergh reaction where bilirubin is coupled to diazotized 
sulphanilic acid to form azobi1 irubin. This compound is 
strongly coloured in strong acid or alkali and adaptations 
produced the two most common laboratory methods which allowed 
colorimetric quantitative analysis, the Malloy and Evelyn method 
and the Jendrassik and Grof method. Two colorimetric reactions 
occurred, the first in aqueous solution was known as direct 
bilirubin and the second which only coloured after addition of 
alcohol was called indirect bilirubin. After the discovery 
that bilirubin is excreted as a water soluble conjugate the 
direct bilirubin was identified as the diconjugate and the 
indirect bilirubin as the unconjugated form. Research has 
shown the Jendrassik and Grof method to be the method of choice 
in the laboratory (Tietz, 1976) and this was the laboratory 
method adopted. Plasma samples were also analysed by
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autoanalyser to determine bilirubin content. These results 
were expressed as total bilirubin content. investigation into 
the various forms of bilirubin in plasma was also investigated 
by HPLC methods. Four fractions of bilirubin have been 
identified in plasma diconjugate, monoconjugate of bilirubin, 
the unconjugated fraction and a fraction tightly bound to 
albumin (Lauff et al, 1981). Bilirubin is light sensitive and 
up to 50% decrease in the pigment can be seen within one hour of 
exposure to direct sunlight. For this reason, where possible 
plasma bilirubin determination was carried out soon after blood 
sampling, and when the plasma/serum samples had been kept dark. 
Samples are stable in the dark at 4°C for one week and for 3 
months if kept at -20°C. All samples were assayed for bilirubin 
content within this time period.
2.7.1 Plasma Bilirubin Measurement by Autoanalyser
Blood from Gunn and control rats was removed and the plasma 
removed by centrifugation. Plasma samples were then stored in 
the dark at -20°C and sent in batches for autoanalysis in 
another department.
2.7.2 Serum Bilirubin Determination by Jendrassik & Grof Method
Non-haemolysed fresh or frozen serum or plasma was analysed 
for conjugated (direct) and unconjugated (indirect) bilirubin 
content. For conjugated bilirubin measurement the sample was 
added to acid (HC1) then diazo reagent (diazotized sulphanilic 
acid) added. Only conjugated bilirubin can react under these 
conditions. The reaction was terminated by ascorbic acid which 
destroyed excess diazo reagent and the solution made alkaline by
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addition of tartrate solution. The strong blue colour was then 
measured at 600nm in a double beam spectrophotometer against a 
blank containing caffeine reagent instead of acid and conjugated 
bilirubin quantitated. For total bilirubin instead of acid 
solution the sample was added to caffeine reagent which acted 
as an accelerator for coupling of bilirubin with diazotized 
sulphanilic acid. The reaction was allowed to proceed for 10 
minutes before addition of alkaline tartrate solution and 
determination of optical density at 600nm against the blank as 
before.
i)Direct Bilirubin
For rats with elevated serum bilirubin lOOpl serum/ plasma 
was analysed, diluted with 150pl water. For rats with serum- 
/plasma bilirubin in the normal range up to 250jul could be 
taken. The plasma was added to 1ml 0.05M HC1, and 250pl fresh 
diazo reagent added. This was made up and used within 30 
minutes and consisted of 10 ml of a solution of sulphanilic acid 
- lg in 3ml concentrated HC1, per 200ml added to 0.25ml of a 
72mM sodium nitrite solution (ie 1 in 40 v/v). After 1 minute 
50/ul 0.23M fresh ascorbic acid was added followed immediately
by 500pl of a solution containing 100g/l sodium hydroxide and 
350g/l sodium tartrate.
The absorbance of this cuvette was measured against a blank 
containing 1ml caffeine reagent before addition of plasma 
instead of HC1 and sulphanilic acid solution described above 
instead of diazo reagent.
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T o ta l B i l i r u b in
For total bilirubin lOOpl sample was diluted with water to 
make 250^1 total and added to caffeine reagent as for the blank. 
Fresh diazo reagent was added as for conjugated bilirubin and 
the azobilirubin product made alkaline for quantitation with 
tartrate solution. Total bilirubin was quantitated against a 
calibration curve of concentrations of 0,2,5,10,15,20mg/100ml 
bilirubin in rat albumin fraction V shown in Figure 16.
For the standards to make up the calibration curve, 
commercial bilirubin 20mg was dissolved in 1ml DMSO, then 2ml 
0.1M sodium carbonate added and the solution made up to 80ml 
with 4% rat albumin fraction V pH 7.4. This was neutralised 
with 2ml 0.1M HC1 and made up to 100ml.
2.7.3 Serum Bilirubin Determination by HPLC
The laboratory method of determination of bilirubin has 
proved useful in determining the fractions of conjugated and 
unconjugated bilirubin in serum and plasma samples. In more 
recent years it has become evident that there are several 
bilirubin conjugates, the diconjugate with glucuronide is the 
most abundant in serum but isomers of monoconjugated bilirubin 
(glucuronidation at position 8 or position 12) are also present. 
In addition to the mono and di-conjugated forms of bilirubin, 
recently a form has been isolated which is covalently bound to 
albumin. This is known as the delta fraction.
As a consequence of these discoveries more detailed methods 
capable of determining all the forms of bilirubin in the blood 
have been developed. HPLC techniques have provided the tool
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ABSORBANCE
UNITS
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BILIRUBIN CONCENTRATION mg/100ml (pMolar)
FIGURE 16 : CALIBRATION CURVE FOR DETERMINATION OF SERUM
BILIRUBIN
f o r  s e p a ra t io n  o f  th e s e  fo rm s  o f  b i l i r u b i n  known as cx,p, and # 
b i l i r u b i n .  Two HPLC s e p a ra t io n  m ethods w ere  used in  th e s e  
expe rim en ts .
G ra d ie n t S ep a ra tion  o f  B i l i r u b in  Species
The initial method used was that of Lauff (Lauff et al, 
1981), a gradient separation on a reversed phase column (octyl 
silane, 10pm) maintained at 41°C. Detection of bilirubin 
species was carried out on a UV/Visible wavelength detector at 
450nm. Both components of the mobile phase contained 
phosphoric acid. The initial mobile phase was aqueous and 
contained 0.05Molar of 2Molar phosphate buffer and 5% methoxyet- 
hanol, in distilled water at pH 2 (adjusted with phosphoric 
acid). The organic mobile phase contained 5% 2-methoxyethanol 
in 95% isopropyl alcohol acidified with 2.5% phosphoric acid. 
A linear gradient was efficient in separating the various forms 
and the bilirubins were eluted over 16 minutes at a flow rate of 
1.4ml/minute. The delta fraction eluted last at 80% organic 
phase. This high percentage of organic mobile phase was held 
for 8 minutes to ensure all components had eluted from the 
column. A 7 minute equilibration period with 100% aqueous 
mobile phase followed before application of the next sample.
Preparation of Samples
Application of diluted serum/plasma directly onto the column 
resulted in loss of resolution due to irreversible adherence of 
large molecular weight protein onto the column so the Yeoman 
method of deproteination was used. 0.25ml serum/plasma was 
added to 3.5ml of a 27.7g/l sodium sulphate solution (pH7) at
37°C and shaken for 5 minutes. This caused precipitation of 
proteins with molecular weight greater than 10^ daltons. The 
solution was then passed through a 0.45jjm filter (MILLEX) into a 
5ml volumetric flask containing 0.5ml 10% ascorbic acid solution 
prepared in 1:5 of a 2 Molar phosphate buffer pH 5.8. 
Distilled water made up the volume and the samples were stored 
at -20°C in the dark or immediately applied to HPLC. Bilirubin 
standards were serial dilutions of a 20mg/dl bilirubin dissolved 
in 1ml DM SO, with 2ml 0.1M sodium bicarbonate in 4% human serum 
albumin (HSA) fraction V pH7.4. The pH was adjusted using 0.1M 
HC1. Rat and human serum albumin were found to be interchan­
geable giving similar results.
For application onto the column 0.25ml diluted standard was 
prepared with sodium sulphate solution as with the samples above 
This method allowed clear separation of the various species 
of bilirubin in Gunn rat serum.
Isocratic Separation
A method has recently been developed for isocratic 
separation of the species of bilirubin found in serum (McDonagh, 
personal communication). In this method a small volume of 
serum is mixed with the mobile phase, which leads to 
precipitation of protein. After centrifugation to remove the 
residue,the supernatant is then applied directly onto the 
octadecyl silane (C18) column. The column temperature is 
maintained at 31°C. The organic mobile phase consisted of 
24.15g/l di-N octylamine mixed with methanol with 6.005g/l 
glacial acetic acid added. The flow rate was lml/minute, and
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bilirubin eluted after 8-10 minutes. Addition of a small 
percentage of water gave better resolution of the different 
species of bilirubin but with longer run times.
2.8 IDENTIFICATION OF BILIRUBIN BY THIN LAYER CHROMATOGRAPHY
The true nature of bilirubin in brain homogenate samples or 
in serum samples was determined by thin layer chromatography.
B i l i r u b in  was o r g a n ic a l ly  e x tra c te d  as d esc rib e d  in  s e c tio n  
2.9.1. The c h lo r o fo r m  f r a c t io n  was c o n c e n tra te d  unde r N 2 gas 
in  subdued l i g h t  and th e n  d e v e lo p e d  on a s i l i c a  g e l  H p la t e  
(M erck) w i t h  a c h lo r o fo r m :a c e t ic  a c id  s o lv e n t  (McDonagh & 
A s s is i,  1971). The Rf v a lu e s  o f  r e s u l ta n t  bands were compared 
to  s tandard  b i l i r u b in  from  a com m ercia l source.
The silica gel plates were firstly activated by incubating 
at 120°C for 60 minutes, and allowed to cool before use. The 
solvent consisted of 1% glacial acetic acid in chloroform. Rf 
values found for commercial bilirubin had a corresponding band 
on the samples thought to contain bilirubin in the brain.
2.9 EXTRACTION AND DETERMINATION OF BRAIN BILIRUBIN
2.9.1 Organic Extraction of Brain Bilirubin
Rats were sacrificed as described in section 2.2.3 and the 
brains perfused and removed. Brains were kept cold and 
exposure to light was limited as much as possible. Tissue was 
homogenised in exactly 4 volumes of 0.25 Molar sucrose using a 
polytron homogeniser. The homogenates were kept in the dark at 
-80°C until analysis which was always within 3 months of animal 
sacrifice.
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Bilirubin was extracted from homogenates using the method of 
Katoh (Katoh et al, 1975). 1 volume brain homogenate in
sucrose was added to 18 volumes chloroform: methanol: water 
mixture (2:5:2), and the bilirubin extracted using 10 strokes of 
a PotterElvehjem glass homogeniser with a teflon pestle. 8 
volumes water was then added, the solution vortexed and the 
layers separated by centrifugation at 3000xg for 15 minutes. 
The lower chloroform phase, containing bilirubin, was removed 
and evaporated to dryness under a stream of N 2 gas. The 
residue was resuspended in mobile phase for injection into HPLC.
2.9.2 Quantitation of Bilirubin By Isocratic HPLC
Coumarin 6 (Kodak) was used as internal standard. lOOng 
coumarin 6, dissolved in DMSO was added to bilirubin standards 
and brain homogenates. A standard curve was constructed as in 
Chapter 6. Standardisation of measurement of bilirubin in
brain homogenates was with a bilirubin standard of 1.7nmol/g wet 
weight. This was also regularly run between samples to act as 
a quality control mechanism. Wave l e n g t h  u s e d  w a s  4 0 0 n m .
The lower limit of detection was 0.12pg/g wet weight -
equivalent to 0.2 nmol/g wet weight.
2.10 DETERMINATION OF PROTEIN CONTENT OF SAMPLES
The enzyme assays which form a large part of this thesis 
determine enzyme activity with regard to the amount of protein 
contained in each sample. Therefore a reproducible method of 
measuring protein content was required. The most popular 
method for measurement of protein content in biological tissue
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preparations is the one published by Lowry (Lowry et al, 1951). 
In small volume samples with low concentrations of protein or 
when it was unsuitable to use the Lowry method for other reasons 
a more sensitive method developed recently (BIORAD) was used.
2.10.1 Protein Estimation by Lowry Method
A range of protein standards 25-200pg/ml were prepared using 
bovine serum albumin (BSA). Samples containing unknown protein 
concentrations were diluted to within this range. Samples and 
standards were reacted with Protein reagent, a solution 
containing Cu^+ ions in mild alkali. This was followed by 
addition of Folin and Ciocalteu's reagent. This combination 
reaction detects the presence of peptide bonds and is very 
sensitive. After 30 minutes a deep blue colour developed, the 
intensity of which was proportional to protein content. The 
absorbance of the solution was measured at 750nm. Protein 
content of samples in pg was determined from a standard curve 
prepared from absorbance values of the BSA standards. Samples 
were run in duplicate and the results were corrected for the 
dilution, averaged and expressed in mg/ml.
2.10.2 BIORAD Protein Estimation
Hi is method depends on the colour change of a dye (Coomassie 
Blue) in response to concentration of protein. A range of 
standards were prepared at concentrations 5 to 20ug/ml BSA. 
Samples with unknown protein concentrations were diluted into 
this range. BIORAD protein assay dye reagent was diluted 1:1 
with water, added and the intensity of colour obtained measured 
at 595nm by spectrophotometer. This was proportional to
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protein content and after construction of a standard curve 
protein content of samples could be determined as in 2.10.1. 
Dilution factors were again taken into account.
2.11 STATISTICAL METHODS
For all the analyses undertaken the Mann Whitney U test was 
employed. This non-parametrie test was chosen to compare two 
independent sample groups mainly because of the large 
variations and abnormal distributions which arose in the animal 
experimental work.
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CHAPTER 3
DEVELOPMENT OF THE 5-AMINOLAEVULINIC ACID SYNTHASE AND 
PROTOPORPHYRINOGEN OXIDASE ASSAYS IN RAT BRAIN TISSUE
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3.1 INTRODUCTION
ALA-synthase has been well characterised as the initial and 
rate controlling step of haem biosynthesis in liver tissue and 
the mechanisms of the reaction have been outlined m  section 
1.1.1.
Although the pathway in mammals has been studied in most 
detail in hepatic tissue this has been mostly due to availabili­
ty of this tissue. Studies of ALA synthase have been undertaken 
in many tissues, including the brain. Developmental aspects, 
the effects of ageing and the various effects of administration 
of exogenous agents known to affect ALA-synthase activity in the 
traditionally studied hepatic tissue in mammals and bacterial 
systems have all been examined. The results of these studies 
revealed that the brain enzyme has several unique properties.
In contrast PROTO-O, the penultimate enzyme of haem 
biosynthesis and the most recently discovered enzyme has not 
been investigated so fully. Severe difficulties in isolation 
and measurement of the enzyme from the most abundant tissue 
sources have hindered detailed study in a large number of 
different tissues. Published observations of PROTO-O activity 
appear to be exclusive to hepatic tissue in mammals with proper­
ties of the purified enzyme only available in some of the 
recent literature (Siepker et al, 1987; Dailey & Karr, 1987). 
None of the previous interest in PROTO-O has focused on defining 
activity in the brain. Brain haem biosynthesis studies have 
concentrated on mechanisms of control of the pathway without 
much consideration of the intermediate steps of the reaction. 
Thus PROTO-O activity in the brain has never been identified or
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quantitated previously. In order to analyse any effects of 
bilirubin on the haem biosynthetic pathway of the Gunn rat, 
development of an enzyme assay for PROTO-O in rodent brain is 
required. From various publications it is clear that adapta­
tion of an existing assay to new tissue involves several 
important considerations. All aspects of buffer content and 
concentration need investigation as well as optimal pH.
An existing assay of ALA-synthase developed for bone marrow 
activity measurement (Tikerpae et a l , 1981; Fitzsimons et al, 
1984) appears to present a more sensitive quantitation technique 
than the traditional one which derivatises ALA to a pyrrole and 
separates the product by column chromatography. The suitabili­
ty of this assay for brain tissue is investigated in the first 
sections of this chapter. Following the production of a 
successful assay for brain ALA-synthase an appropriate assay for 
brain PROTO-O will be developed enabling sensitive measurement 
of the early and late steps of haem biosynthesis in Gunn rat 
brain and comparison with activities in control rats.
3.2 BRAIN ALA-SYNTHASE
A large amount of work has focused on the function and 
properties of ALA-synthase in the brain. Purification of the 
enzyme from rodent brain has allowed study of the pattern of 
development. From a very low level immediately after birth 
activity rises, peaking at around 15 days and falling off to 
adult levels at 6 to 8 weeks (De Matteis et al, 1981). This is 
similar to the situation in liver and has been related to the 
increased haem demand while cytochromes are being formed. This
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is in support of a regulatory role for ALA-synthase in brain and 
contrasts with the age dependent maturation of mitochondrial 
cytochromes and respiratory activity in brain where a slow 
steady rise from birth to adult levels is observed (Chepelinsky 
& Arnaiz, 1970; Bull et al, 1979; Land et al, 1977). Adult 
levels of ALA-synthase activity are maintained throughout life 
even up to an age of two years (Paterniti et al, 1978).
ALA-synthase is located within the mitochondrion in brain 
tissue as in liver (Granick & Sassa, 1971) and synthesis is 
similarly thought to occur in the cytosol before translocation 
to the mitochondria, since use of a succinyl CoA generating 
system has demonstrated a cytoplasmic form of the enzyme exists 
(Paterniti et al, 1978). Within brain mitochondria it is likely 
that the enzyme will be loosely bound to the inner mitochondrial 
membrane, facing the matrix, with some free in the matrix 
(Scotto et al, 1983) as has been reported for liver (McKay et 
al, 1969)
Within cranial tissue regional ALA-synthase activity has 
been studied. Highest activity was located in cerebellum 
(Percy & Shanley, 1979; Maines, 1980) but the cerebral cortex 
and midbrain regions also had relatively high activity (Maines,
1980). Much lower but detectable activities were found in the 
striatum, septum, hypothalamus, thalamus, amygdala and hippocam­
pus (Percy & Shanley, 1979; Maines, 1980). Measurement of 
total porphyrin and haem content did not vary greatly although 
less haem was found in the cerebellum (Maines, 1980). Haem 
oxygenase activity appeared to be constant throughout the
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regions studied (Maines, 1980).
The regulatory role of ALA-synthase in liver is well 
documented, with activity of the enzyme under negative feedback 
control by haem as has been discussed in section 1.3.1. In 
the acute porphyrias, a partial deficiency of a particular enzyme 
of the pathway results in block to some extent of the production 
of haem. Impairment of nervous function is a common symptom 
and it has been postulated that disturbances in haem biosynthe­
tic pathway in the brain may account for this (De Matteis et al,
1981). It remains unclear whether this type of disturbance is 
due to depletion of haem or related to the increased levels of 
haem precursors which result from the enzymatic block.
In order to try and determine if ALA-synthase has a regulato­
ry role in brain as postulated by De Matteis and coworkers, the 
effect of various agents on brain ALA-synthase activity have 
been studied to assess inducibility. Early workers who treated 
rats with haematin, an exogenous form of haem, found no effect 
on the brain enzyme but this was thought to be due to lack of 
access to the brain through intravenous administration (De 
Matteis et al, 1981). Haematin intraventricularly produced a 
drop in ALA-synthase activity (De Matteis et al, 1982), an 
effect which would be expected for the regulatory enzyme in the 
presence of excess haem. In addition administration of 
succinyl acetone, a very effective competitive inhibitor of ALA- 
D, caused marked reduction of brain ALA-D in parallel to that 
seen in liver of both rats and mice (De Matteis & Ray, 1982; 
Kang et al, 1987). Also in support of a regulatory role of 
ALA-synthase, when ALA incorporation into haem was reduced in
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rat brain following administration of succinyl acetone to 
deplete haem content, a compensatory increase in ALA-synthase 
activity was observed (De Matteis & Ray, 1982). In mice, 
despite the successful inhibition of ALA-D no increase in ALA- 
synthase could be detected and total brain haem levels were 
unaffected (Kang et al, 1987). Kang and coworkers were also 
unable to pinpoint any behavioural disturbances as a result of 
the increased concentration of ALA but the actual levels were 
not measured so this does not discount the possibility that 
increased levels of ALA may contribute to neurological 
dysfunction.
Manipulation of brain ALA-synthase activity is clearly 
possible but this particular form of the enzyme is not affected 
by the wide range of factors which are well known inducers of 
the liver enzyme. The enzyme is refractory to induction by 
AIA, DDC, ethanol, and nutritional states ( Paterniti et al, 
1978). Some divalent metal ions, especially cobalt and 
manganese (Mn^+) are well known inhibitors of ALA-synthase 
activity in hepatic tissue. A corresponding induction of haem 
oxygenase (Sunderman et al, 1987) . . is likely to result in a
marked reduction in liver haem content. In brain, Co^+ ions 
were ineffective but Mn^+ ions caused inhibition of ALA-synthase 
in various regions of the brain (Maines, 1980; De Matteis et al,
1981). The mechanism is not well established, and no correspo­
nding effect was observed in haem oxygenase activity. This 
suggests the effects of metal ions in the brain are distinct 
from those seen in the liver. In vitro studies failed to show
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any effect of the Mn^+ ion on the enzyme and so it has been 
postulated that the lowering of activity seen hi vivo occurs via 
a disruption of enzyme turnover. Metal ions are known to inhibit 
protein synthesis by electrostatic interactions with DMA 
(Eichorn & Shin, 1968) and Mn can substitute for Mg as the metal 
activator of DMA polymerase so causing errors in nucleotide 
incorporation (Sirover & Loeb, 1976). Experimentation with 
various manganese containing compounds has shown that only the 
free metal ion is effective (Maines et al, 1984).
Decreased ALA-synthase activity has also been observed when 
rats are treated with cycloheximide, a compound which prevents 
stimulation of hepatic ALA-synthase after administration of 
inducers (Maines et al, 1976), or when the methyl ester of ALA 
is given. Conflicting reports exist as to the effect of ALA 
itself on brain haem biosynthesis. De Matteis and coworkers 
(De Matteis et al, 1981) reported a reduction in ALA-synthase 
activity in the brain when ALA was administered intravenously. 
This is in support of a regulatory role for brain ALA-synthase 
as for the liver form. Levels of ALA-synthase activity in
rat brain homogenates were found to be around one fifth of those 
in liver when assessed per milligram wet weight tissue, with 
values of around 40 - 80pmoles ALA formed/hour/milligram protein 
in adult rats (De Matteis et al, 1981; Paterniti et al, 1978) 
with higher values of around 120 to 180pmol/hour/ milligram 
protein found in mitochondrial preparations. in immature 
animals the peak activity has been reported to be 3 to 4 times 
that seen in mature animals. The highest activity was found in 
the cerebellum (Percy & Shanley, 1979), with the cerebral cortex
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and midbrain also having comparatively high values (Maines,
1980). Much lower activities were found in the striatum, septum, 
hypothalamus, thalamus, amygdala and hippocampus.
3.3 BRAIN ALA-SYNTHASE ASSAYS
Measurement of ALA-synthase activity has been possible 
since 1963 when ALA produced by enzyme activity was converted to 
pyrrole by condensation with acetyl acetone. Colorimetric 
analysis could then be achieved by addition of Ehrlich's 
reagent (Granick & Urata, 1963).
3.3.1 Colorimetric Assay of ALA-synthase
The sensitivity of the colorimetric method is relatively 
low and is only of practical use when large amounts of tissue 
with fairly high activity are available. Although endogenous 
activity of rat liver is detectable (Marver et al, 1966) the 
spectrof luorimetric analysis of ALA-synthase activity was not 
considered for brain tissue as both amounts of tissue and 
activity of the enzyme are low.
3.3.2 Fluorometrie Assay of ALA-synthase
A fluorometric assay for ALA-synthase has been developed 
which measures ALA production at low levels, but this method is 
indirect. Since ALA does not itself fluoresce the assay is 
coupled to ALA-D and PBG-D assays and formation of oxidised to 
uroporphyrin I is quantitated. Use of this assay was rejected 
since intermediates can under some circumstances be elevated so 
giving falsely high values for ALA-synthase activity.
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3.3.3 Radiochemical Assay of ALA-synthase
Other sensitive methods for assay of ALA-synthase activity 
involve incorporation of a radiochemical precursor into ALA and 
quantitation of the activity in the product. Radio label ling of 
the direct substrates is more easily achieved by [2^C] glycine 
since [^C] succinyl CoA is unstable for storage and so would 
have to be manufactured on site, an expensive process.
[2-l^C] glycine has been used as the labelled precursor and 
the radioactive product separated from contaminants by thin 
layer chromatography (t.l.c.) (Freshney & Paul, 1970). In 
Friends cells the time required for separation has been reduced
by use of high voltage electrophoresis followed by oxidation of
►
the resolved ALA into scintillation cocktail for determination 
of DPM content (Rutherford et al, 1979). This method has 
proved successful for measuring ALA-synthase activity in 
leucocytes (McColl et al, 1982) and was investigated for use on 
liver and brain tissue for this thesis.
Alternatively either [-^C] oc ketoglutarate or [2,3^C] 
succinate can be used. Although not direct substrates for the 
enzyme both of these compounds result in production of labelled 
succinyl CoA through the citric acid cycle. Most commonly in 
animal preparations [2,3-^C] succinate is used. In assay of 
each tissue many of the essential requirements and cofactors in 
the incubation medium are similar but actual concentrations 
often vary. In addition some specialised factors may be neces­
sary to enable measurement of ALA-synthase activity in certain 
tissues another reference to the tissue specific nature of the 
enzyme. This emphasises the necessity for optimising the
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conditions of assay for each new tissue studied. In brain 
[14C] succinic acid has previously been most commonly used and 
it was decided to use this substrate.
Separation of [^^C] ALA
In the published assays of measurement of ALA-synthase 
activity using [2,314C] succinate the most common difference is 
in the method for isolation of the [^4C] ALA product. In 
murine liver and spleen homogenates [^4C] ALA has been directly 
determined after separation on a Dowex 50 chromatography column 
(Ebert et al, 1970). A three step process of ion exchange 
resulted in better recovery (Strand et a l , 1972). In brain 
these separation techniques proved insufficient to separate 
[-*-4C] ALA from radioactive contaminants (De Matteis et al,
1981). Conversion of the labelled ALA to a pyrrole allowed 
adequate separation either by extraction and colorimetric 
analysis (Maines, 1980) or ion exchange chromatography (De 
Matteis et al, 1981). In bone marrow a successful HPLC techni­
que has been used to isolate [^4C] ALA produced.
3.3.4 Choice of ALA-synthase Assay for Brain
For these experiments initial studies on activity of ALA- 
synthase in brain homogenates and mitochondria were carried out 
using the [2-*-4C] glycine method described in section 2.3.1. i) 
Unfortunately the high voltage electrophoresis of [^4C] ALA did 
not produce clear separation of the labelled ALA from radioac­
tive contaminants. This problem was encountered in previous 
assays of brain ALA-synthase using the [2,3^4C] succinate as
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substrate. To resolve the labelled ALA the pyrrole of ALA with 
ethylacetoacetate {2-methyl-3-carbethoxy-4-(3-propionic acid) 
pyrrole} was formed but separation still proved to be a 
problem. Reverse phase HPLC, adapted from the method used by
Tikerpae and coworkers (Tikerpae et al, 1981) was insufficient 
to separate the radioactive contaminant from the ALA peak, so 
rendering [^C] ALA production unquant if iable.
The unsuitability of [2^C] glycine prompted attempts to use 
[2,3-^C] succinate, an indirect substrate which has been 
successfully resolved by HPLC. Conditions for brain assay 
using [2,3-^^C] succinate have been optimised, as have 
conditions for separation of the labelled ALA for the bone 
marrow preparations but the two have not yet been combined.
3.4 CONDITIONS FOR ASSAY OF BRAIN ALA-SYNTHASE
Brain tissue homogenates and mitochondrial preparations 
were prepared as described under methods section 2.3.3. The 
best tissue preparation was first determined on rats with ALA- 
synthase activities within the normal range (Wistar or Sprague 
Dawley adult animals) then components of the enzyme assay system 
optimised.
3.4.1 Determination of the Best Tissue Fraction for Brain ALA- 
synthase Activity Measurement
In brain, ALA-synthase has been studied in both homogenates 
and mitochondria but most frequently tissue homogenates have 
been used. Comparisons were carried out between activity of 
brain ALA-synthase in brain homogenate and mitochondrial prepa­
rations and the results are presented in Table 1. The assay
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ALA-SYNTHASE ACTIVITY 
pinoles ALA formed/mg protein/hour
HQMOGENATE
14.1 
12.8
18.1 
20.0
14.2
15.2 
22.6 
10.5
8.6
MITOCHONDRIA
70.9
57.7
43.1
34.0 
30.5
34.0
43.0
p<0.001 by Mann Whitney U test
TABLE Is MEASUREMENT OF ALA-SYNTHASE ACTIVITY IN BRAIN
HOMOGENATE VERSUS MITOCHONDRIAL PREPARATIONS
medium used was that found to produce optimum activity of ALA- 
synthase. Each figure in the table is the mean of duplicate 
determinations on rats of similar age and weight. The results 
clearly show that ALA-synthase activity recorded from mitochon­
drial preparations is significantly higher than the results 
using homogenised brain (25% w/v) (p<0.001 by Mann Whitney U 
test). This result is the expected one for the subcellular 
location of the enzyme, and it was decided to carry out all 
subsequent determinations of ALA-synthase activity on 
mitochondrial preparations.
3.4.2 Inclusion of Sucrose
In previous methods for brain ALA-synthase assay, tissue 
has been homogenised in sucrose buffer which maintains the 
osmotic stability of the e n z y m e , then added to an incubation 
medium containing all the requirements for the assay. In assay 
of bone marrow where very small amounts of tissue are available 
the tissue sample is prepared directly in an incubation buffer 
containing sucrose. Since the ultimate aim of this work was to 
concentrate on brain tissue of immature rats with a limited 
amount of brain tissue 0.25 Molar sucrose was included in the 
incubation buffer, and all tissues were prepared in this medium.
3.4.3 Choice of Buffering System
Tris HC1 is the most common buffer used in the assay of 
brain ALA-synthase activity but sodium phosphate has also been 
used (Maines,1980). A combination of Tris HC1 and phosphate 
buffer has proved successful when HPLC is used to quantitate 
ALA-pyrrole (Tikerpae et al, 1981) but the exact concentrations
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of Tris and phosphate are unknown and may vary slightly in each 
batch of buffer. The use of phosphate buffer alone was discou­
nted by these authors because extraction into ether formed an 
emulsion. Liquid/liquid extraction was not adopted in this 
thesis and the optimum pH for formation of the pyrrole is above 
pH 6 so a 50mMolar potassium phosphate buffering system, at pH 
7.5 was measured against the combined buffer and a Tris buffer 
system and the results presented in Table 2 show that the buffer 
combining Tris HC1 and phosphate consistently gave better 
results. These results were also the tightest with a wider 
spread being observed on use of the other two buffer systems. 
Thus a mixture of Tris and potassium dihydrogen phosphate was 
used in the buffering system.
3.4.4 Glycine
As one of the substrates for ALA-synthase, sufficient 
glycine is required to saturate the enzyme. 50 - 100 millimo- 
lar quantities have been previously used for brain tissue 
assays. The optimal concentration, 50 millimolar, has been 
determined for brain homogenates but not mitochondria (Paterniti 
et al, 1978). Studies were undertaken to determine the optimum 
concentration of glycine in brain mitochondrial preparations and 
results are presented in Figure 17. Adult Wistar male rats, 
fasted for 24 hours, were used in each case. Each point repre­
sents the mean of three determinations. 45 millimolar glycine 
was subsequently included in all brain assays of ALA-synthase 
activity.
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ALA-synthase activity 
pmol/mg protein/hour
TRIS HCl BUFFER 38.9 + 14.5
KH2P04 BUFFER 36.4 + 9.5
TRIS HCl AND
KH2P04 BUFFER 47.6 + 8.3
Results are expressed as mean + SD 
n=6
TABLE 2: THE OPTIMAL BUFFERING MEDIUM FOR MEASUREMENT OF ALA-
SYNTHASE ACTIVITY IN BRAIN MITOCHONDRIA
pmolALA/mg protein/hour
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FIGURE 17 : THE EFFECT OF DIFFERENT CONCENTATIONS OF GLYCINE 
ON RAT BRAIN ALA-SYNTHASE ACTIVITY
3 . 4 . 5  In c l u s i o n  o f  M ag n es iu m  C h lo r id e  (M g C l2 )
Magnesium ions are essential for succinate thiokinase 
activity and so are necessary for conversion of [2,3-^C] 
succinate to the radiolabelled succinyl CoA. MgCl2 is necessa­
ry when an external succinyl CoA generating system is added to 
the assay medium, and has been included in incubation media for 
several published brain ALA-synthase assays. The use of a 
succinyl CoA generating system is investigated in section 3.4.9 
and MgCl2 at a concentration of 5mMolar was routinely included 
in the incubation medium.
3.4.6 Inclusion of EDTA
Tn hepatic systems EDTA is reported to inhibit ALA-D 
activity and prevent formation of aminoacetone, an intermediate 
which may interfere with measurement techniques and make quanti­
tation of the true amount of ALA formed more difficult. The 
presence of EDTA in brain preparations assayed for ALA-synthase 
appears to have no effect on activity (Paterniti et al, 1978) 
but no reduction in activity was observed by these authors and 
so a low concentration (2mMolar) was included m  the assay 
medium.
3.4.7 Optimum Concentration of Succinate
[2,3-^C] succinic acid had specific activity of 45mCunes- 
/mmole. 2.5 pCi was included in each assay. [2,3-^^C] 
succinic acid powder was dissolved in a solution of 20mMolar 
"cold" succinate. The optimum concentration for succinate has 
been determined as 3mMolar, the Km for succinate being much 
lower than that for glycine and so this ensured excess succinate
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was present to allow the reaction to proceed.
3.4.8 Concentration of Pyridoxal phosphate
Pyridoxal phosphate is well documented as an essential 
cofactor for ALA-synthase activity. A concentration of 
0.4mMolar is generally used to give optimum measurement of 
activity. Several concentrations of pyridoxal phosphate were 
added to the incubation medium and results agreed well with 
those of other authors. The results are presented in Figure 18 
with each point the mean of three determinations. The 
concentration of 0.4mMolar was the value chosen since this was 
on the plateau. Formation of ALA was linear with respect to 
time (Figure 19).
3.4.9 Effect of an External Succinyl-CoA Generating System on ALA- 
synthase Activity
In brain preparations there is dispute over whether addition 
of an external succinyl CoA generating system will produce 
higher ALA-synthase activities. Homogenates appear to supply 
enough intermediates but some improvement has been seen in 
mitochondria after addition of external GTP and succinate 
thiokinase. Results of the comparison of ALA-synthase 
activities with and without incorporation of the external 
succinyl CoA generating system in homogenate and mitochondria 
are shown in Table 3.
In fresh tissue, whether mitochondria or homogenate prepara­
tions were used, the succinyl CoA generating system did not give 
higher results for ALA-synthase enzyme activity.
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FIGURE 18 : THE EFFECT OF DIFFERENT CONCENTRATIONS OF 
PYRIDOXAL PHOSPHATE ON RAT BRAIN ALA-SYNTHASE ACTIVITY
pmolALA/mg protein/h 
60 -
50 -
40
30 -
20 -
10
0.0
O
O
O
O
0 20 40 60 80
O
120
TIME (MINUTES)
FIGURE 19 : FORMATION OF ALA WITH RESPECT TO TIME
ALA-SYNTHASE ACTIVITY 
pmol ALA formed/mg protein/hour
MINUS SUCCINYL CoA 
GENERATING SYSTEM
13.4 
12.2
17.4
32.9
PLUS SUCCINYL CoA 
GENERATING SYSTEM
14.1 
12.8
18.1 
20.0
TABLE 3: THE EFFECT OF AN EXOGENOUS SUCCINYL CoA GENERATING
SYSTEM ON ALA-SYNTHASE ACTIVITY IN BRAIN HOMOGENATES
3.5 ISOLATION OF TOE ALA PRODUCT FROM BRAIN ALA-SYNTHASE ASSAY
3.5.1 Pyrrole Formation
Direct measurement of [^C] ALA produced in the brain ALA- 
synthase assay has not proved possible due to a contaminating 
factor which co-elutes with ALA on chromatography (Paterniti et 
al, 1978; Percy & Shanley, 1979; De Matteis et al, 1981). 
Conversion of ALA to a pyrrole derivative allows separation and 
quantitation. Pyrrole derivatives have been formed with 
acety1-acetone and ethylacetoacetate see Figure 20. Ethylace-
toacetate is preferred when HPLC is used to separate the [^C] 
ALA pyrrole. Cold ALA (4mMolar) was added to each sample prior 
to pyrrole formation to enable easy quantification of the ALA- 
pyrrole. Purification of the derivatised mixture was achieved 
using solid phase sample preparation.
3.5.2 Reverse Phase HPLC of ALA—pyrrole
High performance liquid chromatography (HPLC) is a fast 
efficient method of separation of biological molecules with a 
wide range of applications. The main advance from traditional 
chromatography is the use of much smaller molecules within the 
column (10 microns or less) resulting in much larger surface 
areas for interaction with samples. Separation of molecules 
can be based on size (molecular sieve chromatography) or charge 
(ion exchange chromatography) but the most common form in 
separation of small biological molecules is based on the hydrop­
hobic or hydrophilic properties of the molecules.
Although these types of separation have different principles 
the system used in each case is essentially the same. A
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FIGURE 20 : FORMATION OF ALA - PYRROLE DERIVATIVES
solution containing the sample is dissolved in liquid (mobile 
phase) and pumped through a column consisting of small particles 
(stationary phase) where separation occurs. The size and tight 
packing of the column necessitates use of a high pressure pump 
to push the sample through the column. On elution a detector 
measures a peak and this is reported and can then be quanti­
tated .
Normal and reverse phase HPLC are especially useful for the 
separation of small molecules. In reverse phase chromatography 
the stationary phase is composed of silica with hydrocarbon 
chains covalently bound to their surface. Increasing the length 
of the hydrocarbon chains makes the stationary phase more 
hydrophobic. The mobile phase is a hydrophilic medium so that 
more hydrophilic components of the sample will remain dissolved 
in this medium and will pass through the column while lipophilic 
components can interact with the hydrocarbon chains on the 
column and are retained.
The range of molecules which can be separated is widened by 
addition of varying amounts of an organic component such as 
methanol or acetonitrile to the mobile phase. For separation 
of several similar molecules from complex mixtures a gradient 
type of elution, where the organic content of the mobile phase 
is gradually increased, can be employed. Interactions of 
molecules with the stationary phase can be altered to improve 
separation in other ways. In some cases a change in the pH of 
the mobile phase improves resolution. The presence of charged 
groups on the molecule of interest can prevent maximum interac­
tion with the stationary phase by reducing solubility so
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limiting contact. Alternatively the reaction can be modified 
by addition of an ion pairing agent. These compounds may 
complex with the molecule of interest resulting in an alteration 
of the reaction with the stationary phase. However interac­
tions of the ion pairing agents with the stationary phase or 
both sample and stationary phase may be responsible for improved 
separation. Thus weak acids can be made more hydrophobic by 
acidifying the mobile phase and similarly, for weak bases, raising 
the pH increases interaction with the stationary phase.
For resolution of ALA, 1-hepatanesulphonic acid, an ion 
pairing agent, was added to aqueous mobile phase containing 37% 
methanol. The stationary phase, C18 bound silica, was 
contained in a 250 x 4.5mm column. In HPLC of ALA-pyrrole from 
bone marrow samples the same ion pairing agent, but in the form 
of PIC B7 (Waters) was used. When 0.005 Molar 1-hepatanesul­
phonic acid was dissolved in 20ml/litre IMolar acetic acid and 
added to the mobile phase no loss of resolution resulted. 
Mobile phase containing this solution was made up fresh daily.
Flow rate is an important factor in determining sharpness of 
peaks. Low flow rates can result in peak broadening but 
increasing the rate too much prevents maximum interaction with 
the stationary phase lowering resolution. Optimum flow rate
for separation of ALA was 1.5 ml/minute. ALA was eluted at
approximately 8 to 9 minutes after injection, but retention time 
could be decreased by addition of a slightly higher percentage 
of methanol (up to 40%).
The column eluent was collected in 0.5 minute fractions
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around and during the ALA peak and the fractions were added to 
scintillant for counting. Background DPMs were subtracted and 
the results calculated as in the Methods, section 2.3.1.
Before application to the HPLC column samples were purified 
using solid phase sample preparation. This increased column 
life and reduced background DPMs.
3.5.2 [14C] ALA-pyrrole Purification
Liquid/liquid extraction of ALA has previously been used in 
brain assays but the tolumes obtained would require much concen­
tration before application to a HPLC method could be achieved. 
Recently solid phase sample preparation has been used to detect 
ALA pyrrole in bone marrow samples (Fitzsimons et a l , 1986). 
The sample is applied to a small disposable column which prefe­
rentially retains the molecule of interest, in this case ALA 
pyrrole, while other components which are more soluble in the 
application buffer pass through in a similar manner to the 
situation on HPLC. Elution is achieved by changing to a 
solvent which has higher affinity for the molecule than the 
column. A Sep-pak cartridge (Waters) containing C18 bound 
silica binds non-polar molecules. ALA pyrrole, applied in a 
slightly acidic aqueous solution will bind to the column 
allowing more polar components of the sample to pass through. 
The cartridge can then be dried before application of methanol 
which strips the column of the pyrrole. Prewetting of the 
column with a water miscible solvent, in this case acetonitrile, 
is necessary to activate the column when samples are applied in 
aqueous solution. This "clean-up" step allowed many more
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samples to be injected into each column and simultaneously 
removed any contaminating radioactivity.
3.5.4 Results of HPLC of ALA-pyrrole
An example of an HPLC trace of ALA-pyrrole is included in 
Figure 21. The peak of interest is clearly identified and 
cannot be mistaken for any other peak on the chromatogram. The 
full method used to measure ALA-synthase activity in rat brain 
is quoted in the methods section 2.3.1. The results obtained 
for rat brain are within a similar range to those previously 
obtained (Paterniti et al, 1978).
ALA-synthase activities in liver and brain mitochondria were 
both measured and compared. The brain ALA-synthase activities 
were found to be significantly lower as previously determined in 
the literature. Examples of liver and brain ALA-synthase 
activities are demonstrated in Table 4.
3.6 PROTO-OXIDASE IN RAT BRAIN
As stated earlier PROTO-O is the most recently identified 
enzyme of the haem biosynthetic pathway, the concrete evidence 
for its existence as a separate entity emerging only in the last 
15 years. (Jackson et al, 1974; Poulson & Polglase, 1975). 
The enzyme has now been isolated, purified and measured in 
hepatic tissue of mouse, (Dailey & Karr, 1987) and ox (Siepker 
et al, 1987) but no work has concentrated on other tissue 
sources of the enzyme. Thus existing assays have been 
developed for hepatic sources of enzyme in animals and for plant
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a = solvent front
b = Peak due to ALA-pyrrole
FIGURE 21 : TYPICAL HPLC TRACE OF ALA-PYRROLE PEAK
ALA-SYNTHASE ACTIVITY 
pmol ALA/mg protein/hour
LIVER
BRAIN
Results are expressed as mean + SD 
n=9
TABLE 4: ALA-SYNTHASE ACTIVITIES IN BRAIN AND L I VER
MITOCHONDRIA DETERMINED WITH 14C SUCCINATE AS 
SUBSTRATE
356 + 46 
49.1 + 8.3
and bacterial sources. Even many of these assays list several 
problems with their existing PROTO-O assays. It is likely that 
modifications to these assays will have to be carried out in 
order to adequately measure the enzyme in the brain.
3.6.1 Choice of PRQTO-O Assay
Two types of PROTO-O assay exist at present. Both quanti­
tate appearance of the strongly red-coloured PROTO from the 
enzymatic substrate, straw coloured PROTO'gen. PROTO has a 
well defined spectrum in the visible range and this has been 
measured spectrophotometrically. In addition PROTO fluoresces 
and this provides another method of quantitating the emergence 
of enzyme product. [n both assays an accurate result depends 
on a linear relationship existing between the concentration of 
PROTO in the reaction mixture and the absorbance/fluorescence. 
Evidence has been obtained that at low protein concentrations 
the linearity of the relationship between absorbance and PROTO 
concentration may be compromised (Jacobs & Jacobs, 1982). The 
assay of choice for brain PROTO-O must be useful at low protein 
concentrations as the source of brain tissue is limited. As 
the ultimate aim of the project is to examine PROTO-O activities 
in neonatal Gunn rats and compare enzyme activities with matched 
control and drug treated rats availability of all tissues will 
be low, necessitating the use of the fluorometric assay.
Reliability of the PROTO-O assay depends on production of a 
relatively pure substrate for the enzyme. Problems can occur 
when full reduction of PROTO does not occur. Significant 
levels of PROTO leads to product inhibition of the enzyme
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activity (Jacobs & Jacobs, 1982). A strong reducing agent is 
therefore necessary. Auto-oxidation is another major problem, 
with PROTO'gen reverting to PROTO spontaneously on exposure to 
light. This necessitates all steps after conversion of PROTO 
to enzyme substrate having to be carried out under conditins 
which as far as possible exclude light. Even with these 
precautions a reagent blank containing buffer and substrate is 
included in the assay and any increase in fluorescence 
subtracted from all results obtained.
In the fluorometric assay mitochondria are resuspended in 
PROTO-O buffer, Tween 20 added, the solution sonicated and an 
aliquot diluted and GSH added to prevent auto-oxidation. This 
solution is then allowed to reach 37°C before addition of the 
freshly prepared substrate. This is the reaction mixture, and 
small aliquots are removed at pre-determined times and diluted 
further into measuring tubes before the fluorescence is 
determined.
3.6.2 Choice of Buffering System
The most common choice of buffering system previously used 
for the PROTO-O assay has been a Tris buffer. The pH values 
found to be optimal for measurement of PROTO-O activity have 
varied according to the source of tissue, but in general this 
has been above neutral, ranging from pH 7.45 in yeast (Poulson & 
Polglase, 1975) to pH 8.7 in rat liver (Jacobs & Jacobs, 1982) 
The concentration of Tris used has been fairly constant at 
around 100mmoles/litre. From previous experience in these 
laboratories pH 9.2 was discovered to be optimal for PROTO-O
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assay in rat liver mitochondria. The optimum pH for assay of 
rat brain mitochondria was determined with lOOmmolar Tris HCl. 
The results of these determinations are presented in Figure 22. 
Each point represents the mean of 3 duplicate determinations. 
The optimal pH for assay of rat brain PROTO-O was found to be at 
pH 9.2. The PROTO-O buffer was also saturated with air so that 
there would be no shortage of oxygen to accept the electrons 
which are lost from PROTO'gen.
The optimal concentration of Tris HCl for assay of the brain 
enzyme was also determined. The best results were obtained 
with lOOmMolar Tris HCl as shown in Figure 23.
EDTA has previously been included in assays of PROTO-O. 
Its presence helps prevent chelation of other metals, especially 
zinc which can lead to a block of incorporation of iron into 
haem (Jacobs & Jacobs, 1982). EDTA at a level of lmmol/1 was 
routinely included in all PROTO-O assay buffers of brain and 
other tissues.
3.6.3 Presence of a Reducing Agent
Auto-oxidation has been mentioned as a considerable problem 
in attempts to measure PROTO-O activity. The presence of a 
reducing agent in the assay medium has been shown to 
significantly reduce the rate of auto-oxidation (Jacobs & 
Jacobs, 1982). 5mmol/l glutathione (GSH) was added to both 
reaction vials and measuring tubes. Auto-oxidation still 
occurred at a significant rate and this change in fluorescence 
not attributable to PROTO-O activity was subtracted from true 
activity.
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PROTO-O ACTIVITY 
nmol PROTO / 
mg protein / hour
10 J
7.0 7.6 8.0 8.2 8.4 8.6 8.8 9.0 9.2 9.4 9.6 9.8 10.0
pH UNITS
FIGURE 22 : OPTIMUM pH OF ANALYSIS OF PROTOPORPHYRINOGEN
ACTIVITY IN RAT BRAIN
10
5
•  PROTO-O ASSAY AT 100 mmol/l TRIS Cl
O PROTO-O ASSAY AT 50 mmol/l TRIS Cl
A  PROTO-O ASSAY AT 25 mmol/l TRIS Cl 
Results are expressed as mean + SD
FIGURE 23 : OPTIMAL BUFFERING CAPACITY FOR 
PROTOPORPHYRINOGEN IX OXIDASE 
ACTIVITY IN BRAIN
3.7 PRODUCTION OF PROTOPORPHYRINOGEN SUBSTRATE
Reduction of PROTO to substrate for the enzyme, PROTO'gen, 
has proved difficult. Previous authors have noted a lack of 
reproducibility of results with the assay. Each batch of 
PROTO'gen substrate appears to result in a slightly different 
rate of oxidation in mitochondrial preparations (Jacobs & 
Jacobs, 1982). This heterogeneity of substrate leads to a high 
variability of rates of formation of PROTO and it would be 
useful to try and remove this variability.
On contact with sodium/mercury amalgam, the PROTO reacts 
violently. This leads to production of a large amount of foam 
resulting in a low volume of PROTO'gen. Addition of a larger 
ratio of PROTO to amalgam simply leads to partial conversion 
with a visible proportion of PROTO present. If the violence of 
the reaction could be reduced more substrate would be produced. 
Changes from classical dissolution agents for PROTO and addition 
of antifoaming agents were attempted.
3.7.1 Preparation of PROTO for Reduction
PROTO methyl ester was hydrolysed overnight as described in 
the methods section 2.3.4., freeze dried and stored at -20°C 
until use. PROTO was allowed to reach room temperature in the 
absence of light then dissolved and reduced to PROTO'gen 
immediately. The classical dissolution agent of lOmmolar KOH 
containing 20% ethanol was compared to N/7 sodium bicarbonate. 
The results showed no significant differences in production of 
substrate but the reaction with bicarbonate was slightly less 
violent. Quicker dissolution also occurred on use of this
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solution and N/7 sodium bicarbonate was chosen as an agent of 
choice to dissolve PROTO in all experiments.
3.7.2 A d d i t io n  o f  a n  A n t i fo a m  Agent
An antifoaming agent, a silicon based product, is manufac­
tured by Sigma. It was hoped that addition of a small volume 
of this type of preparation to the PROTO solution before 
addition to amalgam would reduce the amount of foam produced so 
maximising the amount of PROTO'gen generated.
Initial experiments on the fluorescence properties of the 
antifoam agent were first carried out. The spectrophotometric 
profile of PROTO and PROTO'gen, with and without antifoam were 
analysed and found to be identical. Solutions of PROTO had 1%, 
2%, and 5% Antifoam A added, before addition to amalgam. The 
experiment was successful in reducing the amount of foam 
produced by the reaction while having no effect on the spectrop­
hotometr ic profile of the substrate. Fluorometric analysis of 
PROTO'gen prepared in the presence of antifoam showed that a 
higher blank value was obtained. This was thought to reflect a 
higher proportion of unconverted PROTO in the solution, but when 
substrate produced in the presence of antifoam was reacted with 
mitochondrial preparations the rate of conversion of PROTO'gen 
to PROTO appeared to be greatly increased. Unfortunately this 
also proved to be true for the tissue blank sample, indicating 
that this result was a false positive, likely to be due to 
increased auto-oxidation. Addition of an antifoaming agent as 
an aid to production of improved character of PROTO'gen 
substrate was therefore abandoned.
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3.7.3 Purification of PROTO'gen by Solid Phase Sample Preparation
It has been previously been recorded in the literature that 
contaminating PROTO can be removed from converted PROTO'gen by 
solid phase sample preparation (Li et al, 1987). A strong 
anion exchange column (SAX, manufactured by Bond-Elut) could be 
conditioned with buffer and converted PROTO'gen applied such 
that any unconverted PROTO would adhere to the column, producing 
a purer solution of PROTO'gen for use as substrate in the PRQTO- 
0 assay. The column was conditioned using successively 
methanol, water and 0.25 Molar Tris buffer pH 7.2. Reduced 
substrate was added to an equal volume of Tris buffer pH 7.2 and 
passed through the column. The resulting solution was used in 
a PROTO-O assay but it was discovered that no PROTO-O activity 
could be recorded. On conversion with acid very little PROTO 
was measured. It appeared that PROTO'gen was also being 
retained by the SAX column. This step was therefore not used 
prior to assay.
3.7.4 Adopted Method of Production of PROTO'gen Substrate
lmg PROTO methyl ester was hydrolysed overnight with 70% HC1 
as in methods section 2.3.4. Prior to assay the freeze dried 
PROTO was suspended in the absence of light with N/7 sodium 
bicarbonate to give a working solution of concentration 
approximately 400pMolar. The resuspended PROTO was added to 
6 g sodium/mercury amalgam in a boiling tube and the solution 
shaken on ice in the absence of light until no fluorescence was 
visible under UV illumination. PROTO'gen was filtered through 
a fine porosity glass sinter funnel under pressure and the pH
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lowered to approximately pH 9 by titration with 1 molar 3-(N- 
morpholino)propane-sulphonic acid (MOPS acid), which has a more 
favourable pka (7.2) than phosphoric acid and is less likely to 
cause overshoot of pH into the acidic range (Dailey & Karr, 
1987). lOOpl of the PROTO'gen was added to the reaction vial 
containing 1 .5 ml enzyme/ buffer mixture and the reaction 
started.
3.8 ASSAY OF BRAIN PROTO-O ACTIVITY
Brain mitochondria were prepared as in the methods section 
and resuspended in 0.15 Molar KC1 to a final protein concentra­
tion not exceeding 5 mg/ml. 0.4 ml was then added to a reaction 
vial at 37°C containing 1.1ml Tris buffer (100mmol/l, pH 9.2), 
lmmol/1 EDTA and 5mmol/l GSH. The temperature was allowed to 
reach 37°C then freshly prepared PROTO'gen added. On mixing 
50pl of the sample was removed and used as a zero time, to 
determine fluorescence of tissue before reaction occurs. After 
10 and 20 minutes further 50pl aliquots were removed and the 
fluorescence determined. Auto-oxidation was determined by 
subtracting the change in fluorescence over the same time period 
by a tissue sample containing PROTO-O enzyme inactivated by 
heat.
PROTO-O activities in rat brain were found to be comparable 
with the levels detected in liver with Gunn-Wistar and Wistar 
rats showing values of 8.2 + 2.9 nmol PROTO formed/mg protein/ 
hour (mean + SD). These levels are very similar to the 
activities recorded in liver by other authors (Poulson, 1976; 
Brenner & Bloomer, 1980). It was consistently found that auto­
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oxidation was lower in brain tissue than in liver. This was 
thought to reflect a cleaner preparation.
3 . 9  SUMMARY
Accurate and specific assays for both ALA-synthase and 
PROTO-O activities in the brain have been developed. From the 
existing ALA-synthase assay slight changes have optimised the 
method for brain tissue. With respect to PROTO-O activity, the 
optimal assay method has proved to be identical to that which 
has previously been used in other tissues. The lack of 
specificity required for the PROTO-O assay may reflect that the 
enzyme is homologous with that in other tissues. This is 
already known not to be the case for ALA-synthase which seems to 
have tissue specific properties. The erythroid and hepatic 
forms of the enzyme are distinct, with different genes coding 
for the two enzyme proteins (Riddle et al, 1989; Bishop et al, 
1990). Brain ALA-synthase activity is dependent on stage of 
development (De Matteis et al, 1981) and certain other factors 
such as the presence of certain metals (Maines, 1980? Maines et 
al, 1984) or succinyl acetone (De Matteis & Ray, 1982) but no 
such information is available on activities of PROTO-O in the 
brain. More information on PROTO-O activity is hoped to be 
obtained from the studies in this thesis.
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CHAPTER 4
THE GUNN RAT AS A MODEL OF HYPERBILIRUBINAEMIA
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4.1 INTRODUCTION
Hyperbilirubinaemia in humans has been discussed in Chapter
1 . 5  but man is not the only species to suffer from the effects 
of elevated bilirubin. Mutant forms of various different 
species exist, and these can display either conjugated or uncon­
jugated hyperbilirubinaemia. These mutant species have been 
very useful to the research carried out on this range of 
conditions and have provided answers to many of the important 
questions in this area which can then be related to the human 
disease states.
Only one popular animal model exists for hereditary 
conjugated hyperbilirubinaemia and this animal, the mutant 
Corriedale sheep, displays a condition which compares well to 
Dubin-Johnson syndrome (Cornelius et al, 1965). Whether the 
metabolic basis for this disease is the same as that in humans 
remains to be determined.
The various hereditary unconjugated hyperbilirubinaemias 
provide more than one animal model system with another sheep, 
the mutant Southdown sheep, arguably a model for the moderate 
unconjugated hyperbilirubinaemia of Gilbert's syndrome. The 
Gunn rat has a defect in hepatic conjugation (Carbone & Grodsky, 
1957; Schmid et al, 1958) and this has been compared to the 
defect in Crigler-Najjar syndrome. The homozygous rat is 
unable to form bilirubin conjugates and in this way is similar 
to Type I of the syndrome
On closer study the mutant Southdown sheep has reduced 
clearance of bilirubin and various other organic anions which
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are removed from the circulation by the same system (Cornelius 
et al, 1968; Gronwall, 1970) and has been compared with the 
situation in Gilbert's syndrome (Mia et al, 1970). In contrast 
to Gilbert's syndrome much of the unconjugated bilirubin in the 
plasma appears to efflux from liver, with no reduction in 
glucuronidation rates obvious. Thus the basis behind the 
hyperbilirubinaemia in the mutant Southdown sheep is thought to 
differ from that in Gilbert's syndrome.
The two sheep models have been useful but work on live 
animals of this size is difficult, and in most situations occurs 
at veterinary establishments. Much of the animal work which 
has led to our present understanding of states of hyperbi­
lirubinaemia has been carried out on the Gunn rat, a mutant of 
the Wistar strain which suffers from congenital unconjugated 
hyperbilirubinaemia.
THE GUNN RAT
The Gunn rat was first identified in 1938 (Gunn, 1938). On 
observation these rats were suffering from congenital jaundice 
which within a few hours of birth resulted in the skin 
displaying a yellow tinge. Growth in the Gunn rat was 
consistently stunted when compared to Wistar counterparts, 
resulting in a lower adult body weight. Most Gunn rats 
displayed nervous symptoms and brain damage was evident from 
defects in balance often described as "wobbly gait". Serum 
bilirubin levels were found to be elevated when compared to 
normal and values range from 3 to 20 mg/dl or 51 to >300jjmolar 
(Wolkoff et al, 1982). When it was established that excretion
of bilirubin was achieved by glucuronidation to more 
water soluble conjugates the hepatic conjugating system of the 
Gunn rat was investigated. A severe defect in this pathway was 
consistently demonstrated in these rats (Schmid et al, 1958) 
and it was quickly confirmed that Gunn rats were unable 
to conjugate bilirubin in the normal manner. Despite this, the 
rats did not die as a result of high bilirubin levels. Instead 
withi a few weeks of birth the serum bilirubin levels 
stabilised and circulating bilirubin, though remaining elevated 
evened out. Thus bilirubin was still excreted in these animals 
at virtually normal rates but the unconjugated bilirubin was 
metabolised by unknown routes. It was discovered that unusual 
derivatives were formed and the mechanisms leading to these 
compounds have been investigated.
Phenobarbital is a well known inducer of hepatic mono­
oxygenase and UDP-GT systems in normal animals (Renmer, 1972). 
Effects of this drug on Gunn rats have been studied and results 
showed it to be ineffective in increasing glucuronidation of 
bilirubin (Vainio & Hietanen, 197*0. In accordance with this, 
recent genetic evidence has showed that the UDP-GT enzyme 
protein responsible for conjugating bilirubin is absent (Scragg 
et al, 1985). Evidence suggests that a number of isoenzymes of 
UDP-GT exist and the presence of UDP-GT activity towards phenol 
in Gunn rats supports the evidence for existence of 
isoenzymes. Activity is lower than that found in control 
animals but the defect is incomplete and this form of the 
enzyme remains inducible (Harding et al, 1989). The decreased
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activity towards phenol is thought to result from a mutation 
which affects a number of the isoenzymes of UDP-GT (Harding et 
al, 1989) including the bilirubin UDP-GT system. Gunn rats do 
retain the ability to excrete bilirubin but the route used leads 
to production of unusual derivatives of bilirubin. This 
pathway has been linked to another of the mixed function 
monooxygenase enzyme systems. Administration of 2,3,7,8-tetra- 
chlorodibenzo-p-dioxin which is known to stimulate the microso­
mal P448-dependent monooxygenases, led to increased bilirubin 
catabolism and reduced total serum bilirubin levels (Kapitulnik 
& Ostrow, 1977). Conjugation was not stimulated but production 
of excretable polar derivatives of bilirubin was increased.
The heterozygous Gunn rat has reduced activity of the UDP- 
GT enzyme system but does retain enough activity to maintain 
serum bilirubin levels within the normal range seen in Wistar 
rats (Schmid et al, 1958). It has been suggested that this 
heterozygote may provide a model for Gilbert’s syndrome (Carbone 
& Grodsky, 1957)
For many years yellow staining has been observed in the 
brain tissue of human fatalities resulting from kernicterus and 
in Gunn rats. The mechanism by which the neurotoxicity occurs 
after deposition of bilirubin however is poorly understood. 
In the homozygous Gunn rat there is marked cerebellar hypoplasia 
(Schutta & Johnson, 1967) with degeneration of the Purkinje 
cells occurring postnatally (Mikoshiba et al,1980). There is 
reduced production of neurotypic and gliotypic proteins and this 
reduction is consistent with the extent of morphological change 
and behavioural impairment (O'Callaghan & Miller, 1985). It
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has been documented that the Purkinje cells are most sensitive 
to bilirubin damage when rats were aged between 5 and 7 days old 
(Takagishi & Yamamura, 1987), but reports show that this is 
prior to the period in which bilirubin is preferentially 
deposited in the cerebellum (Yamamura et al, 1974; Aono et al, 
1989). This is a discrepancy which merits further investiga­
tion.
Although there is little doubt that bilirubin is present in 
the central nervous tissue of both Gunn rats and icteric infants 
there is great dispute over its route of entry. It is still 
unclear whether bilirubin bound to albumin crosses the blood 
brain barrier or if only the circulating unconjugated form is 
able to do so. Certainly it seems that the unconjugated form is 
responsible for the neurological damage. If the blood brain 
barrier of infants is immature then bilirubin may enter the 
brain more readily (Bakay, 1953; Ernster et al, 1957). Studies 
which showed that bilirubin deposition in the brain occurred 
less frequently in adult animals, and resulted in less marked 
staining, were concurrent with the belief that free bilirubin 
was able to enter the brain (Robinson & Rapoport, 1987), and 
that this was likely to occur when the blood brain barrier was 
immature . However Davis and Yeary showed similar uptake of 
bilirubin into brain by newborn and adult Gunn rats and so the 
increased sensitivity of the neonatal model is in question 
(Davis & Yeary, 1975; Robinson & Rapoport, 1987).
Under certain conditions, levels of unconjugated bilirubin 
in Gunn rats may be elevated even further allowing observation
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of a condition similar to severe kernicterus. This situation 
can occur naturally, for example when infection which leads to 
increased bilirubin production occurs, or it can be experimenta­
lly induced. Experimental kernicterus is usually achieved by 
injection of a competitive agent for bilirubin binding to 
albumin. The common one used is sulphadimethoxine or a related 
sulphonamide (Rose & Wisniewski, 1979; Davis & Yeary, 1975). 
When these drugs were first administered to neonates a much 
higher incidence of kernicterus resulted and these drugs are now 
contraindicated in infants. In the newborn the bilirubin 
conjugating system is immature and is unable to cope with the 
increased level of unconjugated bilirubin which is released from 
albumin during treatment putting the infant at risk of kernicte­
rus. On administration to Gunn rats signs of neurotoxicity are 
observed within hours (Rose & Wisniewski, 1979; Davis & Yeary, 
1975) and death often follows.
4.3 DEVELOPMENT OF A GUNN RAT COLONY
Gunn rats are very difficult to breed. When this study was 
undertaken there were only two known breeding centres in 
Britain. The first batches of animals were received from 
Dundee and these were in a successful breeding colony originally 
started from rats obtained from the other breeding centre, "The 
Royal Free Hospital" and run by Professor B. Billing. Primari­
ly it was intended to breed Gunn rats on site since ultimately 
it was our aim to look at kernicterus induced by sulphonamides 
in 14 day old rats. This task proved alternately easy and 
difficult with some of the breeding pairs producing two or three
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litters and some not breeding at all.
Within the period of this project the intensely inbred 
colony at Dundee died out and subsequently all rats were 
received from The Royal Free Hospital.
4.3.1 Breeding Stock
Gunn rats were caged in pairs. This was in contrast to the 
harem system used by other breeding centres. The animals were 
subjected to a twelve hour light and dark cycle with minimal 
disturbance. The breeding pairs were fed a special diet with 
high lipid content. A high content of lipid in the diet of 
Gunn rats has been shown to lower serum bilirubin levels (Gollan 
et al, 1975). This has not been attributed to increased 
excretion but to altered distribution of the bilirubin and 
deposition in tissues (Gollan et al, 1979).
Under these conditions pregnancy did occur but unreliably 
with only two or three litters being produced at most, over a 
period of more than a year. Pregnant female rats were fed with 
a supplement of dried milk made up to 250ml containing an egg 
yolk. By the time the infant rats were weaned at approximately 
four weeks of age the mothers' special diet had been gradually 
reduced and exchanged for water.
After the lack of success of this system male Gunn rats were 
teamed with two female Gunn rats. Unfortunately this did not 
produce any improvement in breeding.
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4.3.2 Gunn Rat Litters
The Gunn rat litters produced in our department were 
invariably small with at most three or four siblings. Often 
one or more of the infants would die before they could be 
weaned. In addition the female Gunn rats made very bad
mothers. For this reason in other colonies a heterozygous Gunn
female is often used as the mother but this experiment was not 
tried in our breeding programme. The size and sickly manner of 
the Gunn rat infants suggested that serum bilirubin levels would 
be high but the high mortality rate was disappointing. This 
combined with the unreliability of the breeding of two homozy­
gous Gunn rats led most of the work to be carried out on 
imported rats.
Gunn rat females either pregnant or with young litters (less 
than a week old) were transported from the Royal Free Hospital 
and allowed to settle before the offspring were used.
4.3.3 Control Rats
Commonly Sprague Dawley rats have been used in this 
department as controls for the experimental work. In these 
experiments it was decided that Wistar rats would be used, since 
the Gunn rat is a mutant of the Wistar strain. It was hoped 
use of this control would minimise any cross strain differences 
which could affect results. The Wistar rats provided a better 
match genetically for the Gunn rat but wide variations in levels 
of urinary porphyrin excretion have been recorded in these 
animals and it has been suggested that two separate populations 
of rats may exist with one population having lower porphyrin
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excretion than the other (Gartzke & Burck, 1986). The urinary 
porphyrin excretion in Gunn and control rats will be compared in 
the experiments in Chapter 5.
Since the ultimate aim of the experimental work was to 
establish the effects of hyperbilirubinaemia on haem biosynthe­
sis the merits of the heterozygous Gunn-Wistar cross rat as a 
control were also considered.
The heterozygous Gunn rat has lower than normal activity of 
the enzyme UDP-GT but enough activity is present to produce 
serum bilirubin levels within the normal range. Thus interfe­
rence of bilirubin with any of the haem biosynthetic enzymes in 
these animals is unlikely. In addition it proved extremely 
easy to breed heterozygous Gunn rats from a female Wistar and 
male Gunn parentage. This produced the ?2 generation, one 
hundred percent heterozygous.
The difficulty in homozygous breeding programme led us to 
take this generation one step further and produce the F^ genera­
tion by breeding heterozygotes of different parentage. The 
generation produced both homozygous and heterozygous rats see 
Figure 24. Theoretically one quarter should be homozygous for 
the hyperbilirubinaemia gene one half will be heterozygous and 
not display hyperbilirubinaemia since the gene is recessive and 
the remaining quarter will be genetically true Wistar. The 
results of comparison of the serum bilirubin levels in the F^ 
generation showed this to be true with ratios of 1  homozygous 
for hyperbilirubinaemia to 3 with normal serum bilirubin levels. 
It is likely that one third of the rats with normal serum 
bilirubin levels are true Wistar but this was not exclusively
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FIGURE 24 : PRODUCTION OF GUNN, WISTAR, AND GUNN-WISTAR 
CROSS LITTERMATES
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proven as coat colour was found not to be linked to the 
expression of hyperbilirubinaemia ie occasionally a white coated 
animal was found to have high levels of unconjugated bilirubin 
in serum. This breeding programme provided the advantage of 
exactly age matched test and control rats. Differentiation 
between homozygous and heterozygous animals was carried out at 
the same time as weaning by extracting a small amount of tail 
vein blood for centrifugation. In homozygous Gunn rats the 
plasma was clearly yellow when compared to the relatively clear 
plasma of heterozygotes.
As previously mentioned the Gunn rats grew more slowly than 
either the heterozygous animals or Wistar animals and their 
adult body weight remained lower than in control animals by an 
average of 25%. This led to some deliberation over whether 
controls for each experiment should be age or weight matched. 
It was felt that there were advantages and disadvantages in each 
case. Enzyme activities, in the case of ALA-synthase at least, 
can be raised during the first few weeks of life (Paterniti et 
al, 1978) and so for experiments carried out on young animals 
(less than two months of age) where enzyme activities were being 
determined, age matching was considered the better alternative.
Excretion of intermediates of the haem biosynthetic pathway 
in Gunn rats and control rats was also measured. For this work 
the merits of age and weight matching were compared and are 
presented in Chapter 5 on the haem biosynthetic pathway of adult 
Gunn rats.
Within both the department bred Gunn rat colony and imported
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Gunn rats, serum bilirubin values were obtained. This gave an 
indication of the severity of hyperbilirubinaemia suffered by 
each rat and the serum bilirubin levels which constitute a 
normal range of hyperbilirubinaemia. Serum bilirubin levels in 
control rats were also determined for comparison to the levels 
obtained in Gunn rats and to establish a normal range in non­
jaundiced animals.
4.4. PLASMA BILIRUBIN LEVELS IN GUNN RATS AND CONTROLS
As stated in the introduction the serum unconjugated 
bilirubin level in the mutant Gunn rat is much higher than in 
the native Wistar strain. Gunn/Wistar cross rats bred from 
male Gunn and female Wistar rat still retain some UDP-GT 
activity. This is sufficient for conjugation to occur such 
that serum bilirubin levels are in the same range as Wistar 
rats.
Measurement of serum bilirubin in rats was carried out under 
light ether anaesthesia by nicking the tail vein after heating 
to dilate the tail vessels. Whole blood was collected in a 
heparinised eppendorf tube and maintained at 4°C until it could 
be centrifuged at 2000g for 10 minutes to separate plasma. 
Plasma bilirubin levels were determined by autoanalyser. For 
comparison the diazo method of Jendrassik and Grof was employed 
in the lab as described in the methods section 2.7.2. Results 
from the two methods were comparable with no significant 
difference as determined by the Mann Whitney U test.
Haemolysis was a problem which could be largely avoided when 
samples of whole blood were kept cool and mixed gently.
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The original colony of Gunn rats in the department consisted 
of 46 Gunn rats obtained from the colony in Dundee. The
average serum bilirubin value from autoanalyser determination 
was 58.5 +_ l6.7umol/l (mean +_SD). By Jandrassik and Grof
method values of 65.2 + 19.0 (mean + SD) were obtained. The
range of serum bilirubin levels in Gunn rats is represented in 
Figure 25 and is very wide and values tended to be lower than 
those previously recorded (Davis & Yeary, 1975; Gollan et al, 
1975; Gollan et al, 1979). Autoanlyser values were for total 
bilirubin.
The lab method was not always sensitive enough to detect 
plasma bilirubin levels in Wistar and Gunn/Wistar cross rats 
and so the results quoted in Table 5 for these animals are 
calculated by autoanalyser. Both these groups of control rats 
had total plasma bilirubin levels in the same range ( <
5umol/l). In general, this was in the region of one tenth or 
less of those values recorded for Gunn rats and is demonstrated 
in Table 6.
4.5 SUMMARY
The Gunn rats used in all experiments in this thesis have 
statistically higher serum bilirubin levels when compared to 
Wistar or Gunn-Wistar counterparts (p < 0.001 by Mann Whitney U 
test). Gunn-Wistar cross rats were chosen as controls in the 
majority of the experimental work as these rats while 
maintaining normal serum bilirubin levels appeared to be most 
closely matched to the Gunn rats. No overlap in serum 
bilirubin levels was seen at any time between the Gunn rats and 
the chosen controls.
The nature of haem biosynthesis in Gunn rats has not been
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F'GURE 25 : DETERMINATION OF PLASMA BILIRUBIN LEVELS IN GUNN RATS 
BY AUTOANALYSER AND LABORATORY JENDRASSIK GROF METHOD
PLASMA BILIRUBIN LEVEL pmol/1
WISTAR GUNN/WISTAR CROSS
1  6
2 3
2 2
1 1
3 2
8 6
4 2
6  1
1
TABLE 5: PLASMA BILIRUBIN LEVELS IN CONTROL RATS
DETERMINED BY AUTOANALYSER
WISTAR
PLASMA BILIRUBIN LEVEL pmol/1
3.1 + 2.3
GUNN/WISTAR CROSS 2.9 + 1.9
GUNN 55.1 + 4.7
In the Wistar group n=9, for the Gunn/Wistar cross group 
n=8 and in the Gunn group n=7.
Gunn rats have significantly higher plasma bilirubin 
levels (p<0.001)
Results are expressed as mean + SD
TABLE 6: PLASMA BILIRUBIN LEVELS IN GUNN RATS AS
COMPARED TO CONTROLS
closely studied and so hepatic enzyme activity and blood 
porphyrin levels along with porphyrin excretion patterns will be 
studied prior to examining brain haem biosynthesis in detail.
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CHAPTER 5
HAEM BIOSYNTHESIS IN THE GUNN RAT
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5.1 INTRODUCTION
Although the Gunn rat is a recognised model of hyperbiliru- 
binaemia most previous studies have concentrated on characteri­
sation of the defect in the conjugating system for bilirubin and 
the resultant effect on bilirubin at certain intracellular sites 
such as respiratory cytochromes or jin vivo. Little work has 
concentrated on the haem biosynthetic pathway and how it may be 
affected in these animals.
Recent work in vitro has shown that bilirubin is a competi­
tive inhibitor of the penultimate enzyme of the haem biosynthe­
tic pathway, PROTO-O (Ferriera & Dailey, 1988). In support of 
this, the enzyme also appears to have reduced activity in humans 
presenting with the mild hyperbilirubinaemia of Gilbert's 
syndrome (McColl et al, 1986). The mechanism by which 
bilirubin inhibits PROTO-O has not been fully determined but the 
suggestion is that the similarity in structure to PROTO'gen 
allows access of bilirubin to the active site of the enzyme 
where it competes with the substrate. PROTO-O activity in Gunn 
rats has not been so far been measured. Since these rats 
display a more severe hyperbilirubinaemia than that of Gilbert's 
syndrome patients, it may be expected that enzyme activity would 
be reduced when compared to controls.
Additionally, activity of the rate controlling enzyme ALA- 
synthase, was measured in these rats. A large reduction in 
PROTO-O activity could lead to partial block of the haem 
biosynthetic pathway resulting in lower than normal haem 
production. In variegate porphyria a hereditary partial 
deficiency of PROTO-O activity occurs, and leads to further
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disruption of the haem biosynthetic pathway at the rate
controlling step. Thus increased activity of ALA-synthase as 
seen in porphyric states may be expected. Any block in the 
pathway would also be likely to affect the excretion pattern of 
haem precursors. Initially study of the porphyrin excretion 
patterns of Gunn and control rats was undertaken.
5.2 PORPHYRIN PROFILES IN GUNN RATS AND CONTROLS
The diagnostic tests for human porphyria consist of determi­
nation of porphyrin and porphyrin precursor excretion. ALA, 
PBG and porphyrins are measured in urine, porphyrin levels are 
measured in faeces and these figures are combined with blood 
porphyrin measurements to give a complete picture of the extent 
of porphyrin and precursor accumulation in the body and their 
excretion. Porphyric patients have abnormally high excretion 
of porphyrins in a pattern unique to the type of porphyria 
suffered, and this depends on the enzyme which is affected. 
Porphyrin profiles in Gunn rats have not been determined. The 
pattern of porphyrin excretion in these rats was observed and 
compared to the excretion pattern in control rats. Blood 
porphyrin levels in Gunn rats and control animals were also 
determined and compared. At present there is some controversy 
over whether the presence of high levels of circulating 
bilirubin may affect the accuracy of blood porphyrin measurement 
by an automated method using a zinc haematofluorimeter (Buhrmann 
et al, 1978). As the Gunn rats have high serum bilirubin 
levels blood porphyrin measurements were undertaken by liquid/ 
liquid extraction as well as by haematofluorimeter.
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5.2.1 Blood Porphyrin Levels
Routinely erythrocyte protoporphyrin measurement in rat and 
human samples was carried out in the lab using a zinc haematof- 
luorimeter. The main advantages of this method are the speed 
by which a large number of samples can be analysed and the lack 
of specialised reagents required. After calibration of the 
machine 50pl blood was spotted onto a coverslip and oxygenated 
before a reading was obtained. This value could be related to 
erythrocyte protoporphyrin concentration. As noted earlier, 
some controversy has arisen over whether the presence of biliru­
bin interferes with the results obtained by this automated 
method. The alternative and more traditional extraction method 
separates porphyrins from bilirubin in the plasma and allows 
determination of both COPRO and PROTO content of whole blood as 
shown in Table 7. In general only protoporphyrin values were 
considered, as the amount of COPRO was very small in comparison. 
To assess the potential source of error of the zinc haematofluo- 
rimeter, blood porphyrin levels from control and Gunn rats were 
measured by extraction and the automated method.
The results obtained when both extraction and haematofluoro- 
metric measurement was carried out in Gunn-Wistar cross rats and 
Wistar rats were comparable as shown in Figure 26. For Gunn 
rats the levels of blood protoporphyrin were consistently higher 
(1058 + 219) (mean + SD) than those obtained by extraction (659 
+ 229) (mean + SD) - see Figure 26. These results agree with 
the hypothesis of Buhrmann and coworkers (Buhrmann et al, 1978) 
who maintain that the presence of bilirubin interferes with
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COPRO PROTO
GUNN-WISTAR CROSS 26 + 6  609 + 106
GUNN RAT 3 2 + 4  678 + 93
Results were determined from liquid/liquid extraction in nmol/1 
and are expressed as mean + SD
n= 6
TABLE 7: BLOOD PORPHYRIN LEVELS IN RATS
a)
800 __
600
400 __
200 _
b)
800
600
400
200
C)
1200
1000
800
600
400
200
O MEASUREMENT BY HAEMATOFLUORIMETER
•  MEASUREMENT BY EXTRACTION
results expressed as mean ± SD
a) Wistar Rats b) Gunn Wistar Cross Rats c) Gunn Rats
FIGURE 26 : BLOOD PROTOPORPHYRIN LEVELS IN CONTROL AND GUNN RATS 
A COMPARISON OF EXTRACTION & HAEMATOFLUORIMETER MEASUREMENT
0
0
accurate measurement of blood porphyrins by haematofluorimeter. 
Consequently blood protoporphyrin levels in Gunn rats were 
compared to those in controls by using the extraction method. 
As can be seen in Table 8 , when extraction techniques were 
applied there was no significant difference in the protoporphy­
rin content of Gunn rat blood when compared to Gunn-Wistar cross 
controls when assessed by Mann Whitney U test.
5.2.2 Urinary Porphyrin and Porphyrin Precursor Excretion
ALA, PBG and porphyrin excretion patterns in the Gunn and 
control rats were investigated. In urine the main excretory 
products were ALA and PBG although some porphyrins were detected 
and these were expressed as total porphyrin.
i) Column Determination of Urinary Intermediates
Gunn rats of approximately two months of age and Gunn-Wistar 
rats aged one month were confined to metabolic cages and urine 
collected over a 24 hour period. Collections were not exposed 
to light. These groups of rats, although different ages, were 
in the same weight range (140-180g). Excretion was also
compared to that of 5 week old Wistar rats, weight 14'0-18 0g. 
The results of the urinary excretion studies in Gunn rats and 
controls are presented in Table 9 as mean results + SD. ALA 
excretion in the Wistar rat of 191 + 41.7 nmol ALA/24h was 
significantly higher than in either Gunn, 46.4 + 32.1nmol 
ALA/24h - (pCO.OOl) or Gunn-Wistar animals, 61.3 + 13.2nmol 
ALA/24h (pCO.OOl) by Mann Whitney U test. When ALA excretion 
in Gunn-Wistar and Gunn rats was compared, excretion in the 
control rats was significantly higher (p<0.05). There was no
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WISTAR 
GUNN WISTAR 
GUNN
Results are 
For Wistar ;
BLOOD PROTOPORPHYRIN LEVELS 
nmol/ 1
670 + 270
CROSS 659 + 229
647 + 199
expressed as mean + SD 
1=7, Gunn n= 8  and cross n=9
TABLE 8: RELATIVE BLOOD PROTOPORPHYRIN LEVELS IN GUNN RATS AS
COMPARED TO CONTROLS WHEN EXTRACTED
TYPE OF RAT EXCRETION
ALA PBG TOTAL PORPHYRIN
nmol/24h nmol/24h pg/24h
WISTAR 191 + 41.7 32.5 + 29.3 4.5 + 3.7
GUNN/WlSTAR 61.3 + 13.2 39.6 + 20.8 8.0 + 4.3
GUNN 46.4 + 32.1 43.7 + 50.5 1.1 + 1.0
Results are expressed as mean + SD
For Wistar rats n=9 for all groups. For Gunn/Wistar 
controls n= 6  for ALA excretion, n=4 for PBG excretion, n=9 
for total porphyrin excretion. For Gunn rats n= 6  for ALA 
excretion, n=5 for PBG excretion and n=9 for total 
porphyrin excretion
TABLE 9: DAILY URINARY PORPHYRIN EXCRETION IN GUNN RATS
AS COMPARED TO CONTROLS
significant difference in PBG excretion between any of the three 
groups of rats.
Total porphyrin excretion was highest in Gunn-Wistar control 
rats with 8.0 + 4.3pg total porphyrin excreted in 24 hours. 
Wistar rats excreted significantly less porphyrin (4.5 + 
3.7pg/24 hours) (p<0.05). Porphyrin excretion in Gunn rats was 
even lower with mean levels of 1.1 + 1.0^jg/24 hours, a more 
significant reduction when compared to heterozygous rats at 
p<0.001 by Mann Whitney U test. With Wistar rats as controls 
the reduction was significant compared to Gunn rats at p<0.01. 
From the results obtained for ALA and PBG excretion in Table 9 
these Wistar rats exhibited high ALA and total porphyrin 
excretion. It has been previously described that Wistar rats 
appear to excrete porphyrin in a distribution pattern which is 
bimodal (Gartzke & Burck,1986). In contrast, investigation of 
the distribution of other parameters i.e. hippuric acid and 
creatinine, showed normal distribution. The Gunn rat is a 
mutant of the Wistar strain. Possibly the low porphyrin 
excretion observed in these animals is a result of the animal 
from which the mutant Gunn animal arose belonging to the group 
of Wistar animals with low porphyrin excretion. The greater 
amount of porphyrin excreted by the Gunn Wistar cross rats would 
be consistent with the crossing of a Gunn rat with low porphyrin 
excretion with a Wistar rat which excreted porphyrin at the top 
end of the distribution. Any possibility that the lower levels 
of porphyrin excreted in the Gunn and Gunn-Wistar groups of 
animals was due to day to day variation were discounted since 24
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hour collections on Gunn and Gunn-Wistar cross rats on three 
consecutive days showed no significant changes - see Table 10. 
Animals were weight matched and excreted similar volumes of 
urine in 24 hours. Differences due to age were discounted by 
checking excretion patterns in Gunn-Wistar cross rats of a 
similar age to the Gunn rats in this study (2 months of age). 
No significant differences were found in excretion of these 
animals when compared to the one month old animals if results 
were calculated from a spot sample of urine.
The colorimetric method used to measure total porphyrins in 
urine is not sensitive enough to determine the pattern of 
porphyrin excretion. Details of the exact composition of the 
urine with respect to porphyrins can be obtained by HPLC 
techniques. To examine whether the changes in porphyrin 
excretion in Gunn rats reflected a different composition of 
urine from these animals compared to controls, HPLC was applied 
to pooled urine.
ii) HPLC of pooled urine
Due to the small volumes of urine collected from Gunn rats 
and Gunn/Wistar cross rats over a 24 hour period, urine from 72 
hours of collection were pooled and derivatised to the 
reciprocal porphyrin esters. HPLC was then applied to the 
ester if ied porphyrins as in the methods section 2.4.4. By this 
sensitive method the relative amounts of each porphyrin 
intermediate could be determined. The results are shown in 
Table 11. In each of the different classes of rats the highest 
amount of porphyrin was excreted as COPRO. The pattern of
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GUNN GUNN/WISTAR CROSS
DAY 1 2.5 ±  1 A 14.3 + 1.0
DAY 2 2.7 + 1 . 2 15.7 + 1.3
DAY 3 2 . 0 + 1 . 2 12.0 + 5.7
Results are expressed in jug per 24 hours.
Each figure (mean + SD) is taken from porphyrin excretion 
in three animals. —
TABLE 10: LACK OF DAILY VARIATION IN TOTAL PORPHYRIN
EXCRETION IN GUNN AND GUNN/WlSTAR CROSS RATS
PORPHYRIN
INTERMEDIATE
WISTAR GUNN/WISTAR
CROSS
GUNN
PROTO 4.5 + 1.8 2.2 + 1.8 4.6+ 0.1
COPRO 48.3 + 5.5 77.9 + 4.1 43.1 + 4.6
PENTA 5.7 + 1.6 4.1 + 0.9 8.4 + 1.6
HEXA 2.0 + 1.7 2.2 + 0 10.7 + 2.9
HEPTA 9.3 + 2.3 5.9 + 1.6 10.8 + 0.3
URO 10.0 + 7.2 6.3 + 1.5 10.0 + 7.0
Results are expressed as mean + SD
TABLE 11: RELATIVE PERCENTAGES OF VARIOUS PORPHYRIN
ESTERS EXCRETED IN URINE OF GUNN AND CONTROL RATS
excretion in Gunn and Wistar rats appeared to be similar while 
the Gunn-Wistar cross rat excreted a much higher percentage of 
COPRO in urine than Gunn rats. Despite the similarities in 
percentages of excretion between the groups of rats, the actual 
amount of total porphyrin excreted was significantly lower in 
Gunn rats compared to controls as larger volume of urine from 
the mutant rats had to be applied to the HPLC column to give 
results comparable to control rats. This is consistent with the 
Gunn rats originating from a Wistar rat with low porphyrin 
excretion and was expected after the results obtained in Table 
9. Each percentage quoted is from chromatography of urine from 
4 groups of rats (mean + SD).
5.2.3 Faecal Porphyrin Excretion
i)Extraction of faecal porphyrins
The faecal porphyrin excretion was examined in detail in Gunn 
rats and control rats. The major constituents COPRO and PROTO 
were extracted from faecal matter as described in the methods 
section 2.5. Daily excretion for all groups is presented in 
Table 12. The results showed that COPRO excretion in faeces of 
Gunn rats was significantly reduced when compared to either 
Wistar or Gunn-Wistar cross controls (p<0.001 in both cases). 
PROTO excretion in Gunn rats was significantly reduced when 
compared to Wistar controls (p<0.05) and there was a trend 
towards lower PROTO excretion as compared to heterozygous 
controls although this did not quite reach significance. From 
these results it is likely that the lower faecal porphyrin 
excretion is a consequence of the type of Wistar rat which the
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EXCRETION
PROTO
nmol/24h
426 + 104 
290 + 82.1 
157+ 69.5
Results are expressed as mean + SD 
In each group n= 6
TYPE OF 
RAT
WISTAR
GUNN /Wl STAR 
CROSS
GUNN
COPRO 
nmol/24h
236 + 150 
163 + 26.9 
41.8 + 18.4
TABLE 12: DAILY EXCRETION OF FAECAL PORPHYRINS IN GUNN
AND CONTROL RATS AS DETERMINED BY EXTRACTION
mutant Gunn rat arose from.
ii)HPLC of faecal porphyrins
Analysis of faecal samples was also carried out by a similar 
HPLC method to that used for urine (see methods section 2.5). 
The results obtained emphasised the reduction in COPRO excretion 
which occurs in the Gunn rat, with a ration of PROTO:COPRO of 
3:1 in control heterozygous rats and 5:1 in homozygous Gunn 
rats. Typical chromatograms are shown in Figure 27.
5.3 HAEM BIOSYNTHETIC ENZYMES IN THE GUNN RAT
In contrast to previous intracellular studies on bilirubin 
toxicity my aim was to study the interaction of bilirubin with 
enzymes of the haem biosynthetic pathway in the brain. The 
inhibition of PROTO-O activity previously observed may be a 
cause of the brain damage which results when kernicterus is 
induced. This involved study of the haem biosynthetic enzymes 
in rat brain. Before these studies were initiated the hepatic 
and renal activities of the enzymes of interest were determined 
in adult Gunn rats and control rats. Because of the known 
effect of bilirubin in reducing PROTO-O activity (Ferriera & 
Dailey, 1988; McColl et al, 1986) this enzyme activity was 
measured. ALA-synthase activity was measured to determine if 
disruption of the pathway at the penultimate step was causing 
induction of the rate controlling step of the reaction. These 
experiments were valuable in identifying the normal enzymic 
pattern of the haem biosynthetic pathway in the Gunn rat. It 
was hoped that any enzyme abnormalities due to bilirubin would 
be recognised in the easily accessible hepatic and renal
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a)
b)
a) represents faecal porphyrin pattern from Gunn-Wistar cross rat
b) represents faecal porphyrin pattern from homozygous Gunn rat
Peak 1 = solvent front 
Peak 2 = PROTO 
Peak 3 = COPRO
FIGURE 27 : TYPICAL HPLC TRACES OF FAECAL PORPHYRINS FROM
GUNN AND CONTROL RATS
tissues.
As has already been seen from the excretion results, no 
increases in ALA or PBG excretion are evident. However these 
results do not exclusively prove that there is no effect on ALA- 
synthase activity in these animals. It has been reported that 
ALA-synthase activity is raised compared to normal in leucocytes 
of patients with acute porphyria even when porphyrin excretion 
patterns are in the normal range (McColl et a l , 1982). Thus 
ALA-synthase activity was studied in Gunn rat and control rat 
tissues. Activity of the enzyme COPRO-O was also determined to 
act as a marker enzyme. Measurement of hepatic cyt. P450 was 
carried out to assess whether hepatic haemoprotein production in 
Gunn rats was abnormal as compared to controls.
5.3.1 PROTO-O Activity in Adult Gunn Rat Hepatic and Renal Tissue
Hepatic PROTO-O activity proved easier to measure than the 
activity in renal tissue due perhaps to a combination of the 
small amount of renal tissue available and a lower intrinsic 
activity in the kidney. Groups of Gunn and control rats were 
starved for 24 hours, anaesthetised in ether and the liver and 
kidneys removed and perfused free of blood as in the methods 
section 2.2.3 The results of the hepatic and renal PROTO-O 
measurements are presented in Table 13. In the liver both 
groups of controls had similar activities with Wistar rats 
recording values of 6 . 6  + 2 . 2  nmol proto formed/mg liver/hour 
(mean + SD) and Gunn-Wistar cross rats activities of 7.1 + 3.7 
nmol proto formed/mg protein/h. PROTO-O activities were 
significantly lower in the homozygous Gunn rats (4.2 +_ 2.2nmol
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WISTAR
GUNN-WISTAR
CROSS GUNN
HEPATIC 6.6 + 2.2 7.1 + 3.7 4.2 + 2.2
n 6  1 0  1 1
RENAL 6 . 6  + 2.1 7.0 + 2.8 5.8 + 2.4
n 6  6 6
Results are expressedas nmol proto formed/mg mitochondrial 
protein/hour and as the mean + SD
Gunn rat hepatic PROTO-O activity is significantly lower 
(p< 0.05) by Mann Whitney U test when compared to cross rats.
TABLE 13: HEPATIC AND RENAL PROTO-O ACTIVITIES IN GUNN RATS
COMPARED TO CONTROLS
PROTO/h) (mean + SD) - p< 0.05 when compared to activities in 
heterozygotes by Mann Whitney U test, but no significant 
differences were found in the PROTO-O activities recorded for 
Wistar rats compared to the other groups. The mean activities + 
SD in hepatic tissue are shown in Figure 28. The Gunn Wistar 
cross rat was chosen as the best control in these and all other 
experiments as it was decided it most closely resembled the Gunn 
rat strain. In contrast to hepatic findings, renal PROTO-O 
activities were found to be similar in all three groups of rats 
with mean values of 6 . 6  + 2.1 in Wistar, 7.0 + 2.8 in Gunn- 
Wistar cross rats and 5.8 + 2.4 nmol PROTO/mg protein/hour in 
Gunn rats (means + SD). The mean activities shown in Figure 
28 and in Table 13 have a large standard deviation. However 
this is due to the difficulty in producing a consistently pure 
PROTO'gen substrate. Variations in production of PROTO by the 
enzyme reaction occur on an inter assay basis. When 
comparisons were made on the same day control rat hepatic 
activities were found to be consistently higher.
5.3.2 COPRO-O Activity in Adult Gunn Rat Hepatic and Renal Tissue
Activity of COPRO-O, the enzyme which catalyses conversion 
of coproporphyrinogen to protoporphyrinogen was also measured. 
No evidence has so far been obtained showing that activity of 
this enzyme is affected by the presence of bilirubin and so 
measurement of COPRO-O activity was chosen as a marker for
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®  represents Gunn rats n = 11 
O  represents Wistar rats n = 6
A  represents Gunn-Wistar cross rats n = 10
Units are in nmol protoporphyrinogen IX / mg protein / hour 
Results are expressed as mean ± SD
significantly different to Gunn-Wistar cross (p<0.05) by Mann Whitney U test
FIGURE 28 : HEPATIC PROTOPORPHYRINOGEN OXIDASE 
ACTIVITES IN GUNN AND CONTROL RATS
enzyme activity in the Gunn and control rats. The results 
obtained are shown in Table 14. In all cases the COPRO-O 
activity of hepatic tissue was significantly higher than that of 
renal tissue. In liver the mean activity was 135.7 + 54.6nmol 
PROTO/g protein/hour (mean + SD) in Wistar rats. No signifi­
cant difference was found between these activities and those in 
Gunn-Wistar cross rats (103.8 + 40.2nmol PROTO/g protein/hour), 
or Gunn rats (117.4 + 43.8nmol PROTO/g protein/h). The renal 
COPRO-O activities were also similar in all three groups of 
rats, Wistar, cross and Gunn rats having COPRO-O activities of 
72.2 + 33.3, 59.5 + 27.8 and 90.5 + 40.4nmol COPRO/g protein- 
/hour respectively.
5.3.3 ALA—synthase Activity in Adult Gunn Rat Hepatic and Renal Tissue
Hepatic and renal activity of the initial, rate controlling 
step of haem biosynthesis was measured in adult Gunn rats and 
compared to controls. The method used was the one quoted in 
the methods section 2.3.1 part ii) for liver. After sacrifice 
the liver and kidneys were quickly excised and perfused with 
ice-cold saline. Tissue was homogenised in ALA-synthase buffer 
and mitochondria prepared. All mitochondria were washed to 
remove bilirubin from the solution before ALA-synthase activity 
was measured. Results were expressed in pmolALA formed/mg 
protein/h. The hepatic ALA-synthase activities were all within 
the same range with 374 + 70.0, 386 + 67.4 and 307 +_ 83 pmol 
ALA/mg protein/hour recorded in Wistar, Gunn-Wistar cross and 
Gunn rats respectively. Renal activities were significantly 
lower than hepatic levels (p< 0 .0 0 1 ) and no significant differe-
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GUNN-WISTAR
WISTAR CROSS
HEPATIC 135.7+54.6 103.8+40.2 117.4+43.8
n 7 14 12
REi:AL 72.2 + 33.3 59.5 + 27.3 90.5 + 40.4
R e s u lts  a re  expressed in  nmol PRCTO/c p r o te in /  ana as rr.ea + SD
TABLE 14: HEPATIC AND RENAL COPRO-O ACTIVITIES IN GUNN RATS
COMPARED TO CONTROLS
nces in activities were evident between the Gunn rat group (138 
+ 29.9 pmol ALA/mg protein/h) and the control groups (148 + 26.1 
for Wistar and 124 + 23.8pmol ALA/mg protein/h for Gunn-Wistar 
cross rats). The mean results + SD are shown in Table 15.
5.4 DISCUSSION AND SUMMARY
Several aspects of haem biosynthesis have been assessed in 
this chapter. Blood porphyrin levels in Gunn rats were found 
to be similar to those in either group of control rats when 
porphyrin was extracted by the traditional method. My 
experiments clearly showed that the zinc haematof luorimeter was 
unsatisfactory for measurement of blood porphyrin when bilirubin 
is present in significant quantities.
Porphyrin patterns showed unique patterns in the different 
groups of rats with a significant lack of uniformity being found 
in the two control groups. Wistar rats excreted the highest 
amount of ALA but Gunn-Wistar rats excreted correspondingly 
higher porphyrin. Gunn rats excreted the lowest amount of 
precursors and porphyrin and this can not be explained by a 
lower body weight since weight matched rats were compared. 
Chromatographic separation of the various porphyrins present in 
urine did not provide any explanation of the lower excretion in 
Gunn rats as similar proportions of most of the porphyrins 
PROTO through to URO were found. The most likely explanation of 
the lower porphyrin excretion in Gunn rats is relating to the 
recently discovered bimodal distribution of excretion of 
porphyrin in Wistar rats. Two populations of this strain of rat 
exist when porphyrin excretion in urine is considered (Gartzke &
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WISTAR
GUNN-WISTAR
CROSS GUNN
HEPATIC 374 + 70 386 + 67 307 + 83
n 8 1 1  1 1
RENAL 148 + 26.1 124 + 23.8 138 + 29.9
Results are expressed in pmol ALA/mg protein/hour, and as 
mean + SD
TABLE 15: HEPATIC AND RENAL ALA-SYNTHASE ACTIVITIES IN GUNN
RATS COMPARED TO CONTROLS
Burke, 1986). One population excretes a much lower amount of 
porphyrin than the other. Since the Gunn rat is a mutant of 
the Wistar strain it is possible that the original parentage 
from which the mutant rat developed was from mating two Wistar 
rats with porphyrin excretion in the lower range. This would 
explain the levels of porphyrins recorded. COPRO excretion in 
Gunn-Wistar rat urine was proportionally higher than in the 
other two groups of rats. Measurement of faecal porphyrin 
excretion showed that the COPRO excretion was reduced in Gunn- 
Wistar heterozygotes compared to Wistar rats, not unexpected as 
more COPRO had been excreted in the urine of these animals. 
Thus the balance of excretion of COPRO between urine and faeces 
appeared to be different in Wistar rats compared to the cross 
rats. The balance appeared to be regained when faecal excretion 
was taken into account.
PROTO-O activity in Gunn rat hepatic tissue was lower than in 
the control rats. It is reasonable to suggest that this is due 
to an effect of bilirubin competitively inhibiting the enzyme 
activity. The reduction seen was not in the region recorded in 
vitro by Ferriera and Dailey (1988) but the mitochondrial 
preparations which were used in these experiments were thoroug­
hly washed to remove excess bilirubin from the surrounding 
medium. This ensured that no direct effects of bilirubin could 
be seen on the fluorescence values recorded for PROTO-O 
activity. No similar reduction was observed in the renal 
tissue of these rats and this was more unexpected but may be due 
to a lower residual content of bilirubin in this tissue compared 
to liver where bilirubin is retained in the hepatocyte bound to
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ligandin before the conjugation process occurs. The 
mitochondrial washing process in kidney may also have been more 
efficient at removing the bile pigment as it had no intracellu­
lar binding site equivalent to ligandin. This theory is 
consistent with bilirubin inhibiting PROTO-O activity in a 
competitive manner as removal by efficient wash of kidney 
mitochondria would result in a return to normal PROTO-O 
activities. It is impossible to predict the results of studies 
on PROTO-O activity in brain tissue as yellow staining 
signifying bilirubin deposition has been frequently reported and 
so the bile pigment once deposited may remain to cause 
competitive inhibition.
Measurement of ALA-synthase activity in the three groups of 
rats showed no significant differences in liver or kidney. 
This would suggest that the inhibition of PROTO-O assumed to 
occur in the liver in vivo is insufficient to result in a block 
in the pathway of haem biosynthesis in the way which is observed 
in variegate porphyria. ALA-synthase activity was found to be 
within the ranges previously observed by other workers (Strand 
et al, 1972; Marver et al, 1966) showing that the method
employing HPLC to quantitate the ALA pyrrole produced in the 
assay (Fitzsimons et al, 1986) was satisfactory. COPRO-O 
activities in all three groups of animals and in both tissues 
were similar and this was expected as this enzyme activity is 
not inhibited by bilirubin and is not a point of control of the 
pathway of haem biosynthesis.
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CHAPTER 6
BILIRUBIN LEVELS IN GUNN RAT BRAIN
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6.1 INTRODUCTION
Bilirubin, the end product of haem degradation, is known to 
be toxic. As has been described in Chapter 4 the Gunn rats 
used in these studies have a congenital defect in bilirubin 
conjugation and consequently have elevated circulating 
unconjugated bilirubin. The increased bilirubin load leads to 
deposition in tissues. Liver, kidney, and fat deposits under 
the skin are generally stained yellow. As they age the Gunn 
rats fall into one of two groups - either suffering from 
disturbances in movement, or behaviourally remaining relatively 
normal although of a lower body weight and appearing hyperexci­
table compared to control animals of the same age. The wobbly 
gait and behavioural disturbances observed are thought to result 
from brain damage caused by toxicity of bilirubin in the brain 
in a manner similar to the brain damage observed in kernicterus. 
However, as in patients with kernicterus, there appears to be a 
lack of correlation between serum bilirubin levels and the 
extent of the neurological symptoms at least in young rats (Sato 
& Semba, 1978).
This lack of predictability in development of kernicterus has 
caused serious difficulties in diagnosis of the condition since 
bilirubin levels can rise very quickly causing brain damage. 
The mechanism by which bilirubin exerts its toxic effect is 
still unclear although many putative suggestions have been made 
and these have been summarised elsewhere in the thesis (chapter 
1.2.3) .
Although bilirubin deposits have been found in many 
tissues, these appear to be most concentrated in the brain.
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This tissue has high lipid content and so is a favourable 
environment for lipophilic bilirubin. Brain bilirubin levels 
have been previously measured and levels appear to be fairly 
low, in the range of 1 to 3 nmoles/ gram wet weight tissue 
(Katoh et al, 1975; Aono et al, 1989). The recent discovery 
that bilirubin in vitro inhibits the penultimate enzyme of haem 
biosynthesis, PROTO-O (Ferriera & Dailey, 1988) prompted 
interest on the situation _iri vivo. Depression of PROTO-O 
activity in leucocytes of patients with Gilbert's syndrome 
(McColl et al, 1986) supports the theory that bilirubin may have 
an effect on haem biosynthesis _m vivo. The results presented 
in Chapter 5 on the levels of haem biosynthetic enzymes in Gunn 
rat liver and kidney show that in hepatic tissue PROTO-O 
activity in Gunn rats is reduced as compared to control Gunn- 
Wistar cross rats, while renal activity of the enzyme is similar 
in both groups. From these results it is impossible to predict 
whether PROTO-O activity in the brain of Gunn rats will be 
reduced or normal. The lipophilic nature of bilirubin, the 
high lipid content of brain tissue and the obvious yellow 
staining, signifying bilirubin deposition suggests that enough 
of the pigment may be present to compete with PROTO'gen and 
cause inhibition of PROTO-O activity.
The work in Chapter 5 on the hyperbilirubinaemic Gunn rats 
constitutes the first investigation into the effect of bilirubin 
on the haem biosynthetic pathway in tissues _in vivo. This 
chapter continues the work by developing a method to accurately 
measure bilirubin content in the brain of the Gunn rat and so
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determine whether a correlation between these levels and the 
levels in serum exists.
6.2 DEVELOPMENT OF METHODS FOR MEASUREMENT OF BRAIN BILIRUBIN
Measurement of brain bilirubin levels has up until now 
proved difficult with the most commonly used technique 
consisting of an organic extraction of bilirubin from the tissue 
followed by direct spectrophotometric quantitation. However 
this method may not be sensitive enough to detect slight 
differences in bilirubin content between various Gunn rats and 
additionally does not take into account losses of bilirubin 
which are likely to occur on extraction thus failing to provide 
a quantitative measure of brain bilirubin levels. Initially it 
was decided in our laboratory to try and determine the level of 
bilirubin in the brain of Gunn rats by using a combination of an 
extraction method similar to that previously employed (Katoh et 
al, 1975), and a modification of the Jendrassik-Grof diazo 
method which is generally used to calculate serum bilirubin and 
one of the methods used to determine serum bilirubin levels in 
this thesis.
6.2.1 Extraction of Bilirubin from Brain Tissue
Bilirubin is a lipophilic molecule, and is soluble in 
organic solvents. A mixture of methanol, chloroform and water 
has provided a successful method of isolation of bilirubin in 
previous work (Bratlid & Winsnes, 1971) with the bilirubin 
containing organic layer separating out under centrifugation. 
Rat brains were perfused and removed from deeply anaesthetised 
animals as described in the methods section 2.2.3 part iv).
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Brains were homogenised in exactly 4 volumes 0.25 Molar 
sucrose and frozen at -80°C in the dark until measurement. 
Various proportions of chloroform : methanol : water mixtures 
were used as described in Figure 29. The optimum combination 
of chloroform : methanol : water was determined. From Figure 
29 the best recovery of bilirubin from the organic phase of the 
mixture was obtained with 2:5:2 v/v chloroform : methanol : 
water mixture similar to that described by Katoh (Katoh et al, 
1975). One volume of brain in sucrose was added to 18 volumes 
of the 2:5:2 v/v mixture already described. The bilirubin was 
then extracted using ten strokes of a Potter Elvehjem glass 
homogeniser with teflon pestle and a further 8  volumes of 
distilled water added. This step resulted in a milky 
suspension being formed. In samples spiked with high 
concentrations of bilirubin a yellow colour could be clearly 
seen at the bottom of the homogeniser tube. However in brains 
from Gunn rats no obvious yellow colour was observed at this 
stage. Separation of the organic and aqueous phases was 
achieved by centrifugation at 3000g for 15 minutes. The 
centrifugation step produced two clear phases with a white disc 
at the interface. To account for any loss of bilirubin into 
this interface, after removal of the lower organic phase the 
extraction process was repeated three times until the interface 
was clear. Brain homogenates spiked with bilirubin, {lmg/1 or 
2 mg/l} were extracted with chloroform : methanol : water mixture 
as in the methods section 2.9.1 and the optical density measured 
at 450nm after one extraction and then multiple extractions.
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%
RECOVERY
100-
SOLVENT MIXTURE
SOLVENT A : 2:5:2 CHLOROFORM: METHANOL : WATER, 18 PARTS TO 1 PART 
1:5 HOMOGENATE FOLLOWED BY 8 PARTS DISTILLED WATER
SOLVENT B : 5:12:4 CHLOROFORM: METHANOL : WATER, 21 PARTS TO 1 PART 
1:5 HOMOGENATE FOLLOWED BY 8 PARTS DISTILLED WATER
SOLVENT C : 3:5:2 CHLOROFORM: METHANOL : WATER, 18 PARTS TO 1 PART 
1:5 HOMOGENATE FOLLOWED BY 8 PARTS DISTILLED WATER
FIGURE 29 : RECOVERY OF BILIRUBIN FROM ORGANIC EXTRACTION
Table 16 clearly shows this step did not lead to any significant 
increase in the amount of bilirubin extracted but did significa­
ntly increase the volume of the organic phase containing 
bilirubin. The lack of significant increase in recoveries of 
bilirubin from the aqueous and interface phases may have been 
due to the presence of bound fractions of bilirubin where the 
biomolecule attached was insoluble in the organic phase. 
Degradation of bilirubin which occurs slowly but significantly 
on exposure to light must be considered as a negating factor 
when time consuming extraction processes are considered. It 
was therefore decided to discard this further step in future 
exper iments.
6 .2 . 2  I d e n t i f i c a t i o n  o f  t h e  E x t r a c t  a s  T r u e  B i l i r u b i n
The above spectrophotometric method of measurement of the 
yellow coloured extract from rat brain showed that in Gunn rats 
the product had the same spectrum as commercial bilirubin 
extracted from gall stones (Sigma). The identity of the 
extract as bilirubin was confirmed using thin layer 
chromatography. The organic phase prepared as in the methods 
section 2.9.1 was concentrated under a stream of N 2  gas to a 
volume of 200pl. Simultaneously commercial bilirubin was pre­
pared as in the methods in both brain homogenate and in human 
serum albumin (the standard used for serum bilirubin determina­
tion). The concentrated extracts were developed on a silica 
gel H plate (MERCK) with 1% glacial acetic acid in chloroform 
solvent (McDonagh & Assisi, 1971). The results obtained showed 
Rf values which were very similar for commercial bilirubin and
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% RECOVERY RANGE
72-79 
70-79 
68-74
Results were the mean of 6  determinations
MEAN % RECOVERY
NUMBER OF 
EXTRACTIONS
X 1 76
x 2 78
x 3 72
TABLE 16: THE EFFECT OF REPEATED EXTRACTIONS ON RECOVERY OF
BILIRUBIN FROM BRAIN HOMOGENATES
bilirubin extracted from samples and confirm that bilirubin is 
extracted from the Gunn rat brain while no band comigrated from 
Gunn-Wistar cross brain extracts. Slower migration was 
observed for bilirubin in 4% HSA and is likely to be due to the 
different medium of dissolution.
6.2.3 Determination of the Nature of Brain Bilirubin
Determination of the nature of the bilirubin content of 
brain tissue has not previously been carried out. Bilirubin 
has simply been identified and assumed to consist of the 
unconjugated pigment. It was decided to check whether any 
conjugated pigment was also present in the brain. The method 
initially used to measure the conjugated and unconjugated 
fractions was based on the Jendrassik and Grof method used to 
measure serum bilirubin. All brain tissue was perfused free of 
blood prior to homogenising in sucrose as described in methods 
section 2.9.1. Extraction of bilirubin was by the method 
previously described in this section of the methods. After the 
organic layer containing bilirubin had been separated, the 
solution was evaporated to dryness and the resulting residue 
resuspended using the same medium for preparing standards for 
serum bilirubin determination. Brain bilirubin levels were 
measured and serum bilirubin levels were read off a calibration 
curve constructed as in the methods section 2.7.2. The results 
of serum and brain bilirubin levels of 3 Gunn animals and age 
matched Gunn-Wistar controls are presented in Table 17. Brain 
total bilirubin concentration was calculated from the optical 
density and initially reported in mg/ml. This was then
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RAT SERUM BILIRUBIN BRAIN BILIRUBIN
TOTAL CONJUGATED UNCONJUGATED UNCONJUGATED
jjmolar jjmolar jjmolar nmol/gram wet wt.
GUNN 1 122 10 112 143
GUNN 2 109 8 101 129
GUNN 3 100 11 89 126
CONTROL 1 12 6 6 116
CONTROL 2 10 4 6 112
CONTROL 3 4 2 2 29
TABLE 17:
SERUM AND BRAIN BILIRUBIN LEVELS IN GUNN RATS COMPARED TO 
CONTROLS BY MODIFIED JENDRASSIK GROF METHOD
corrected for the 1 in 4 dilution of brain tissue with sucrose 
and the final result converted to nmol/g wet weight from pg/gram 
wet weight tissue. These results clearly show several things; 
serum total bilirubin levels in Gunn rats are elevated far above 
that of controls and the raised fraction is predominantly 
unconjugated pigment. This method for measurement of brain 
bilirubin appears to show that brain bilirubin content of 
control rats is almost as high as that of Gunn rats. This is 
in contrast to the results obtained by t.l.c. and use of direct 
spectrophotometric measurement has previously revealed little or 
no bilirubin content of control rat brain. In addition, the 
observation of whole brain where yellow staining can be clearly 
seen in Gunn rats and is absent in controls. The high final 
results obtained for all the rats suggests that the high 
absorbances recorded are due to another component of brain which 
is being resuspended along with bilirubin. It is also worth 
noting that on resuspension of the residue before quantitation 
it is difficult to obtain a non-turbid solution suitable for 
spectrophotometric analysis.
Separation of bilirubin from the component of brain causing 
the artificially high absorbances was attempted by several 
methods,
a) Detergent
Addition of detergent (Triton X-100) at concentration 
500jul/ml at the homogenisation stage only resulted in turbidity 
which could not be sufficiently removed for accurate spectropho­
tometric measurement.
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b) Filtration
Filtration, using Millipore filters (0.45pm, material) prior 
to diazo-conjugation resulted in a tenfold reduction in apparent 
total bilirubin as measured by Jendrassik Grof method. However 
it is likely that a large proportion of the bilirubin content of 
the homogenate was also removed on filtration. Filtration by 
the same system after diazo conjugation also reduced the 
apparent brain bilirubin level but to a lesser extent supporting 
this theory and this is shown in Table 18. Unfortunately this 
method of filtration failed to include an assessment of recovery 
of bilirubin and so was not pursued as a useful method of 
purifying bilirubin extracted from brain tissue.
6.2.4 Purification of Brain Bilirubin and Gradient HPLC
At this point the validity of attempting to use a modifica­
tion of the method of Jendrassik-Grof was reassessed. Measure­
ment had so far been unsuccessful due largely to turbidity of 
solution and lack of solubility of the successfully extracted 
bilirubin from brain tissue in the reagents used for diazo 
measurement. Filtration and separation techniques so far tried 
were unhelpful.
One of the most powerful tools of separation is HPL£. These 
techniques have been previously applied to bilirubin in serum 
and are described in the methods section 2.7.3. Because of the 
failure of the above techniques to adequately isolate and 
quantitate bilirubin it was decided to change the direction of 
the work and concentrate on trying to produce a method for
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BILIRUBIN LEVELS 
nmol/gram wet weight tissue
TOTAL CONJUGATED UNCONJUGATED
A 700 210 490
B 60 60
C 320 10 310
A: Gunn rat brain prepared as in methods with no filtration
B: Gunn rat brain prepared as in methods, filtered prior to 
diazo-reaction
C: Gunn rat brain prepared as in methods, filtered after diazo 
reaction prior to absorbance measurement
All samples were prepared from one original rat brain
TABLE 18: EFFECT OF FILTRATION ON DETERMINATION OF BRAIN
BILIRUBIN LEVELS
measurement of brain bilirubin by HPLC. As described in the 
methods sections 2.7.3 two methods for serum bilirubin measure­
ment were successfully used in the construction of this thesis 
to qualitatively analyse bilirubin. The hope was that either 
or both of these methods could be adapted as necessary to 
quantitatively measure bilirubin in brain. As in the 
experiments in secton 6 .2 .2 , brain homogenate from control rat 
brain spiked with a known concentration of bilirubin was used to 
develop a method for isolation of bilirubin with adequate 
recovery for application to an HPLC column. For preservation 
of the octadecyl (C18) column the preparations had to be as free 
from contaminating proteins and lipids which are endogenous to 
brain as possible. Several attempts were made before the 
optimal clean-up procedure for brain bilirubin was determined.
a) Protein Precipitation
i) TCA Precipitation 
Brain tissue homogenised in sucrose as described in methods
2.9.1 was added to an equal volume of 10% TCA. The mixture was 
vortex mixed and then centrifuged at 3000 xg to remove precipi­
tated protein. The pH of this solution was then raised to 
neutral, compatible with mobile phase for injection into HPLC.
This crude method of protein removal was unsuccessful since 
the majority of bilirubin remained in the precipitate. 
Consequently only a very small peak attributable to bilirubin 
was detectable by HPLC.
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i i )  Sodium, S u lp h a te  P r e c ip i t a t i o n
A near saturated solution of sodiurr, sulphate has been used 
to successfully precipitate serum proteins and so extend column 
life by Lauff (Lauff et al, 1981) and a micro method has been 
used to identify serum bilirubin fractions in chapter 4 of the 
thesis. For orain 0.5ml of homogenate in sucrose was added to 
7ml sodium sulphate solution (27.7g/10Oral) at 37°C and the 
solution occasionally shaken for 5 minutes. The resulting 
suspension was then filtered (HILLEX, 0.45pm) into a 20ml 
volumetric flask containing 1ml ascorbic acid and made up to 
volume with more sodium sulphate solution. The resulting 
solution was not as observed for serum a clear solution suitable 
for injecton into HPLC. This was thought to be due to the 
presence of non-protein entities, in addition to proteins 
outwith the molecular weight range precipitated by this molarity 
of sodium sulphate solution. Thus use of protein precipitating 
methods suitable for serum is incompatible with removal of 
contaminating molecules in brain.
c) Sol id Phase Extraction
One method which has proved successful in purifying various 
biological compounds has been that of solid phase extraction. 
This has already been employed elsewhere in this thesis, in 
isolation of ALA-pyrrole in the HPLC assay for ALA synthase.
The chemical structure of bilirubin shown in figure 10 
(Introduction) means there are several sites which may be 
charged, and these could form tei^porary bonds under suitable 
conditions with the right solid medium. After isolating
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so releasing the more concentrated bilirubin into solution for 
quantitation. The strongest charges on bilirubin are those of 
the carboxyl groups of the unconjugated form. These groups are 
strongly anionic (COCT) in alkali. The strong anion exchanger 
(SAXflcm^BOND-ELUT) was a suitable solid phase. The SAX column 
was activated with methanol and primed with buffer consisting of 
CHCl-^MeOHrt^O 2:5:2 at pH 11. Methanolic KOH was used for 
raising pH of solutions.
Brain spiked with bilirubin was extracted in the normal way 
and the pH of the organic phase raised with methanolic KOH to 
approximately pH 11. The solution was then applied to the SAX 
column where it bound in a tight band. The column was thoroug­
hly dried to remove all traces of buffer. Various combinations 
of buffer were tried to remove the bound bilirubin. The most 
successful one was a mixture of chloroform, methanol and HC1. 
3:5:5 v/v CHCl^MeOH^Cl (1 Molar) removed the highest propor­
tion of bilirubin but there were still large losses of bilirubin 
which remained irreversibly bound to the column. Use of 
alternative alcohols with higher polarity eg isopropyl alcohol 
resulted in conversion of the yellow colour to a green colour 
which did not separate on HPLC to give the same retention time 
as bilirubin. It appeared the bilirubin had been converted or 
degraded by mixing with this alcohol.
Due to the large volumes of buffer required to recover 
substantial bilirubin from the SAX column, concentration of the 
solution for application to HPLC was tedious and likely to 
result in losses due to exposure to light. Solid phase sample
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preparation as a means of purification of bilirubin before 
application to HPLC by this method were abandoned.
None of the above attempts used to try and isolate 
bilirubin and make measurement easier were successful more often 
resulting in such poor recoveries that little or no peak could 
be detected on HPLC using the gradient system of HPLC used for 
qualitatively identifying serum bilirubin. More success was 
achieved using the isocratic method of HPLC quoted in the 
methods section 2.7.3.
6.2.5 Isocratic Reversed Phase HPLC of Bilirubin
An isocratic method for measurement of bilirubin isomers in 
serum was developed by McDonagh (McDonagh, unpublished observa­
tions) and the conditions are described in the methods section
2.7.3 part ii). For serum determination, either serum or 
plasma is added to mobile phase directly, the resulting suspen­
sion centrifuged by an eppendorf centrifuge and the supernatant 
directly injected onto the column. Resolution of bilirubin 
isomers is achieved by addition of a percentage of distilled 
water to the organic mobile phase.
In our laboratory through trial and error using spiked serum 
bilirubin standards and serum from human and rat sources the 
optimum proportion of water was determined to be 5%. This 
allowed resolution of the bilirubin isomers in approximately 1 2  
to 13 minutes, with the unconjugated peak having a retention 
time of between 8  and 10 minutes. A further increase to 8 % 
water led to doubling of the retention times with significant 
loss of resolution and peak sharpness.
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Brain tissue homogenate was directly added to mobile phase 
in the proportion 1:4 as recommended for serum. After 
centrifugation in an eppendorf centrifuge, the resulting 
supernatent was injected onto the column. As might have been 
expected from previous attempts to measure bilirubin without 
extraction no bilirubin was observed emphasising the need for 
removal of bilirubin from heterogeneous medium of brain.
After organic extraction with CHCl^rMeOHit^O the chloroform 
phase was concentrated under N 2 and mixed with mobile phase. A 
peak attributable to unconjugated bilirubin was seen with a 
retention time of 8 . 6  minutes. This method of concentration 
under gas followed by mixing with mobile phase was not ideal for 
quantitation and so the solution was evaporated to dryness and 
then resuspended in a known volume of mobile phase. These 
samples were still fairly cloudy and so a guard column was used 
to extend column life. This method still failed to accurately 
quantitate bilirubin content in brain since losses incurred on 
extraction were not accounted for. Thus the losses on 
extraction were taken into account by use of an internal 
standard.
6.2.6 Identification of an Internal Standard for HPLC of Bilirubin
Losses of bilirubin extracted from brain tissue by organic 
solvents were high as described in Figure 29. The easiest way 
to compensate for these losses was to identify an internal 
standard for addition at the homogenisation stage of rat brain. 
Study of coloured compounds which would be detected at the same 
wavelength as bilirubin revealed a laser dye Coumarin 6  (Kodak)
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with a similar spectrum. This was one of a range of laser dyes 
which have often been used as internal standards for HPLC.
Coumarin 6  was found to dissolve easily in organic solvents, 
including the mobile phase for this HPLC method to give a highly 
fluorescent yellow/green colour. On injection, retention time 
was found to be between 2 and 3 minutes, early enough to be 
totally separate from the unconjugated bilirubin peak and so 
likely to be useful as an internal standard. DMSO was chosen 
to dissolve Coumarin 6 since it exhibited no peak on HPLC and 
was a component used to dissolve cofimercial bilirubin used as 
standard. Stock Coumarin 6 was made up as described in the 
methods and lOOng was added in 20/ul aliquots to brain homoge- 
nates. This gave a peak in the same range as bilirubin 
extracted from brain tissue and is shown in Figure 30.
6.2.7 Quantitation of Brain Bilirubin
A standard curve for quantitation of bilirubin in brain was 
set up using brain samples spiked with commercial bilirubin and 
extracted. The standard curve obtained is shown in Figure 31. 
Quality control samples containing 1.7nmol/g wet weight 
commercial bilirubin in brain homogenate, extracted as with the 
samples were regularly run. Results were corrected for 
bilirubin recovery by the presence of internal standard.
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1.
Peak 1 is internal standard (Coumarin 6, 100ng) - retention time 2.74 minutes 
Peak 2 is brain bilirubin - retention time 7.30 minutes
FIGURE 30 : A TYPICAL HPLC TRACE FOR BRAIN BILIRUBIN
Peak Areas x 106
nmol / g wet weight
FIGURE 31: CALIBRATION CURVE FOR BRAIN BILIRUBIN LEVELS
6.3 BRAIN BILIRUBIN LEVELS IN ADULT GUNN RATS COMPARED TO CONTROLS
Adult Gunn rats were anaesthetised using ether and the 
brains perfused through the heart with 0.9% NaCl as described in 
section 2.2.3. Brain tissue free of blood was removed and 
homogenised in sucrose. Internal standard (Coumarin 6, lOOng) 
was added. Bilirubin was extracted using the method in 
section 2.9.1, resuspended in lOOpl mobile phase for isocratic 
determination of bilirubin and injected onto the column. The 
results of measurement of brain bilirubin in 6 adult Gunn rats 
and 6 control rats are presented in Figure 32. Levels in Gunn 
rat brain of 2.9 + 0.5 pg/gram wet weight tissue or 5.0 + 
0.9 nmol/gram wet weight tissue are within the same range as 
those values in the literature (Katoh et al, 1975; Sawasaki et 
al, 1976; Aono et al, 1989). The total lack of recording of 
bilirubin in control Gunn-Wistar cross rats also agrees with 
the literature which quotes no spectrophotometric peak for 
bilirubin (Sawasaki et al, 1976). No peak was seen on the HPLC 
trace.
6.3.1 Effect of Anaesthetic Used on Brain Bilirubin in Gunn Rats
The ether used up until now in these experiments was as an 
inhaled drug which induced anaesthesia. Any possibility that 
ether may cause partition of bilirubin to tissues other than the 
brain was discounted by comparing the bilirubin content of Gunn 
rat brains anaesthetised with ether to that of rats injected 
with a barbiturate anaesthetic. In these experiments sacrifice 
by cervical dislocation was impractical as an intact CNS 
capillary circulation was required to allow perfusion of the
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nmol / g wet weight
2
represents the mean of Gunn rat brain bilirubin determination. 
Levels in Gunn-Wistar cross rats were not measurable.
FIGURE 32: BRAIN BILIRUBIN LEVELS IN GUNN RATS
brain free of blood which would contain contaminating bilirubin 
and may give falsely high results. There was no significant 
difference in the bilirubin content of rat brains by either 
method of anaesthesia. Bilirubin content of Gunn rat brain 
anaesthetised with ether was 3.1 _+ 0.4 /jg/g wet weight tissue 
while comparative content of Gunn rat brain using barbiturate 
anaesthesia was 2.9 + 0.4 /jg/g wet weight tissue. These were 
the results of 3 experiments repeated in duplicate.
6.3.2 Sex Difference in Bilirubin Content of Gunn Rat Brain
Using the isocratic HPLC method previously described the 
bilirubin content of Gunn rat adult male brain tissue was 
compared to that of female Gunn rats of similar age. The 
results are presented in Table 19. The rats used were 10 
months old. Adult female Gunn rats had significantly lower 
body weights (275g ) than their male counterparts (325g). 
Bilirubin content in male rat brain was significantly higher 
than that of the female. Interestingly no significant differe­
nce was found in the weights of Gunn rat female and male brains, 
1.94 + 0.21g in male rats as compared to 1.81 + 0.32g. It is 
postulated that the different hormonal balance may have some 
bearing on bilirubin deposition in Gunn rat brain. Additionally 
lipid content of female peripheral body cells is likely to be 
higher than their male counterparts, as a result of hormone 
balance. The lower bilirubin content of brain may reflect 
higher deposition of bilirubin in peripheral tissues. The 
fact that there was no significant difference in the serum 
bilirubin levels between male and female rats is in agreement
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GUNN RAT 
MALE
GUNN RAT 
FEMALE
AGE (MONTHS) 10 10
MEAN WEIGHT (g) 326 + 24 274 + 26
WEIGHT RANGE (g) 300-375 250-320
aTOTAL SERUM BILIRUBIN 66.2 + 15.8 70.7 + 8.3
pmol/litre (mean + SD)
aBRAIN BILIRUBIN 4.9 + 0.8 2.7 + 0.7
nmol/g wet wt (mean + SD)
n 6  6
a - each result is the mean of duplicate determinations 
* p< 0.01 by Mann Whitney U Test 
** p< 0.001 by Mann Whitney U Test
*
**
TABLE 19: BILIRUBIN LEVELS IN ADULT MALE GUNN RAT BRAIN AS
COMPARED TO FEMALE RATS
with the citing in the literature that little correlation exists 
between serum total bilirubin levels and brain bilirubin 
content.
6.4 DISCUSSION AND SUMMARY
A method has been developed for accurate measurement of 
bilirubin content in Gunn rat brain.* This method utilises the 
separation abilities of HPLC to provide a more sensitive method 
than the previous spectrophotometric ones. Brain bilirubin 
levels in adult Gunn rats in these experiments were discovered 
to be in the same range as reported in the literature. The use 
of ether as an anaesthetic for the studies proved to have no 
different effect on the bilirubin levels found in Gunn rat brain 
when compared to a barbiturate as anaesthetic. Study of the 
sex differences of brain bilirubin levels showed that female 
rats appeared to have less deposition of bilirubin centrally 
than their male counterparts. Even with this method which had 
a lower limit of detection of 0.2 nmol/g wet weight of tissue no 
bilirubin could be detected in the brains of control Gunn-Wistar 
cross rats or Wistar rats. It is possible that levels in these 
animals are lower than the limit of detection of this method.
*  s e e  a p p e n d i x  1
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CHAPTER 7
THE EFFECT OF BILIRUBIN ON BRAIN HAEM BIOSYNTHESIS
160
7.1 INTRODUCTION
From the details given in previous chapters and from the 
literature the Gunn rat appears to be the animal model which 
most closely resembles the human clinical condition of kernicte- 
rus in infants. The behaviour of adult Gunn rats is not 
entirely normal when compared to the heterozygous Gunn-Wistar 
cross or Wistar rats. The rats are prone to excitability 
especially when disturbed and this is attributed to the 
neurological damage caused by hyperbilirubinaemia. However the 
extent of the brain damage suffered is thought to be mild. In 
contrast to infants with kernicterus the rats lead fairly normal 
and active lives. These animals can suffer from more severe 
symptoms but these tend to die within the first few days of 
life. The haem biosynthetic pathway in the brain of the Gunn 
rat has not previously been studied. The results in Chapter 5 
clearly show that the presence of bilirubin can lead to 
inhibition of PROTO-O activity in an in vivo model of hyperbili­
rubinaemia. In this section of the thesis haem biosynthesis in 
the brain of these animals with elevated bilirubin will be 
examined.
7.2 HAEM BIOSYNTHESIS IN THE ADULT GUNN RAT BRAIN
Adult Gunn and control (Gunn-Wistar) rats were starved for 
24 hours and sacrificed. Blood was removed for serum bilirubin 
determination. Brain tissue was perfused through the heart, 
quickly removed and evenly divided between the hemispheres. 
Tissue was kept on ice after removal from the animal. Oie half 
of the brain was homogenised in 0.15 Molar KC1 and mitochondria
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were prepared for PROTO-O assay as in the methods section 2.3.4. 
The other half was homogenised in 0.25 Molar sucrose and 
homogenates stored at -20°C until extraction of brain bilirubin 
could be carried out. Bilirubin was extracted as in section
2.9.1 and assayed using the isocratic HPLC method described in 
section 2.9.2.
In agreement with the results obtained in previous chapters 
serum bilirubin and brain bilirubin levels were significantly 
higher in Gunn rats as compared to controls when statistically 
compared by Mann Whitney U test (p<0.001). PROTO-O activities 
in Gunn rat brain tissue were comparable to those in control rat 
brain (8.7 + 2.7nmol PROTO/mg protein/hour as compared to 9.2 + 
3.0nmol PROTO/mg protein/hour). All these results are shown in 
Table 20. Therefore the levels of bilirubin found in the 
brain of adult Gunn rats appears to be insufficient to cause 
disruption of the haem biosynthetic pathway.
It is possible that the bilirubin levels in Gunn rat brain, 
while elevated far above normal levels as recorded both in 
Chapter 6 and in this chapter are still not in parallel with the 
levels which result in human kernicterus and that the brain 
damage observed is of a far milder form. If this is the case 
then a truer model of kernicterus may result if brain bilirubin 
levels in Gunn rats were further elevated.
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GUNN
GUNN-WISTAR
CROSS
ALA-synthase
activity 54.7+9.3 46.9+8.9
PROTO-O"
activity 8.7 + 2.7 9.2 + 3.0
BRAIN BILIRUBIN 5.4 + 1.4 *
SERUM BILIRUBIN 6 5 + 1 3 *  4.0+2.0
Results are expressed as mean + SD
n=5 in all cases
* significantly higher (p<0.001) by Mann Whitney U test.
ALA-synthase activity is in pmol ALA/mg protein/h, PROTO-O 
activity is in nmol PROTO/mg protein/h. Brain bilirubin is 
expressed in nmol/g wet weight tissue and serum bilirubin is 
expressed as pmol/1.
TABLE 20: HAEM BIOSYNTHETIC ENZYME ACTIVITIES AND BILIRUBIN
LEVELS IN ADULT GUNN RAT BRAIN COMPARED TO CONTROLS
ELEVATION OF BRAIN BILIRUBIN IN GUNN RATS
The lack of inhibition of the penultimate enzyme of haem 
biosynthesis in brain by bilirubin as was observed in liver of 
adult Gunn rats was disappointing. it appears levels of 
bilirubin in Gunn rat brain require to be increased further 
before effects of a similar nature to those in human kernicterus 
are seen. The brain damage observed in Gunn rats can be 
increased. Several mechanisms of producing symptoms 
resembling kernicterus have been employed. use of the neonatal 
animal is popular (Sawasaki et al, 1976). The popularity of 
this model was thought to lie in the immaturity of the blood 
brain barrier which made access of bilirubin to the brain 
easier, but the validity of this observation is now disputed 
(Davis & Yeary, 1975). The most common method of observation 
of an icteric state has been by administration of a displacing 
agent for bilirubin from albumin ( Katoh et al, 1975; Rose & 
Wisniewski, 1979; Aono et al, 1989). Displacement of bilirubin 
from albumin in the circulation greatly increases the proportion 
of free bilirubin, and this would then have access to the 
tissues. Several classes of drugs themselves bind tightly to 
albumin so causing release of bilirubin from albumin and 
potentially allowing free access to brain tissue for deposition. 
In the literature sodium buculome (Aono et al, 1989), novobiocin 
(Katoh et al, 1975) and a range of sulphonamides have been used 
to stimulate release of bilirubin. The most common sulphona- 
mide used has been sulphadimethoxine (Davis & Yeary, 1975; Rose 
& Wisniewski, 1979). Another model which has become popular more 
recently is one where the blood brain barrier is disrupted in
some way (Levine et al, 1982; Wennberg & Hance, 1986), allowing 
free access of both the free form of bilirubin and the albumin- 
bound form. As previously discussed in section 1.5.2 several 
authors believed that the increased toxicity of bilirubin in 
newborns was a result of an immature blood brain barrier. 
Recent observations are more of the opinion that entry to the 
brain increases under conditions where the blood brain barrier 
has been disrupted and rendered open by hypoxia, hypertension or 
other abnormal states. Certainly in adult rats where the BBB 
is intact even treatment with high doses of bilirubin displacing 
drugs does not appear to cause the extensive brain damage seen 
in icteric infants.
Much evidence is consistent with the theory that free 
bilirubin is the form which can enter the brain and cause the 
brain damage (Diamond & Schmid, 1966; Maisels et al, 1981; 
Cashore & Oh, 1982). Despite these reports conclusive proof 
on a role of free bilirubin as the cause of the neurological 
damage is absent from the literature (Levine, 1979; Levine et 
al, 1982). A recent report suggests that both the state of 
BBB and free bilirubin level are important (Wennberg & Hance, 
1986) .
For the remainder of the experiments to determine the effect 
of bilirubin on haem biosynthesis in the brain it was elected to 
use neonatal Gunn rats at 15 days old. It was elected to 
produce symptoms of kernicterus by displacing bilirubin from 
albumin in these animals. The combination of these two methods 
has been successful in the past (Katoh et al, 1975; Rose &
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Wisniewski, 1979; Aono et al, 1989). One of the most
successful drugs has been sulphadimethoxine. This sulphonamide
was used to raise free bilirubin levels in the experiments using 
neonatal Gunn rats to determine effects of bilirubin on brain 
haem biosynthesis. The intention was to study the possible 
effects which bilirubin might have on the haem biosynthetic 
pathway in the brain. Assays for measurement of ALA-synthase 
and PROTO-O activity have been worked up for brain tissue. 
Bilirubin in serum and brain has also been measured. From the 
results obtained in Chapter 5 of the effect of bilirubin on 
PROTO-O activity in hepatic tissue it was hoped study of a 
potential effect of bilirubin on the brain haem biosynthetic 
pathway may be another aspect of the toxicity to the CNS 
suffered in kernicterus. Groups of age matched Gunn and Gunn- 
Wistar control rats were compared. Several characteristics of 
the rats were considered.
7 .3 .1  T h e  E f f e c t  o f  B i l i r u b i n  o n  p h y s ic a l C h a r a c t e r is t ic s  o f  N e o n a ta l 
Gunn B a ts
The physical characteristics, body weights and tissue 
weights of 15 day old Gunn rats were compared to matched Gunn- 
Wistar controls.
Body weights of Gunn rats aged 15 days were compared to body 
weight of Gunn-Wistar cross rats of the same age. The Gunn 
rats were from the same litter. The cross rats were from one 
litter but were not littermates of the Gunn animals. As Table 
21 clearly shows Gunn rats were significantly lighter than their 
cross counterparts of the same age - p<0.001 by Mann Whitney U 
test. In all cases cross rats were at least 150% the weight of
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GUNN-WISTAR
GUNN CROSS
MEAN
PHYSICAL WEIGHT 18.1 + 4.6 27.5 + 4.6*
RANGE 10.0 - 25.0 20.0 - 35.0*
MEAN
LIVER WEIGHT 0.51 + 0.11 0.86 + 0.21 *
MEAN
KIDNEY WEIGHT 0.16 + 0.02 0.31 + 0.04 *
a = results expressed as mean + SD
* = significantly higher (p<0.001) by Mann Whitney u test. 
n= 10 in all cases
TABLE 21: PHYSICAL WEIGHTS AND TISSUE WEIGHTS OF 15 DAY OLD
GUNN RATS COMPARED TO CONTROLS
the Gunn animals. As might be expected from these observations 
the tissue weights from Gunn animals were also significantly 
lower - p< 0.01 by Mann Whitney U Test.
7 . 3 . 2  Haem B io s y n th e s is  in  H e p a t ic  an d  B e n a l T is s u e  o f  1 5  D ay O ld  G unn  
R a ts  C om pared t o  C o n tr o ls
Haem biosynthesis in hepatic and renal tissue of Gunn and 
age matched Gunn-Wistar cross rats were compared to establish 
that the oattern was similar to the one seen in adult rats.
15 day old Gunn and Gunn-Wistar cross rats were 
anaesthetised in ether, blood removed for serum bilirubin 
determination and livers and kidneys excised and perfused as in 
section 2.3.2. Tissues were then equally divided and half was 
homogenised in buffer for ALA-synthase assay while the remainder 
was homogenised in KC1 for PROTO-O assay as previously described 
(2.3.1. and 2.3.4.). Both assays were carried out after 
preparation of mitochondria. Tissue weights were small and 
tissues from two animals were pooled wherever possible to 
provide enough tissue for all analyses.
Hepatic and renal ALA-synthase levels in Gunn and Gunn-Wistar 
cross rats were not significantly different in the two groups 
with activities of 365 + 74 and 305 + 81pmol ALA/mg protein/h 
respectively, mean + SD seen in liver and 107 + 42 and 74 + 
28pmol/mg protein/h in kidney. These results are shown in Table 
22. The adult pattern of a lower activity in kidney in both 
groups of animals was maintained. From these results the 
enzyme activities in liver and kidney of neonatal rats are in 
the same range as those seen in adults demonstrated in Table 15
166
GUNN
HEPATIC 365 + 74
pmol ALA/- 
mg protein/h
n 7
RENAL 107 + 42
pmol ALA/ 
mg protein/h
Results are expressed as mean + SD
GUNN-WISTAR
CROSS
305 + 81
8
74 + 28
TABLE 22: AIA-SYNTHASE ACTIVITIES IN HEPATIC AND RENAL TISSUE
OF 15 DAY OLD GUNN RATS AND CONTROLS
of Chapter 5. Similarly PROTO-O activities in the same groups 
of Gunn and Gunn-Wistar cross rats were compared and the 
activities in hepatic tissue of the Gunn rat group were found to 
be significantly lower than those in the heterozygous group 
(p<0.05 by Mann Whitney U test) as is demonstrated in Table 23.
7.4 T R E A T M E N T  OF 15 DAY OLD GUNN AND C O N T R O L  RATS W I T H  
SULPHADIMETHOXINE AND DETERMINATION OF BRAIN ENZYME ACTIVITIES
15 day old Gunn rats, where possible from the same litter 
were divided into two groups. One group of animals were 
injected ip with a dose of 50mg/kg body weight sulphadimethoxine 
and these constituted the drug treated animals. The remainder 
were injected with carrier only and were the control Gunn group. 
Concurrently, age matched Gunn-Wistar cross rats were similarly 
divided into control and drug treated groups. After 
administration of the drug or placebo the animals were separated 
from their dams and maintained under a heat lamp for 5 hours to 
enable the drug to displace bilirubin and for deposition in the 
brain to occur. After the 5 hour period, rats were sacrificed, 
blood was collected for bilirubin estimation, and body tissues 
perfused free of blood. The brain was then excised, weighed 
and divided such that bilirubin content, PROTO-O and ALA- 
synthase activities could be measured. Due to the small 
amounts of tissue available in most cases the brains of two 
animals were pooled. Brain tissue was halved between the 
hemispheres, and the halves from different rats combined. 
Before homogenisation in the appropriate buffer a small portion 
was removed from each of the combined brains and prepared for 
brain bilirubin estimation as detailed in section 2.9.
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GUNN-WISTAR
GUNN CROSS
HEPATIC 12.3 + 3.5 17.7 + 1.5
RENAL 18.2 + 1.8 12.6 + 0.9
n=8 in all cases
Results are expressed as mean + SD and in nmol PROTO/mg 
protein/hour
TABLE 23: PROTO-O ACTIVITIES IN HEPATIC AND RENAL TISSUE OF
15 DAY OLD GUNN RATS COMPARED TO CONTROLS
7.4.1 Bilirubin Levels in Serum and Brain of Treated and Untreated 
Rats
FromTable 24 serum bilirubin levels in 15 day old Gunn rats 
which have been untreated are significantly higher than those of 
their Gunn-Wistar cross controls (p<0.001 by Mann Whitney U 
test) as was expected since these rats exhibit the congenital 
defect in bilirubin conjugation. Serum bilirubin levels in the 
Gunn-Wistar cross rat group did not overlap with those levels 
seen in Gunn rats (11.7 + 1.0, 12.6 + 1.2pmol/l compared to 148 
+ 12.9, 68.3 + 4.8pmol/l) (mean + SD) but the Gunn-Wistar serum 
bilirubin levels were higher than those observed in adult rats. 
This may be explained by the immaturity of the bilirubin 
conjugating system in these young rats. There was no 
significant change in the serum bilirubin levels of cross rats 
after treatment with sulphadimethoxine. In contrast there was 
a significant decrease in serum bilirubin level of Gunn rats 
after treatment with the drug - demonstrated in Table 24 and 
Figure 33. This shows that the drug is successfully displacing 
bilirubin from albumin. The significant rise in brain 
bilirubin from 4.2 + 0.1 nmol/g wet weight to 9.8 + 0.4 nmol/g 
wet weight after administration of the drug reflects successful 
entry of bilirubin into this tissue. Since there is little 
free bilirubin in cross rats no bilirubin was detected in the 
brain of these rats either before or after sulphadimethoxine 
treatment. Since the lower limit of detection of the adopted 
brain bilirubin assay was O.lpg/g wet weight tissue the levels 
of bilirubin in the brain of these rats must have been below
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BILIRUBIN LEVEL
SERUM BRAIN
pmol/1 nmol/g wet wt
CROSS RATS
UNTREATED 12.6 + 1.2
CROSS RATS
TREATED 11.7 + 1.0
GUNN RATS
UNTREATED 148 + 13 4.2 + 0.1
GUNN RATS
TREATED 68.3 +4.8 9.8 +0.4
n = 8 in all groups
Results are expressed as mean + SD
Treated refers to administration of sulphadimethoxine 50mg/kg 
four hours prior to sacrifice.
TABLE 24: BILIRUBIN LEVELS IN SERUM AND BRAIN OF TREATED AND
UNTREATED RATS
150 -
100 I
before after
treatment 50mg/kg sulphadimethoxine
treatment
The left ascending axis shows pmol / 1 for serum bilirubin 
The right ascending axis shows nmol / g wet weight for brain bilirubin 
®  represents serum bilirubins of homozygous Gunn rats before and after 
treatment
o represents brain bilirubins of homozygous Gunn rats before and after 
treatment
Results are mean of 8 experiments, calculated in duplicate.
FIGURE 33 : EFFECT OF SULPHADIMETHOXINE ON GUNN RAT 
SERUM AND BRAIN BILIRUBIN LEVELS
this level.
For completeness the weights of the brains of Gunn rats and 
Gunn-Wistar cross rats were measured, both on treatment with 
sulphonamide and without. Treatment with sulphadimethoxine 
made no difference to the weights of the tissue, but there was a 
significant difference in the brain weights of Gunn rats 
compared to control Gunn-Wistar rats. Gunn rat brains were 
consistently of a lower weight than cross rat brain - p<0.01 by 
Mann Whitney U test see Table 25.
7.4.2 Activity of Brain Haem Enzymes in 15 Day Old Gunn Rats With 
Elevated Brain Bilirubin Levels
In a similar group of experiments to those in section 7.3/ 
groups of 15 day old Gunn rats and Gunn Wistar rats were divided 
to give four groups. Generally eight animals were used. Ihe 
Gunn rats were divided into two groups of two, and one group was 
treated with 50mg/kg sulphadimethoxine while the other group 
were administered with carrier only (saline). An identical 
regime was carried out with the Gunn-Wistar cross rats. All 
animals were separated from their dams and allowed free movement 
for five hours to allow equilibration between the drug and 
albumin in the system and maximal displacement of bilirubin. 
The rats were then sacrificed, blood removed for serum bilirubin 
determination, brains perfused and removed on ice for enzymatic 
measurement (ALA-synthase and PROTO-O activities) and bilirubin 
determination. Brain tissue from two animals was pooled for 
each determination.
The mean (+ SD) results obtained for enzyme activities are 
represented in Table 26 and in Figures 34 & 35. Even with
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BRAIN WEIGHT 
(9)
CROSS RATS
UNTREATED 1.12 + 0.07
CROSS RATS
TREATED 1.11 + 0.11
GUNN RATS
UNTREATED 0.90 + 0.08
GUNN RATS
TREATED 0.92 + 0.05
Results are expressed as mean + SD
Treated refers to administration of sulphadimethoxine 50mgAg 
four hours prior to sacrifice.
TABLE 25: BRAIN WEIGHTS IN 15 DAY OLD GUNN AND CONTROL RATS
ENZYME ACTIVITIES
PROTO-O ACTIVITY ALA-synthase ACTIVITY
nmol PROTO/mg protein/h pmol ALA/mg protein/h
CROSS RATS
UNTREATED 18.3 + 4.3 108 + 35.6
n 10 11
CROSS RATS
TREATED 20.5 + 5.4 100 + 27.0
n 8 8
GUNN RATS
UNTREATED 16.7 +3.3 130 + 46.2
n 8 8
GUNN RATS
TREATED 16.3+4.1 115 + 29
n 9 9
Treated refers to administration of sulphadimethoxine 50mg/kg 
four hours prior to sacrifice.
Results are expressed as mean + SD
TABLE 26: ACTIVITY OF BRAIN HAEM ENZYMES IN SULPHADIMETHOXINE
TREATED RAT BRAIN AND CONTROL RAT BRAIN OF 15 DAY OLD 
GUNN AND GUNN-WISTAR CROSS RATS
100 _
Units are pmol ALA / mg protein / hour
•  represents untreated Cross rat brain tissue
O represents Cross rat brain tissue, in rats treated with
50mg/kg sulphadimethoxine
A  represents untreated Gunn rat brain tissue
▼  represents Gunn rat brain tissue, in rats treated with
50mg/kg sulphadimethoxine
Results are expressed as mean ± SD
FIGURE 34 : ALA-SYNTHASE ACTIVITIES IN GUNN RAT BRAIN AND 
CROSS RAT BRAIN, WITH AND WITHOUT BILIRUBIN DISPLACEMENT
20
10
Units are nmol PROTO / mg protein / hour
®  represents untreated Cross rat brain tissue
O represents Cross rat brain tissue, in rats treated with
50mg/kg sulphadimethoxine
A  represents untreated Gunn rat brain tissue
▼  represents Gunn rat brain tissue, in rats treated with
50mg/kg sulphadimethoxine
The results are mean activities ± SD
FIGURE 35 : PROTOPORPHYRINOGEN OXIDASE ACTIVITES IN GUNN RAT 
BRAIN AND CROSS RAT BRAIN WITH AND WITHOUT BILIRUBIN DISPLACEMENT
the elevation of bilirubin in brain clearly seen from Table 24 
and Figure 33 no significant differences could be detected in 
either PROTO-O activity or ALA-synthase activity of Gunn rats. 
In untreated Gunn rats PROTO-O activity was recorded at 16.7 + 
3.3nmol PROTO/mg protein/hour (mean + SD), and this was not 
significantly different to the values obtained in Gunn-Wistar 
cross rats (18.3 + 4.3nmol PROTO/mg protein/hour). By 
increasing brain bilirubin levels to greater than twice those 
seen in untreated 15 day old Gunn rats the PROTO-O activities 
seen were virtually identical with a mean of 16.3 + 4.1 nmol 
PROTO/mg protein/h. The absence of any depression in PROTO-O 
activity seen meant that it was unsurprising that no significant 
differences were recorded in ALA-synthase activity of brain of 
these icteric Gunn rats.
7.5 DISCUSSION AND SUMMARY
Initial experimentaldata obtained on the activity of the 
haem biosynthetic enzymes of interest in the brain of adult Gunn 
rats showed that PROTO-O activity was similar to those 
activities recorded in control, Gunn-Wistar cross rats. From 
the previous data obtained on the activity of PROTO-O in other 
tissues of Gunn rats this was a disappointing result, as the 
brain is known to be a major site of deposition of bilirubin. 
However the levels of bilirubin found in this tissue are still 
far below those reported in the liver, where bilirubin is 
sequestered for excretion and where in vitro inhibition of 
PROTO-O activity has previously been measured. The brain
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damage which occurs during kernicterus seems only to be produced 
in young mammals under normal conditions. In adult humans 
kernicterus does not develop and this is thought to be due to 
the efficiency of the excretion routes which are then fully 
developed. Icteric states have been induced in adult animals 
but these require extensive disruption of the blood brain 
barrier, after administration of bilirubin displacing agents, to 
allow access of large amounts of free bilirubin to the brain. 
No similar type of condition is observed in humans.
The lack of successful inhibition found in adult Gunn rat 
brain, the fact that kernicterus develops in the newborn only 
and the success of displacing agents for bilirubin in mimicking 
the symptoms of kernicterus in rat models led to the decision to 
use neonatal Gunn rats and to elevate brain bilirubin levels by 
displacement of bilirubin from its binding to albumin in plasma 
with sulphadimethoxine.
After treatment with sulphadimethoxine bilirubin was 
successfully raised in the brain of Gunn animals. Despite this 
increase no inhibition of PROTO-O activity by bilirubin was 
detected. One aspect observed was the increase in both ALA- 
synthase activity and PROTO-O activity in the neonatal animal as 
compared to the adults. High ALA-synthase activities during 
early animal development is well documented (Paterniti et al, 
1978) and these results show that a similar increase in PROTO-O 
activity is present in the first few weeks of life.
With respect to bilirubin as an inhibitor brain haem 
biosynthesis the results obtained here show that no inhibitory 
effect can be demonstrated even after elevation of brain
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bilirubin levels to the same range as those previously shown to 
produce symptoms of kernicterus. The Gunn rats displayed 
abnormal behaviour after treatment with sulphadimethoxine, 
consistent with observations in other models of the disease. 
Thus these experiments are not consistent with the hypothesis 
that a component of the brain damage observed in kernicterus may 
be due to disruption of the haem biosynthetic pathway in this 
tissue, similar to the neurological disturbances which develop 
in porphyria.
The reasons for this lack of inhibition of PROTO-O activity 
in the brain, despite observation in other tissues, must be 
considered. Efficient washout of bilirubin from the tissue was 
not thought to contribute to these results as the tissues were 
prepared in a similar way to liver tissue where the reduction in 
PROTO-O activity found in adults was seen. The _in vitro 
studies which demonstrated effective inhibition of PROTO-O 
activity showed a mean inhibitory concentration of 25uM 
(Ferriera & Dailey, 1988). In these experiments the highest 
concentration of bilirubin recorded in brain after treatment 
with sulphadimethoxine was in the region of 10/jM. Because of 
the lower brain concentration less inhibition than that observed 
by Ferriera's group would be expected. However no percentage 
decrease could be seen in brain tissue of these animals. This 
was despite the fact that the concentrations obtained were 
associated with clear manifestations of brain dysfunction.
Brain bilirubin is known to deposit unevenly in the brain, 
with highest concentrations in the cerebellum (Sawasaki et al,
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1976). All the measurements of brain haem biosynthetic enzymes 
were carried out in whole brain mitochondrial preparations. 
The manifestations of brain damage seen are associated with 
dysfunction of this particular area of the brain and it is 
therefore a possibility that on entry to the brain bilirubin 
preferentially deposits in this area. Further experiments 
where dissection of the brain and measurement of PROTO-O 
activity in the various regions would be interesting and may 
point to a local effect. One problem with these type of 
experiments would be the number of animals from which tissue 
would have to be pooled to provide enough tissue for accurate 
assay. There is scope for producing a micro method for 
measurement of PROTO-O activity for this type of work.
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CHAPTER 8
THE EFFECT OF TIN PROTOPORPHYRIN 
ON HAEM METABOLISM IN PORPHYRIA
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8.1 INTRODUCTION
The work so far contained in this thesis has 
concentrated on the haem biosynthetic pathway in the brain. 
The experimental data obtained has shed little light on the 
mechanism by which bilirubin exerts its toxic influence on 
neurological tissue in kernicterus. It appears that 
disruption of haem biosynthesis in the brain may not be a 
factor in the neurological damage sustained in this condition. 
As detailed in the introduction the porphyric disease states 
are a result of disruption of the haem biosynthetic pathway. 
The acute porphyrias are hereditary diseases where a genetic 
lesion occurs resulting in a defect in enzyme activity. 
Neurological manifestations are common in attack, in addition 
to the abdominal pain and photosensitivity reactions suffered 
in some of these conditions. One of the most common forms of 
porphyria is acute intermittent porphyria, where activity of 
the enzyme PBG-D is greatly reduced compared to normal. On 
exposure to certain precipitating factors such as drugs which 
increase the requirement for cyt.P450, the haem produced by 
the inhibited biosynthetic pathway is insufficient to meet 
demand and the resultant haem deficiency leads to derepression 
of synthesis of the rate controlling enzyme and a consequent 
increase in activity. This is in an attempt to increase haem 
production and overcome the block but simply exacerbates the 
condition as porphyrins and precursors build up prior to the 
blocked step. Acute intermittent porphyria and its effects 
are discussed more fully in section 1.4.1.
Treatment of porphyria has always been difficult.
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Administration of haematin (haem dissolved in alkali) to 
replete the intracellular free haem pool has been moderately 
successful (Bonkowsky et al, 1971). Some patients find no 
improvement in their symptoms however in most cases the 
biochemical profile returns to levels approaching normal 
during therapy only to rebound to pretreatment levels after 
stopping therapy. The haematin solution is known to be 
unstable (Mendenhall, 1984) and may decompose in vivo before 
full uptake to liver can occur. This is the probable cause of 
variability in effectiveness recorded in various studies 
(Bissell et al, 1988; Granick & Sassa, 1978). To combat this 
a recent advance has been the introduction of a more stable 
form of haem, bound to the amino acid arginine (Tenhunen et 
al, 1987). Haem arginate has been used to return induced ALA 
synthase activities to normal in AIA induced porphyria in 
animals (Tenhunen et al, 1987; Tokola et al, 1987). This 
treatment has also been successful to some extent in the 
treatment of acute hepatic porphyria (Mustajoki et al, 1986). 
However the improvements in the symptoms of porphyria seen are 
often shortlived. Thus, even increased stability of the haem 
compound for intravenous administration is not a satisfactory 
solution. A major disadvantage is that administration of 
exogenous haem leads to induction of haem oxygenase resulting 
in enhanced metabolism of a percentage of the administered 
haem. Therefore duration of therapy is usually short (over 4 
days) but induction still occurs.
A number of metals, including tin
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molecule,inserted in the nucleus of porphyrins produce 
effective inhibitors of haem oxygenase. These
metalloporphyrins, such as Sn-PROTO inhibit haem oxygenase 
with stronger affinity for the enzyme than haem itself. This 
inhibition of haem oxygenase leads to a reduction in the 
production of bilirubin and CO (Simionatto et al, 1985; 
Milleville et al, 1985). This property of Sn-protoporphyrin 
(Sn-PROTO) led to investigations into the use of this compound 
as a treatment in lowering hyperbilirubinaemia in various 
conditions. Initial work on animals was promising with umolar 
doses effectively reducing bilirubin levels in bile duct 
ligated rats (Simionatto et al, 1985; Anderson et al, 1986) , 
neonatal rats (Drummond & Kappas, 1982) and those with induced 
hyperbilirubinaemia (Drummond & Kappas, 1984). Biochemical 
studies then showed that this synthetic haem analogue had low 
affinity for haem binding proteins in the circulation (Breslow 
et al, 1986). This explained the low half-life of Sn-PROTO in 
the plasma (less than 4 hours in rats). Sn-PROTO was found to 
deposit in tissues and act as an effective long term inhibitor 
of haem oxygenase with one dose resulting in reduction of 
serum bilirubin levels for a minimum of four days (Berglund et 
al, 1988). This metalloporphyrin appeared to be fairly 
harmless with no toxic effects seen at doses 100 times those 
in the therapeutic range in animals. Even after long periods 
of dosage no toxic effects have been seen in animals (Sassa et 
al, 1985). Hyperbilirubinaemia has been safely reduced in 
neonates with Sn-PROTO (Kappas et al, 1988). The only 
recorded side effect in some cases has been a transient
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photosensitivity (Kappas et al, 1988). In response to this, 
manipulations of the PROTO ring structure have been carried 
out and Sn-mesoporphyrin, with the vinyl groups at C2 and C4 
reduced to ethyl groups, was found to be a more effective 
inhibitor of haem oxygenase with potentially less of a 
photosensitizing effect (Drummond et al, 1987). This raises 
the possibility of designing metalloporphyrins which would not 
cause photosensitivity (Delaney et al, 1988).
This approach to treatment of hyperbilirubinaemia is a 
novel one since it treats the condition by reducing production 
of the potentially toxic bilirubin rather than altering 
disposal of the preformed pigment. Thus the haem degradative 
pathway is being manipulated. The reduction in the amount of 
bilirubin produced leads to an increase in the free haem pool, 
evidenced by saturation of the tryptophan pyrrolase enzyme 
within 1 hour of dosing (Kappas et al, 1985). This leads to 
excretion of small amounts of haem in the bile, urine and 
faeces. The increased content of haem in the liver during 
this treatment has led to investigations into whether Sn-PROTO 
would be a useful drug in other conditions.
Studies on the effect of Sn-PROTO in experimental 
porphyria in animals showed that this synthetic 
metalloporphyrin effectively prevented the induction of ALA- 
synthase in rats treated with AIA (Galbraith et al, 1985). In 
porphyric patients Sn-PROTO significantly reduced the 
hyperexcretion of ALA, PBG and porphyrins (Galbraith & Kappas, 
1989). The mechanism of action of Sn-PROTO is still unclear
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b u t  i t  i s  t h o u g h t  t h a t  t h e  s t r u c t u r a l  s i m i l a r i t y  o f  t h e  
com pound t o  haem  a l lo w s  e n t r y  o f  Sn-PROTO t o  th e  a c t i v e  s i t e  
w h e re  b in d in g  o c c u r s ,  le a d in g  t o  i n h i b i t i o n  o f  th e  enzym e  
( S im io n a t t o  e t  a l ,  1 9 8 5 ) .  A l t e r n a t i v e l y ,  o r  a d d i t i o n a l l y ,  t h e  
p o t e n t  i n h i b i t i o n  o f  Sn-PROTO on haem o x y g e n a s e  m ay le a d  t o  a  
s u f f i c i e n t  in c r e a s e  in  en do g en ou s  haem  t o  a l l o w  r e p r e s s io n  o f  
A L A -s y n th a s e  t o  o c c u r .  As d o cu m en ted  e a r l i e r  i n  t h i s  t h e s i s  
no a d v e r s e  e f f e c t s  h a v e  so  f a r  b een  s e e n  on  a d m i n i s t r a t i o n  o f  
Sn-PR O TO . T h u s , u s e  o f  th e  d ru g  in  p o r p h y r ia  s h o u ld  c a u s e  no  
a d v e r s e  e f f e c t s .
T h is  s e c t i o n  co m p ares  th e  m e t a b o l ic  e f f e c t  o f  Sn-PROTO  
w i t h  t h a t  o f  haem  a r g in a t e  i n  in d u c e d  p o r p h y r ia  i n  r a t s .  I n  
a d d i t i o n ,  we r e p o r t  th e  e f f e c t  o f  Sn-PROTO i n  c o m b in a t io n  w i t h  
h aem  a r g i n a t e  i n  t h e  t r e a t m e n t  o f  a c u t e  i n t e r m i t t e n t  
p o r p h y r i a .  A d m in is t r a t io n  o f  an  e x o g e n o u s  haem s o u r c e ,  s u c h  
a s  h a e m  a r g i n a t e ,  w h e n  c o m b in e d  w i t h  a  b l o c k  i n  t h e  
d e g r a d a t iv e  p a th w a y  o f  haem i s  p o t e n t i a l l y  a  v e r y  p o w e r fu l  
t o o l  i n  r e p l e t i n g  haem c o n t e n t  o f  t i s s u e s  w h i le  p r e v e n t in g  t h e  
a c c o m p a n y in g  i n d u c t i o n  o f  haem  o x y g e n a s e  a n d  i n c r e a s e d  
p r o d u c t io n  o f  b i l i r u b i n .  I t  w o u ld  be a d v a n ta g e o u s  i f  Sn-PROTO  
a n d  h aem  a r g i n a t e  c o m b in e d  h a d  a  s y n e r g i s t i c  e f f e c t  i n  
r e d u c in g  th e  p o r p h y r in  e x c r e t i o n  and  r e t u r n i n g  th e  d is r u p t e d  
en zym es  t o  n o rm a l l e v e l s  a l lo w in g  th e  d o s e  o f  haem a r g i n a t e  
r e q u i r e d  t o  b e  r e d u c e d . The Sn-PROTO m ig h t  a ls o  p r o lo n g  t h e  
b e n e f i c i a l  e f f e c t  o f  th e  a d m in is t e r e d  haem .
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8.2 PRODUCTION OF INDUCED PORPHYRIA IN RATS
T h i s  c o m b in a t i o n  t h e r a p y  h a s  n e v e r  b e e n  c l i n i c a l l y  
a p p l i e d  s o  i n i t i a l  s t u d i e s  w e r e  c a r r i e d  o u t  o n  r a t s  w i t h  
in d u c e d  p o r p h y r i a .  S p ra g u e  D a w le y  r a t s  2 0 0 -2 5 0 g  b od y  w e ig h t  
w e re  i n j e c t e d  i n t r a - p e r i t o n e a l l y  ( i . p . )  w i t h  v a r io u s  d o s e s  o f  
4 ,6 - d io x o h e p t a n o ic  a c id  ( s u c c in y l  a c e to n e )  i n  s a l i n e  s o l u t i o n .  
T h is  com pound c o m p e t i t i v e l y  i n h i b i t s  A LA -D  a c t i v i t y  (T s c h u d y  
e t  a l ,  1 9 8 1 )  e f f e c t i v e l y  l e a d i n g  t o  a  b l o c k  o f  t h e  h a e m  
b io s y n t h e t ic  p a th w a y . T he  m o s t common a c u te  h e p a t ic  p o r p h y r ia  
i s  A IP  w h e re  PBG-D a c t i v i t y  i s  r e d u c e d . S u c c in y l  a c e to n e  w as  
c h o s e n  t o  m im ic k  an  e n z y m a t ic  b lo c k  e a r l y  i n  th e  p a th w a y .  
T h is  i s  o n e  s t e p  e a r l i e r  th a n  th e  PBG-D d e f e c t  and  a s  s u c h  w as  
t h o u g h t  t o  b e  m o s t s i m i l a r  t o  t h i s  p o r p h y r i a .  S i m i l a r  
in c r e a s e s  i n  th e  e x c r e t i o n  o f  th e  p r e c u r s o r  ALA t o  th o s e  s e e n  
i n  A IP  a r e  o b s e rv e d  w i t h o u t  a n y  in c r e a s e  i n  PBG e x c r e t i o n .  
U r in a r y  ALA e x c r e t i o n  and  h e p a t ic  A LA -D  l e v e l s  w e re  m e a s u re d  
and  a n  o p tim u m  d o s e  o f  s u c c in y l  a c e to n e  was o b t a in e d  (T a b le  
2 7 ) .  The r e s u l t s  i n  T a b le  27 show th e  enzym e a c t i v i t i e s  an d  
A LA  e x c r e t i o n  l e v e l s  a t  d o s e s  o f  1 0 ,  2 0  a n d  5 0 m g /k g  b o d y  
w e ig h t  p e r  d a y  f o r  2 d a y s  s a c r i f i c i n g  th e  a n im a ls  on  d a y  3 .  
T h e  a n im a l s  w e r e  i n j e c t e d  t w i c e  d a i l y  ( b . d . )  a n d  r e s u l t s  
co m p ared  t o  c o n t r o l s .  I t  c a n  be c l e a r l y  s e e n  t h a t  e a c h  o f  t h e  
tw o  h ig h e r  d o s e s  o f  s u c c in y l  a c e to n e  s u c c e s s f u l l y  i n h i b i t e d  
A L A -D  a c t i v i t y  and  c a u s e d  l a r g e  in c r e a s e s  i n  e x c r e t i o n  o f  ALA  
i n  u r i n e ,  a  m e a s u re  o f  in d u c e d  A L A -s y n th a s e  a c t i v i t y .  T h e  
d o s e  o f  2 0 m g /k g  b od y  w e ig h t  p e r  d a y  was u sed  i n  tw o  lO m g /k g  
i . p .  i n j e c t i o n s .  T h e  m a in  re a s o n s  f o r  t h i s  w e re  t o  l i m i t  a n y
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HEPATIC ALA-D ACTIVITY URINARY ALA EXCRETION 
pmol ALA/g protein/h nmol/24 hours
DAY 1 DAY 2
CONTROL RAT 1 3 .4  +  3 .2  1 6 .5  +  3 .4  2 1 .5  +  1 3 .9
SUCCINYL ACETONE
TREATED RAT 8 .1 8  + 4 .7 8  161  +  4 4 .2  14 6  +  3 6 .6
lOmgAg/day
SUCCINYL ACETONE
TREATED RAT 4 .4 2  +  1 .7 8  2 3 0 1  + 8 4 .9  3 4 9 9  +  9 7 .9
2 0 m g A g /d a y
SUCCINYL ACETONE
TREATED RAT 3 .3 5  +  1 .5 1  4 4 1 9  +  101  4 6 0 3  +  11 8
50mg/kg/day
Results are expressed as mean + SD
n=4 in all cases
T A B L E  2 7 :  T H E  E F F E C T  O F S U C C IN Y L  ACETONE ON RAT H E P A T IC  A L A -D
A C T IV IT IE S  AND URINARY ALA EXCRETION
t o x i c  e f f e c t s  w h ic h  may th e n  be s e e n  on t r e a t m e n t  w i t h  tw o  
t h e r a p i e s  f o r  t h i s  in d u c e d  p o r p h y r i a  a n d  a l s o  t o  m o re  
a c c u r a t e l y  m im ic  t h e  t y p e  o f  b lo c k  s e e n  i n  h e r e d i t a r y  
p o r p h y r ia  w h e re  th e  enzym e a c t i v i t y  i s  re d u c e d  t o  a ro u n d  50% 
o f  n o r m a l  a c t i v i t y .  S u b s e q u e n t  s t u d i e s  u s e d  a  d o s e  o f  
2 0 m g /k g /d a y  o f  s u c c i n y l  a c e t o n e  t o  in d u c e  e x p e r i m e n t a l  
p o r p h y r ia  i n  th e s e  r a t s .
8 . 3  CONTROL OF INDUCED PORPHYRIA W ITH  VARIOUS TREATMENT REGIMENS  
A p r o t o c o l  was d e v is e d  f o r  c o n f in in g  S p ra g u e  D a w le y  
r a t s  t o  m e t a b o l i c  c a g e s ,  m e a s u r in g  t h e i r  u r i n a r y  A LA  
e x c r e t i o n ,  t h e n  i n d u c in g  p o r p h y r i a  w i t h  s u c c i n y l  a c e t o n e  
a d m i n i s t r a t i o n  ( i . p . ) .  S u c c e s s f u l  in d u c t io n  w as shown b y
g r e a t l y  in c r e a s e d  ALA e x c r e t i o n  l e v e l s .  F o r th e  f i r s t  d a y  a l l  
r a t s  w e re  c o n f in e d  t o  th e s e  c a g e s  and u r in e  c o l l e c t e d  so  t h a t  
b a s e l i n e  u r i n a r y  A LA  l e v e l s  c o u l d  b e  d e t e r m i n e d .  T h i s  
c o n s t i t u t e d  D ay 1 o f  th e  e x p e r im e n t .  A c o n t r o l  g ro u p  w as s e t  
up w h ic h  r e c e iv e d  p la c e b o ,  i n j e c t i o n s  c o n t a in in g  o n ly  th e  
c a r r i e r  s o lu t i o n s  f o r  th e  d r u g s .  On th e  n e x t  2 c o n s e c u t iv e  
d a y s  th e  r e m a in in g  f o u r  r a t s  r e c e iv e d  s u c c in y l  a c e to n e  a t  th e  
p r e - d e t e r m i n e d  d o s e  o f  2 0 m g /k g .  O f  t h e  r a t s  i n  w h ic h
p o r p h y r ia  was in d u c e d , w i t h i n  a  fe w  h o u rs  o f  t h e  f i r s t  d o s e ,
e a c h  r e c e iv e d  a  s e p a r a t e  t r e a t m e n t  t o  a l t e r  th e  b io c h e m ic a l
p r o f i l e  o f  th e  p o r p h y r ia  and  p r e c u r s o r  e x c r e t i o n .  One r a t  i n  
e a c h  g ro u p  r e c e iv e d  no f u r t h e r  t h e r a p y ,  and  w as c o n s id e r e d  t o  
b e th e  p o r p h y r ic  r a t .  A n o th e r  o f  th e  r a t s  w as t r e a t e d  w i t h  
haem  a r g i n a t e  a lo n e ,  o n e  was t r e a t e d  w i t h  Sn-PROTO a lo n e  a n d  
t h e  f i n a l  o ne  w as t r e a t e d  w i t h  a  c o m b in e d  t h e r a p y  o f  Sn-PROTO
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followed by haem arginate. Dosage was carried out twice daily 
for 2 days as for the succinyl acetone. In all cases 
succinyl acetone, was administered first (i.p.). This was 
followed after a 10  minute break by Sn-PROTO subcutaneously 
and this after a further 20 minutes by haem arginate i.p. The 
rationale for this order of therapeutic drugs was that earlier 
injection of Sn-PROTO which causes inhibition of haem 
oxygenase activity should be administered first to initiate 
the block in haem degradation. Thus haem arginate should be 
unable to cause any induction of haem oxygenase. The rats 
were sacrificed early on the fourth day of the experiment. 
Doses of the drugs for administration to the rats were 
determined both from previous rat studies and human work and 
based on the fact that rats metabolise drugs approximately 2 . 5  
times faster than humans.
8.3.1 Effect of Succinyl Acetone on Hepatic Haem Biosynthesis and 
ALA E x c r e t i o n
S p ra g u e  D a w le y  r a t s  w e re  t r e a t e d  w i t h  s u c c in y l  a c e to n e  t o  
in d u c e  a  p o r p h y r ic  s t a t e  a t  th e  p r e d e te r m in e d  d o s e  o f  2 0 m g /k g  
b o d y  w e ig h t /d a y  f o r  2 c o n s e c u t iv e  d a y s . U r in a r y  ALA e x c r e t i o n  
w as m e a s u re d  an d  i s  re c o r d e d  i n  T a b le  28  an d  F ig u r e  3 6 .  ALA  
e x c r e t i o n  w as  s i g n i f i c a n t l y  h i g h e r  i n  r a t s  t r e a t e d  w i t h  
s u c c i n y l  a c e t o n e ,  w i t h  20  t i m e s  t h e  a m o u n t o f  p r e c u r s o r  
e x c r e t e d  co m p ared  t o  c o n t r o l  r a t s  (p  < 0 .0 0 1  b y  Mann W h itn e y  U 
T e s t ) . H e p a t i c  A L A - s y n t h a s e  a n d  A L A -D  a c t i v i t i e s  a n d  
c y t o c h r o m e  P 4 5 0  l e v e l s  w e r e  m e a s u r e d  a n d  a r e  r e p o r t e d  i n  
T a b le s  29  and  30 and  F ig u r e s  3 7 ,3 8  and  3 9 .  A LA -D  a c t i v i t i e s
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3000-
2000_
1000
DAY 1 DAY2 DAY3
®  represents porphyric rat (succinyl acetone only) n=8D A vs 1 & 2 ,n = i3 D A Y 3
O represents porphyric rat treated with haem arginate n=9 d a y s  1 & 2 , n = i2 d a y 3
JL represents porphyric rat treated with SN-PROTO n=9 d a y s  1 & 2, n = i2 d a y 3
'W represents porphyric rat on combination therapy n=8 d a y  1 n=9 d a y 2, n=i3  d a y 3
Q  represents control rat n=9 d a y s  1 & 2, n=i2  d a y 3
Units are in nmol ALA excreted / 24 hours
FIGURE 36 : URINARY EXCRETION OF ALA IN PORPHYRIC AND TREATED
RATS
CONTROL
n
P O R P H Y R IC
n
PORPHYRIC  
+ HAEM  
ARGINATE
n
PORPHYRIC  
+ Sn-PROTO
n
PORPHYRIC  
+  C O M B IN E D  
THERAPY
DAY 1 
(n o  t r e a t m e n t )
274 +  165
9
144  + 65  
8
177  +  146
URINARY ALA EXCRETION  
n m o l/2 4  h o u rs  
DAY 2
1 78  + 184  
9
2 2 9 1  +  1231  
8
188  + 121  
9
236 + 165
276 6  +  1514  
9
DAY 3
15 2  +  131  
12
3 1 9 0  +  1 9 9 9  
13
2 0 3 4  + 1 6 8 1  2 3 8 5  +  1 2 8 8
12
2 3 6 2  +  2 0 0 3  
12
2 2 9 6  +  102 6  2 0 9 2  +  86 1
n 13
C o m b in a t io n  t h e r a p y  c o n s is te d  o f  3 0 u m o l/k g  b od y  w e ig h t  Sn-PROTO  
f o l l o w e d  t w e n t y  m in u t e s  l a t e r  b y  6 m g /k g  haem  a r g i n a t e  t w i c e  
d a i l y .  T h e s e  w e re  i d e n t i c a l  t o  th e  d o s e s  in  m o n o th e ra p y  w i t h  
haem a r g i n a t e  and  Sn-PRO TO .
R e s u l t s  a r e  e x p re s s e d  as  mean +  SD.
S t a t i s t i c a l  a n a l y s i s  i s  i n  th e  t e x t .
TABLE 2 8 : EXCRETION OF ALA IN  SPRAGUE DAWLEY RATS W ITH
TREATED PORPHYRIA, UNTREATED PORPHYRIA AND ON 
PLACEBO
A LA -D  A C T IV IT Y  A LA -S  A C T IV IT Y
jjm ol PBG /g p t n / h  pm ol A L A /g  p t n / h
CONTROL
PORPHYRIC
PORPHYRIC  
+  HAEM 
ARGINATE
PORPHYRIC  
+  Sn-PROTO
PORPHYRIC  
+  COMBINED 
THERAPY
1 3 .8  + 6 .1
4 .9  +  2 .4
5 .3  + 3 .6  
4 .2  +  2 .9
4 .9  +  2 .9
2 03  +  1 12  
7 0 3  +  45 7
377  + 154
270  + 207
290  +  16 8
F o r  A LA -D  a c t i v i t y  n=8 f o r  th e  c o n t r o l  and p o r p h y r ic  g ro u p s  and  
n=9 f o r  th e  t h r e e  t r e a t e d  g ro u p s .
F o r  A L A -s y n th a s e  a c t i v i t y  n =10  f o r  th e  p o r p h y r ic  g ro u p  and n = l l  
f o r  a l l  o t h e r  g r o u p s .
R e s u l t s  a r e  e x p re s s e d  a s  mean +  SD
TABLE 29  : H EPATIC  A LA -D  AND ALA-SYNTHASE A C T IV IT IE S  OF
SPRAGUE DAWLEY RATS W IT H  T R E A TE D  P O R P H Y R IA , 
UNTREATED PORPHYRIA AND ON PLACEBO
HEPATIC CYT. P450 LEVELS 
(n) nmol cyt.P450/mg microsomal protein
CONTROL 6 1.04 + 0.36
PORPHYRIC 7 1.58 + 0.72
PORPHYRIC 
+ HAEM ARGINATE 8 1.30 + 0.68
PORPHYRIC 
+ SN-PROTO 6 0.96 + 0.37
PORPHYRIC +
SN-PROTO + HAEM 5 0.87 + 0.46
ARGINATE
Results are expressed as mean + SD.
TABLE 30: HEPATIC CYT. P450 LEVELS IN SPRAGUE DAWLEY RATS,
RATS WITH INDUCED PORPHYRIA AND IN RATS WITH 
TREATED INDUCED PORPHYRIA
15
10
5
n = 9 n = 8n = 8 n = 9 n = 9
®  represents porphyric rat (succinyl acetone only)
O  represents porphyric rat treated with haem arginate
A . represents porphyric rat treated with SN-PROTO .
▼  represents porphyric rat on combination therapy
□  represents control rat
Figures represent mean ± SD
Units are in pmol ALA / g protein / hour
FIGURE 37 : HEPATIC ALA-DEHYDRATASE ACTIVITY IN INDUCED 
PORPHYRIA, AND AFTER VARIOUS TREATMENTS
1500 -
1000_
O
500 -
▲
▲
t
it
▲ * □
•  represents porphyric rat (succinyl acetone only)
o represents porphyric rat treated with haem arginate >
represents porphyric rat treated with SN-PROTO 
▼  represents porphyric rat on combination therapy 
Q  represents control rat
 represents the means
Units are in pmol ALA / mg protein / hour
FIGURE 38 : HEPATIC ALA-SYNTHASE ACTIVITY IN INDUCED 
PORPHYRIA, AND AFTER VARIOUS TREATMENTS
®  represents porphyric rat (succinyl acetone only)
O represents porphyric rat treated with haem arginate 
represents porphyric rat treated with SN-PROTO 
▼  represents porphyric rat on combination therapy 
Q  represents control rat
Units are in nmol cyt. P450 / mg microsomal protein
FIGURE 39: CYTOCHROME P450 CONTENT IN LIVER OF PORPHYRIC 
RATS AND PORPHYRIC RATS ON VARIOUS FORMS OF TREATMENT
for the porphyric group of rats were significantly lower than 
the controls with values of 4.9 + 2.4pmol PBG/g protein/hour 
(mean + SD) in porphyric rats compared with 13.8 + 6.1fiinol 
PBG/g protein/hour in control rats, (p < 0.005 by Mann Whitney 
U Test). No significant differences could be found between 
the ALA-D activities recorded in the three groups of animals 
on the various different therapies and the porphyric group. 
This was still true for the rats treated with haem arginate 
after succinyl acetone treatment (p < 0.05) showing that the 
succinyl acetone was still effective in reducing the enzyme 
activity.
ALA-synthase activities in the porphyric group had a mean 
of 703 +_ 457pmol ALA/mg protein/hour (+ SD) as compared to 
203 +_ 112pmol ALA/mg protein/hour (+_ SD) . The porphyric 
animals ALA-synthase activities were significantly higher than 
the controls (p < 0.005). Therefore, a sufficient block in 
the pathway had been achieved at the step catalysed by ALA-D 
to cause induction of the rate controlling enzyme.
8 . 3 . 2  C o n t r o l  o f  P o r p h y r ia  w i t h  Haem A r g in a t e
A group of animals were treated with succinyl acetone as 
in 8.3.1. Thirty minutes after each succinyl acetone 
injection haem arginate was administered i.p. at a dose of 
12mgA9 body weight daily. As with the animals in section 
8.3.2, ALA excretion, cyt. P450 in liver and hepatic ALA-D and 
ALA-synthase activities were measured. ALA-D activity 
remained low (5.3 + 3.6pmol PBG/g protein/hour, significantly 
lower than in the control group (p < 0.005). This was
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evidence that the block in haem biosynthesis was effective.
Hepatic ALA-synthase activities in rats with induced 
porphyria which had been treated with haem arginate were found 
to be 377 +_ 154 pmol ALA/mg protein/h. This was 
significantly lower than in the group with untreated porphyria 
(703 + 457 pmol ALA/mg protein/h) at p < 0.05. These haem 
arginate treated results remained higher than those recorded 
in the control, non-porphyric animals (203 + 112 pmol ALA/mg 
protein/h).
8 . 3 . 3  C o n t r o l  o f  In d u c e d  P o r p h y r ia  w i t h  Sn-PROTO l l i e r a p y
As described in section 8.3.1 and 8.3.2, a group of 
Sprague Dawley rats were confined to metabolic cages and 
porphyria was induced. Some of the rats were then treated 
with Sn-PROTO to try and control their induced porphyria.
On day one the rats were untreated to determine 
baseline urinary ALA excretion. On days two and three the 
rats were dosed with succinyl acetone followed after 1 0  
minutes by Sn-PROTO at a dose of 30pmol/kg. SnPROTO was made 
up in saline from powder after addition of alkali to dissolve 
the porphyrin (0.2ml of 0.5M NaOH) . The solution was 
neutralised with 0.3M HC1. This solution was made up in 
subdued light immediately prior to use and kept dark using 
aluminium foil. Ten minutes after each injection of succinyl 
acetone, 30pnol/kg Sn-PROTO was injected subcutaneously (s.c.) 
into the back of the neck. After repeating this treatment 
regime for two days (days 2 and 3 of experiment) , on day 4 
animals were sacrificed and hepatic ALA-synthase activity,
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ALA-D activity and cyt. P450 content were determined. The 
results are also presented in Tables 29 and 30 and in Figures 
37,38, and 39.
The rats were successfully made porphyric as 
shown by the significantly lower ALA-D activities recorded 
(4.2 + 2.9 pmol PBG/g protein/hour) compared to the control 
levels already quoted (p < 0.005). Treatment with Sn-PROTO 
successfully lowered the induced ALA-synthase levels from 703 
+ 457pmol ALA/mg protein/h in the porphyric group to 270 _+ 
107pmol ALA/mg protein/h in the treated group (p < 0.01). 
These ALA-synthase activities were not significantly different 
to those recorded for control animals.
Despite the effective normalisation of ALA-synthase 
activity, no significant reduction of ALA excretion was 
observed in these animals as is clear from Table 28. This 
apparent discrepancy will be discussed in section 8.5.
8.3.4 Control of Induced Porphyria with Combination Therapy
In parallel with rats given succinyl acetone to induce 
porphyria and control rats, a group of rats were injected with 
succinyl acetone to induce porphyria then treated with a 
combination of haem arginate and Sn-PROTO to assess any 
synergistic effect the two drugs may have on further improving 
the symptoms of porphyria.
The doses of haem arginate and Sn-PROTO were used 
identical to those in sections 8.3.2 and 8.3.3 respectively. 
Rats were initially dosed with succinyl acetone, followed
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after 10 minutes by Sn-PROTO (s.c. into the neck) then a 
further 20 minutes later by haem arginate i.p. Treatment was 
again for 2 consecutive days: ALA excretion in urine measured 
over the two 24 hour periods and hepatic ALA-synthase, ALA-D 
activities and cyt.P450 content were also measured.
A significant reduction in ALA-D activity (p < 0.05) was 
again seen with a value of 4.9 + 2.9 jjmol PBG/g protein/h 
(mean + SD) recorded.
ALA-synthase activity in the group of rats treated 
with combination therapy was significantly lower (290 + 112 
pmol ALA/mg protein/h) than that of the porphyric group (703 + 
457pmol ALA/mg protein/h) (p < 0.05). The levels recorded 
were not significantly different to those seen in controls 
suggesting that the biochemical profile of porphyria was 
successfully being treated by the combination of the two 
drugs. The only piece of information which was inconsistent 
with this was the ALA excretion values obtained. Urinary ALA 
excretion was found to be significantly higher than control 
excretion (p < 0.001) and not significantly reduced when 
compared to levels in porphyric rats. The mean excretion 
levels (+ SD) are shown in Table 28 and the means represented 
on Figure 36.
8.3.5 Hepatic Cytochrome P450 Levels in Porphyric Rats and Rats 
on Treatment for Induced Porphyria
The hepatic cyt.P450 content of Sprague Dawley 
rats was compared to that of rats in the same age and weight 
range with succinyl acetone induced porphyria and then to rats 
with treated induced porphyria using the treatment regimes
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already described. The findings are presented in Figure 39. 
There was no significant difference in the cyt.P450 content in 
any of the groups of rats. This suggests that haemoprotein 
content in liver of these animals is not being significantly 
altered by the induction of porphyria by succinyl acetone or 
by any of the treatment regimens used.
8.3.6 Comparison of the Ttiree Different Treatment Regimes as 
Successful Therapies for Induced Porphyria
Statistical comparison of the treatments by haem arginate 
alone, Sn-PROTO alone and the combination therapy showed that 
all the treatments were successful in reducing ALA-synthase 
activity with the most significant improvements seen with Sn- 
PROTO treatment alone (p < 0.01). The less marked effect seen 
with haem arginate was surprising since the treatment has been 
shown to be effective previously in rat models of porphyria. 
Combination of Sn-PROTO and haem arginate still produced a 
significant reduction in ALA-S activity in the liver when 
compared to porphyric controls. This is still not as good as 
the result found with Sn-PROTO therapy alone. The most 
consistent reduction was seen in these animals. There was less 
variation in ALA-synthase activities as reflected by the lower 
standard deviation. Unfortunately, these results are not in 
support of an additive effect of Sn-PROTO and haem arginate as 
a combined therapy over either of the two treatments alone. 
The lack of a significant reduction in ALA-synthase activity 
on haem arginate therapy is in contrast to the result seen in 
patients where this treatment results in normalised activities
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and ALA excretion. It is possible that the two day treatment 
regime may not be long enough to see a significant effect.
8.3.7 Finding the Optimum Dose of Haem Arginate to Successfully 
Treat Porphyria Induced with Succinyl Acetone
Two groups of rats were treated with a dose of succinyl 
acetone of lOmg/kg/day in two doses. One group of these rats 
were the porphyric rats and administered placebo in addition 
to succinyl acetone (saline). The other group received haem 
arginate at the dose already described of 1 2 mg/kg/day for two 
days. The AIA excretion levels in urine were determined. It 
was found that the excretion in the porphyric group was 2538 + 
804 nmol ALA/24 hours and in the haem arginate treated group 
was 2340 + 1438 nmol ALA/24 hours (means + SD). The reduction 
seen was not significant and the results are shown in Table 
31.
In a similar experiment the original dose of succinyl 
acetone at 20mg/kg/day was maintained and the dose of haem 
arginate was raised to 24mg/kg/day. The porphyric animals 
recorded ALA excretion levels in urine of 3817 + 1240 nmol 
ALA/24 hours while the treated group excreted 2800 + 881 nmol 
ALA/24 hours. This excretion was significantly lower than the 
porphyric group. It was then hoped to increase the 
improvement seen by a combination of reduction of succinyl 
acetone dose and increase of the haem arginate dose. Groups 
of rats were treated with lOmg/kg/day succinyl acetone and 
compared with a group of animals on the same dose with haem 
arginate at a dose of 24mg/kg/day after 30 minutes i.p. The 
increase in ALA excretion seen in the succinyl acetone treated
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PORPHYRIC PORPHYRIC
+ HAEM ARGINATE 
1 2  mg/kg 
{24 mg/kg}
SUCCINYL ACETONE 2583 + 804 2340 + 1438
lOmg/kg 
(n=6 )
SUCCINYL ACETONE 3817 + 1240 2800 + 881
2 0 mg/kg 
(n=6)
SUCCINYL ACETONE 2678 + 1428 {2138 + 872}
1 0 mg/kg 
(n=8)
Results are expressed as mean + SD and the doses of drugs are 
per day.
TABLE 31: MANIPULATION OF DOSES OF HAEM ARGINATE ON TREATMENT
OF PORPHYRIA INDUCED WITH SUCCINYL ACETONE
animals was to 2678 _+ 1428 nmol ALA/24 hours and this was not 
significantly reduced by the higher dose of haem arginate 
(2138 + 872nmol ALA/24hours).
The lack of effectiveness of haem arginate in porphyria 
induced with succinyl acetone appears to exist even after 
manipulation of the doses of both agents. From these results 
haem arginate is not effective in reducing ALA excretion in 
these animals. The ALA-synthase activity was not measured in 
these rats but would have been unlikely to throw light on why 
the treatment is so ineffective. I conclude that the 
administration of succinyl acetone produces a state of altered 
haem biosynthesis which is not responsive to haem control.
8.4 TREATMENT OF HUMAN ACUTE HEPATIC PORPHYRIA WITH A COMBINATION 
OF HAEM ARGINATE AND SN-PROTO THERAPY
A female patient who was regularly admitted 
suffering from acute attacks of AIP was chosen to compare the 
effects of Sn-PROTO, haem arginate alone and haem arginate in 
combination with Sn-PRQTO. Sn-PROTO was administered in a 
dose of 1 pmol/kg body weight, intravenously in 100ml normal 
saline over 15 minutes and haem arginate in a dose of 3mg/kg 
body weight, intravenously in 100ml normal saline over 15 
minutes. When combination treatment was used, the two drugs 
were given in the above doses with the Sn-PROTO being 
administered 30 minutes before haem arginate. Each treatment 
was given over three consecutive days. The patient had four 
attacks treated with placebo, four with haem arginate, four 
with haem arginate and Sn-PROTO and one attack with Sn-PROTO
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alone.
8.4.1 Biochemical Responses
Urinary excretion of the porphyrin precursors ALA and PBG 
is greatly increased during an .attack of acute porphyria. 
Haem arginate alone or combined with Sn-PROTO resulted in a 
marked reduction in porphyrin precursor excretion to near 
normal levels. The degree of depression of porphyrin 
precursor production during the three days of treatment was 
similar with haem arginate alone or used in combination with 
Sn-PROTO (Table 32 for ALA excretion and Table 33 for PBG 
excretion. Sn-PROTO on its own did not reduce porphyrin 
precursor excretion to a significant extent. Following 
cessation of treatment the urinary excretion of porphyrin 
precursors rapidly rose with haem arginate alone reaching 80% 
of pretreatment values by the fourth day post-therapy (Figure 
40, Tables 32 and 33) . In contrast, when haem arginate was 
co-administered with Sn-PROTO the excretion remained depressed 
being only 15% of pretreatment levels at the fourth day post­
therapy (Figure 40, Tables 32 and 33) . This indicates that 
the Sn-PROTO prolongs the biochemical efficacy of haem 
arginate.
8.4.2 Clinical Response
Information was available on the clinical outcome of 4 
attacks treated with placebo, 23 with haem arginate, 3 with 
combination therapy and 1 with Sn-PROTO alone. There was no 
significant difference between the four treatments with regard 
to duration of admission. However, there was evidence
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FIGURE 40: THE EFFECTS OF VARIOUS DIFFERENT TREATMENTS ON
URINARY ALA EXCRETION DURING PORPHYRIC ATTACK
PERCENTAGE OF MEAN PRETREATMENT VALUES
Day 3 treatment Day 5 Post-therapy
(last day)
PLACEBO 74 80
(n=3) (61-89) (41-119)
HAEM ARGINATE 25 113
(n=3) (13-45) (82-164)
Sn-PROTO 63 44
(n*l)
HAEM ARGINATE
+ Sn-PROTO 8 18
(n=3) (16-13) (16-20)
TABLE 32: URINARY ALA EXCRETION OF ONE PATIENT ON VARIOUS
TREATMENT REGIMES
PERCENTAGE OF MEAN PRETREATMENT VALUES
Day 3 treatment Day 5 Post-therapy
(last day)
PLACEBO 80 82
(n=3) (53-102) (58-98)
HAEM ARGINATE 39 112
(n=3) (24-57) (23-251)
Sn-PROTO 88 24
(n=l)
HAEM ARGINATE
+ Sn-PROTO 12 25
(n=3) (6-21) (14-45)
TABLE 33: URINARY PBG EXCRETION OF ONE PATIENT ON VARIOUS
TREATMENT REGIMES
indicating that the different treatments influenced the 
duration of clinical remission achieved following the 
treatment. With placebo treatment the mean time from 
commencement of treatment to readmission in next attack was 11 
days ( range 4-20); with haem arginate it was 23.4 days (range 
16-31); with SnPRQTO it was 30 days and with the combination 
of haem arginate and Sn-PROTO it was > 74 days (range 36- >97) 
(Figure 41). These results indicate that the co­
administration of Sn-PROTO with haem arginate prolongs the 
clinical as well as the biochemical remission. Following 
treatment with Sn-PROTO alone or in combination with haem 
arginate, patients noted mild cutaneous photosensitivity which 
persisted for up to 3 months after treatment.
8.5 DISCUSSION AND SUMMARY
Production of a porphyria-like state in rats proved 
effective using succinyl acetone, administered twice daily for 
a two day period. ALA excretion was dramatically raised as 
compared to normal with levels around 20 times those in the 
normal range and ALA-D activities effectively a third of 
control activities.
Treatment of this induced porphyria with haem 
arginate was not very effective as shown by the results in 
this chapter. Hepatic ALA-synthase activities remained 
higher than normal. In contrast, in the rats which were 
treated with Sn-PROTO, hepatic ALA-synthase activity 
normalised very quickly which was taken to indicate control of 
the hepatic porphyria. Treatment with a combination of the
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FIGURE 41: LENGTH OF REMISSION FROM ACUTE PORPHYRIC ATTACK
AFTER VARIOUS TREATMENTS
two drugs showed hepatic ALA-synthase activities in the normal 
range. This was likely to be due to the effect of Sn-PROTO, 
with haem arginate not providing any supplementary 
improvement. Measurement of the excretion levels in the rats 
which had been treated with various drugs were inconsistent 
with the biochemical improvement seen. ALA excretion remained 
very high in all of the treated groups of rats as well as in 
the porphyric group. The possibility that this maintained
increase was due to some adverse effect on kidney function was 
discounted as the creatinine levels in the groups of rats were 
determined and these were found to be within the same range 
for all of them. These results indicated that kidney function 
was normal and that ALA excretion levels recorded were a true 
reflection of ALA produced in the rats.
Haem arginate is known to be taken up by the 
liver where it restores the haem deficiency produced by a 
block in the haem biosynthetic pathway. The lack of 
significant reduction in ALA excretion was unexpected in these 
rats. Injections of the haem arginate were carried out i.p. 
and this is not the same as in humans (i.v.) (Tokola, 1 9 8 6 ,  
1 9 8 7 ;  Tokola et al, 1 9 8 6 ) .  However, i.p. administration has 
been used in rats when porphyria has been induced with the 
chemical AIA (Tokola et al, 1 9 8 7 b ) . It is possible that the 
dose of 1 2 mg/kg/day haem arginate was not high enough to be 
effective in reducing the porphyric like state induced by 
succinyl acetone, but this dose of haem arginate has 
previously been shown to be effective in AIA induced porphyria
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in rats (Tokola, 1987b).
In order to see if the dosing regime was 
optimal, the effects of reductions in the succinyl acetone 
dose and increases in the haem arginate dose were studied. 
These results showed that ALA excretion was not efficiently 
reduced in the animals even when this action was taken. 
Unfortunately, this was the only parameter assessed in these 
animals. Enzyme activities would have been a useful guide to 
liver haem biosynthesis.
The results presented in this chapter show that there are 
some inconsistences between the effects of treatment of an 
acute hepatic porphyric attack and the situation which occurs 
on induction of porphyria in rats using succinyl acetone. Hie 
choice of this drug to provide the animal model has already 
been discussed and was mainly due to the ability of this drug 
to block the haem biosynthetic pathway in these animals at a 
similar stage to that in AIP where PBG-D activity is reduced 
in the liver.
The fact that haem arginate treatment seemed to provide a 
poorer treatment for succiny1 -acetone induced porphyria was 
not expected. By way of explanation, it is possible that 
administration of succinyl acetone to these animals may result 
in overproduction of ALA in all tissues and not just in the 
liver. The role of haem in controlling its synthesis is 
specific to the hepatic or housekeeping form of ALA-synthase 
and would not be expected to be effective in erythroid 
synthesis of ALA. Hie control of the ALA production by the 
liver appears to be occurring as shown by the normalised ALA-
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synthase activities but production in other tissues such as 
the bone marrow may not be controlled by the therapeutic 
regimes used. Thus, excess AIA would still be in evidence, 
and would be excreted in the urine.
The above information suggests that succinyl 
acetone administration to produce an animal model of porphyria 
is unsatisfactory and that it would be useful to pursue one of 
the other available animal models of induced porphyria where 
haem arginate therapy has been shown to be effective (Tokola 
et al, 1987b).
The results of the clinical studies comparing the effect of 
the coadministration of haem arginate and Sn-PROTO were more 
encouraging. The degree of suppression of excretion of ALA 
and PBG was similar during the first 48 hours of treatment 
with haem arginate alone and in combination with Sn-PROTO. 
However with the combination treatment the duration of the 
suppression of overproduction was prolonged. This would be 
consistent with Sn-PROTO inhibiting the breakdown of the 
exogenously administered haem by haem oxygenase. The 
increased time between clinical attacks also indicated that 
coadministration of Sn-PROTO with haem arginate considerably 
prolongs clinical remission. These results indicate that co­
administration of these two drugs may have a prophylactic role 
in acute porphyria. The observation of cutaneous 
photosensitivity lasting for several months after the 
administration of Sn-PROTO indicates that it remains in the 
tissues for a long time. This persistence of the Sn-PROTO
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for months is consistent with its ability to prevent attacks 
even several months after its administration. It may be that 
much smaller doses of haem arginate will be equally effective 
when given in combination with Sn-PROTO. Indeed, it is even 
possible that a single injection of haem arginate/Sn-PROTO 
solution could achieve the same results. Further 
investigations of this attractive combination treatment are 
required.
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CHAPTER 9
DISCUSSION AND CONCLUSIONS
9.1 DISCUSSION
The results contained in chapters 4, 5, 6 and 7 provide 
information on haem biosynthesis and porphyrin metabolism in an 
animal model of hyperbilirubinaemia, the Gunn rat (Gunn, 1938). 
These rats exhibit a congenital defect in bilirubin conjugation 
which leads to high levels of unconjugated bilirubin in the 
plasma. Bilirubin deposits in the tissues and has been 
especially noticeable in the brain. This has resulted in the 
animal being used to provide an animal model of kernicterus. 
The investigations have shown that blood porphyrin levels in 
Gunn rats are similar to those in control rats. In contrast, 
both urinary and faecal excretion of porphyrins is lower in the 
Gunn rat than in control rats. As explained fully in section 
5.4, this may be a reflection of the type of porphyrin excretion 
observed in the Wistar animal from which the mutant Gunn 
originated.
The effect of bilirubin on the enzymes of the haem biosynthe­
tic pathway was studied in various tissues of the Gunn rat. In 
the adult Gunn rat the activity of the penultimate enzyme of 
haem biosynthesis, PROTO-O was reduced in hepatic tissue. This 
is consistent with reports that bilirubin may act as a 
competitive inhibitor of this enzyme (Ferriera & Dailey, 1988; 
McColl et al, 1985). The inhibition of this enzyme activity 
was not accompanied by any compensatory increase in the rate 
controlling enzyme, ALA-synthase. This suggests that the 
degree of inhibition of PROTO-O activity was not sufficient to 
impair hepatic haem biosynthesis and thus result in derepression 
of the rate controlling step of the pathway. The absence of
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overproduction of the porphyrin precursors of haem prior to the 
PROTO-O step is also in support of normal activity of ALA- 
synthase being present in the Gunn rat. In human variegate 
porphyria. PROTO-O activity is reduced by approximately 50% yet 
overproduction and increased excretion of porphyrins and their 
precursors is seen in only a proportion of patients.
Within the kidney of the Gunn rat bilirubin appeared to have 
no effect on PROTO-O activities. The reason for this is 
unknown but may be due to a much lower concentration of 
bilirubin in this tissue compared with that of hepatic tissue. 
The presence of much lower concentrations of bilirubin in this 
tissue is not surprising since the kidney does not play a role 
in the excretion of bilirubin and no sequestering protein, such 
as ligandin, is present.
The main objective of the studies was to determine whether 
bilirubin had any inhibitory effect on haem biosynthesis in the 
brain. The mechanism by which bilirubin causes the brain 
damage observed in kernicterus are unclear with reports stating 
adverse effects of the bile pigment on many intracellular 
processes ranging from disruption of various enzyme systems to 
integration into membranes. Abnormalities in neurological 
histology have frequently been observed. The effect of 
bilirubin on the brain haem biosynthetic pathway has not 
previously been assessed. In porphyria where the hepatic haem 
biosynthetic pathway is disrupted by a congenital defect in one 
of the enzymes, neurological dysfunction is frequently observed. 
This was the basis for investigation of the effect of bilirubin
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on brain haem biosynthesis; to determine if disruption of the 
pathway may contribute to the neurological dysfunction which 
results from kernicterus.
The results of Chapter 7 provide the first measurements of 
brain PROTO-O activity. In the adult Gunn rat brain activity 
was found to be similar to the liver enzyme, although ALA- 
synthase activity was much lower in this tissue compared to 
levels seen in hepatic mitochondria. In the brain ALA-
synthase is the point of control for haem biosynthesis. This 
lower activity corresponds with a much lower haem content of 
this tissue and probably reflects the fact that less haem is 
necessary to these cells. Since all other enzymes of the 
pathway except ALA-synthase are thought to be in excess it is 
unsurprising that PROTO-O activity in the brain is not lower 
than in hepatic tissue. The results suggest that the brain 
enzyme is identical to the form found in hepatic tissue. 
Future studies on the genetic loci of PROTO-O will determine if 
the PROTO-O enzyme is identical in brain and liver.
Bilirubin levels in Gunn rat brain were consistently measura­
ble at approximately 4nmol/g wet weight tissue, and these levels 
were comparable regardless of whether ether or a barbiturate 
anaethetic were used on the animal. Cervical dislocation was 
avoided to enable removal of brain tissue undamaged. The 
presence of bilirubin in the brain of the adult Gunn rat did not 
produce any inhibition of PROTO-O activity. The literature 
states that kernicterus cannot be induced in the adult animal 
without disruption of the blood brain barrier. Thus the lack 
of PROTO-O inhibition observed in adult animals (section 7.2)
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does not show whether PROTO-O inhibition is involved in the 
brain damage observed in kernicterus. To produce a more 
satisfactory animal model of kernicterus, bilirubin was 
displaced into the brain of neonatal rats by the drug 
sulphadimethoxine. The effects closely resembled symptoms of 
kernicterus. Despite the successful increase in brain 
bilirubin produced in these animals, no inhibitory effect of 
bilirubin on brain PROTO-O activity could be observed. This 
result does not support the theory that inhibitionof the 
penultimate stage is one of the causes of brain damage in 
kernicterus.
The bilirubin levels which were found in the brain were lower 
than the levels of the bile pigment which resulted in inhibition 
of PROTO-O activity ji_n vitro. This may help to explain the 
lack of inhibition observed in the experiments carried out in 
the thesis. The _in vitro work used a purified form of the 
enzyme and so may not accurately compare to the _in vivo 
situation. The levels of bilirubin which were measured in 
brain in these experiments were up to lOnmol/g wet weight, still 
much lower than the concentrations of bilirubin (8-34pmolar) 
used by Ferriera and Dailey (1988) to induce a 50% inhibition of 
the purified hepatic enzyme jln vitro. Therefore it is probab­
le that the levels of bilirubin which were produced in these 
experiments in Chapter 7 were insufficient to cause inhibition 
of the enzyme provided that the protein is identical to that in 
liver. Development of symptoms which are consistent with 
kernicterus were observed in these animals tends to suggest that
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bilirubin inhibition of haem biosynthesis is not a factor to be 
considered as a possible cause of the toxicity.
Another factor which may be important is the regional 
distribution of bilirubin within the brain. The cerebellum is 
known to contain the highest amount of bilirubin. All 
measurements of bilirubin content and enzyme activity were 
carried out in whole brain preparations, not in specific brain 
regions, and the results may reflect this. Local inhibitory 
effects of bilirubin on the activity of PROTO-O cannot be 
discounted.
The possibility that inhibition of PROTO-O activity may 
occur locally cannot be discounted. Regions of brain 
containing the highest amount of bilirubin, especially the 
cerebellum, could be selectively dissected and assayed for 
PROTO-O activity. In the future it would be interesting to 
examine the effect of bilirubin on purified preparations of 
brain tissue. This would determine whether bilirubin can 
inhibit the brain enzyme, and the concentrations of the bile 
pigment required. Certainly if the enzyme is identical to the 
hepatic form, inhibition would be expected.
Production of kernicterus in another model may also be 
useful. Lowering the plasma pH such that acidosis occurs 
appears to increase the risk of bilirubin encephalopathy (Kim et 
al, 1980). Alternatively disruption of the blood brain barrier 
in order that bilirubin can enter the brain would be yet another 
effective way to induce kernicterus.
It may be that the brain damaging effects of bilirubin act 
selectively on neuronal tissue, the bile pigment being
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preferentially sequestered in nerve cells, so affecting their 
function. Effects observed on mitochondrial function may be 
secondary in this instance.
Analysis of the literature provided much information on haem 
degradation. In addition to stimulating interest in bilirubin 
toxicity, interest in the treatment of hyperbi 1 irubinaemia 
developed. One recent and successful aspect has been the 
administration of Sn-PROTO to inhibit haem oxygenase activity 
and so decrease bilirubin production. Ihe effects of Sn-PROTO 
have already been discussed, both in the introduction and in 
Chapter 8 . This synthetic metal loporphyrin has been used to 
reduce hyperbi1irubinaemia. As a consequence of the inhibitory 
action of action Sn-PROTO on haem breakdown, haem content of 
cells increases. The departmental interest in porphyria 
allowed access to information which suggested that this 
treatment might be beneficial to acute porphyria patients. Sn- 
PROTO has been previously applied to treat an acute porphyric 
attack, but only as monotherapy. The approach which I employed 
and presented in Chapter 8 was to combine haem arginate, to 
replace depleted haem, with Sn-PROTO which would prevent the 
induction of haem oxygenase. Induction of haem oxygenase 
activity after haem arginate administration limits the 
effectiveness of therapy by leading to increased haem breakdown. 
From the experimental data obtained, the animal model which was 
used in these experiments did not appear to adequately mimic 
hepatic porphyria. Both ALA and PBG excretion was elevated as 
compared to normal within a few hours of administration of
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succinyl acetone for induction of porphyria. This was 
consistent with a useful model of acute hepatic porphyria. In 
contrast to the patients with the disease, animals treated with 
haem arginate, the traditional first line therapy, showed no 
reduction in precursor excretion. This was thought to be due 
to persisting overproduction of porphyrin precursors in tissues 
other than the liver. Thus the falling levels of ALA and PBG 
excreted from the liver would be masked. Induction of ALA- 
synthase by either AIA or DDC would be appropriate alternatives.
More encouraging results were obtained when the effects of 
the co-administration of Sn-PROTO and haem arginate were studied 
in patients experiencing acute attacks of porphyria. The 
addition of Sn-PROTO prolonged the reduction in porphyrin 
precursor overproduction produced by haem arginate and also 
prolonged the clinical remission. The co-administration of Sn- 
PROTO therefore provides an exciting new way of increasing the 
effectiveness of haem arginate therapy of acute porphyria. The 
only side-effect found with the Sn-PROTO was cutaneous 
photosensitivity which persisted for several months. Hopefully 
further inhibitors of haem oxygenase will be developed which do 
not have this side effect.
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A P P E N D I X  1
ANAESTHETISE ANIMAL
1
PERFUSE BRAIN - ICE COLD SALINE
1
2 INiHOMOGENISE BRAIN TISSUE IN 4 VOLUMES 0.25M SUCROSE
ADD 1 VOLUME BRAIN HOMOGENATE TO 18 VOLUMES 
CHLOROFORM: METHANOL: WATER (2:5 : 2v/v)
i
ADD 10ng COUMARIN 6 (INTERNAL STANDARD)
i
EXTRACT WITH POTTER ELVEHJEM HOMOGENISER 10 STROKES
i
ADD 8 VOLUMES WATER
i
300C
i
iVAF
i
CENTRIFUGE AT 0g FOR 15 MINUTES
REMOVE LOWER PHASE AND E PORATE TO DRYNESS UNDER N2
RESUSPEND EXTRACT IN DESIRED VOLUME OF MOBILE PHASE FOR HPLC ANALYSIS
